Novel recombinant AAV VP2 fusion polypeptides

By combining AAV VP2 with AAV VP2 capsid polypeptide and polypeptide ligand, the transduction efficiency and target specificity of AAV virions are improved, the problem of low transduction efficiency of existing AAV vectors is solved, and high cell type is achieved Selective and safe gene transfer.

CN118974284APending Publication Date: 2024-11-15NOVARTIS AG
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202380032256.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-06
Filing Date
2023-05-04
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing adeno-associated virus (AAV) vectors are inefficient in transduction in many target organs, resulting in the need of high vector doses, and improving cell transduction and specificity are difficult to achieve. The existing variant AAV capsid polypeptides have not met the improvement. Transduction and targeting specificity requirements.

Method used

Provides AAV VP2 fusion polypeptides, including AAV VP2 capsid polypeptide and polypeptide ligands. The polypeptide ligand is fused directly to the N-terminus of the VP2 capsid polypeptide or through a peptide linker, with a molecular weight of up to 10kDa, for assembling rAAV virions, improving decoration level and Cell type selectivity.

Benefits of technology

Through AAV VP2 fusion polypeptide, the transduction efficiency and tropism in at least one tissue or cell type is significantly improved, providing high cell type selectivity and targeted specificity, suitable for cell type specificity in gene therapy and basic research Sex gene delivery.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005069042880001131
    Figure BDA0005069042880001131
  • Figure BDA0005069042880001141
    Figure BDA0005069042880001141
  • Figure BDA0005069042880001151
    Figure BDA0005069042880001151
Patent Text Reader

Abstract

The present disclosure relates to adeno-associated virus (AAV) VP2 fusion polypeptides comprising an AAV VP2 capsid polypeptide and a polypeptide ligand. The disclosure further relates to rAAV virions comprising such AAV VP2 fusion polypeptides and a library of nucleic acids encoding such AAV VP2 fusion polypeptides, pharmaceutical compositions comprising such rAAV virions, and related methods and uses.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This disclosure provides adeno-associated virus (AAV) VP2 fusion peptides for improving AAV targeting in gene therapy approaches, these AAV VP2 fusion peptides comprising an AAV VP2 capsid peptide and a peptide ligand. This disclosure further provides rAAV viral particles comprising such AAV VP2 fusion peptides and nucleic acid libraries encoding such AAV VP2 fusion peptides, as well as related compositions, methods, and uses.

[0002] sequence list

[0003] This application contains a sequence list that has been electronically filed in ASCII format and is hereby incorporated in its entirety by reference. The ASCII copy (created on May 5, 2022) is named PAT059281-US-PSP_SL and has a size of 54,417 bytes. Background Technology

[0004] Adeno-associated virus (AAV) vectors are among the most promising gene transfer vectors due to their excellent safety and efficacy profile. Established characteristics that distinguish AAV vectors from other vectors include stable long-term expression, broad host range, ability to transduce proliferating and post-mitotic cells, high titers of AAV vectors produced in tissue cultures, derivatization from non-pathogenic viruses, and low immunogenicity of both wild-type viruses and recombinant vectors.

[0005] However, due to its broad tropism, transduction efficacy in many target organs is low, thus requiring the application of high carrier doses. It has become increasingly clear that the full potential of this carrier system will be realized only with modified AAV carriers that exhibit improved cell transduction rates and specificity, resulting in an improved safety profile.

[0006] Retargeting attempts have focused on variable regions of the loop that form protrusions, due to their exposure sites and their function in receptor binding. However, these sites only accept the insertion of small peptides. US20180163229 discloses a variant AAV capsid polypeptide containing DARPin fused to the N-terminus of AAV VP2.

[0007] There remains a high unmet need for additional variant AAV capsid peptides that can mediate improved AAV characteristics for gene therapy, such as increased transduction and / or increased tropism in at least one tissue or cell type, improved cell type selectivity, and / or target specificity. Summary of the Invention

[0008] This disclosure provides adeno-associated virus (AAV) VP2 fusion peptides comprising an AAV VP2 capsid peptide and a peptide ligand, wherein the peptide ligand is fused directly to or via a peptide linker to the N-terminus of the AAV VP2 capsid peptide. The peptide linker has a molecular weight up to 10 kDa. When typically used in conjunction with AAV VP1 and / or VP3 capsid peptides for rAAV virus particle assembly, the AAV VP2 fusion peptides provided herein exhibit a good level of decoration, meaning that a satisfactory number of AAV VP2 fusion peptides are incorporated into rAAV virus particles.

[0009] Compared to an AAV VP2 capsid polypeptide that is not fused with the stated polypeptide ligand but is otherwise identical to the VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide, the AAV VP2 fusion polypeptide described herein can mediate improved transduction and / or increased tropism in at least one tissue or cell type. This improved transduction and / or increased tropism in at least one tissue or cell type can be mediated by the polypeptide ligand, which may have the ability to bind to cell surface molecules expressed on the at least one tissue or cell type. Therefore, rAAV viral particles containing the AAV VP2 fusion polypeptide provided herein and exhibiting the polypeptide ligand on their surface can be used for cell type-specific gene delivery during both therapeutic and basic research applications, as they provide high cell type selectivity and / or target specificity that allows for limited biodistribution and safe gene transfer.

[0010] Therefore, in one respect, this article provides adeno-associated virus (AAV) VP2 fusion peptides comprising an AAV VP2 capsid peptide and a peptide ligand, for example, composed thereof, wherein the peptide ligand is fused to the N-terminus of the AAV VP2 capsid peptide, and wherein the molecular weight of the peptide ligand is up to 10 kDa.

[0011] In other respects, this article provides nucleic acids encoding such AAV VP2 fusion peptides and cells containing such AAV VP2 fusion peptides or nucleic acids encoding such AAV VP2 fusion peptides.

[0012] In other respects, this article provides rAAV viral particles comprising the AAV VP2 fusion peptide disclosed herein and pharmaceutical compositions comprising such rAAV viral particles.

[0013] In other respects, this paper provides nucleic acid construct libraries encoding the AAV VP2 fusion peptides disclosed herein and methods for generating AAV VP2 fusion peptides with desired characteristics using such libraries.

[0014] In other respects, this article provides treatment methods using rAAV viral particles containing the AAV VP2 fusion peptide disclosed herein and pharmaceutical compositions containing such rAAV viral particles.

[0015] On the other hand, this document provides an AAV VP2 capsid polypeptide, wherein a) the AAV VP2 capsid polypeptide has the AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, or wherein b) the AAV VP2 capsid polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the following amino acid substitutions selected from the group consisting of: relative to SEQ ID NO:7. The VP1 amino acid sequence of NO:7 comprises E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, particularly wherein bi) the AAV VP2 capsid polypeptide has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, or wherein bii) the AAV VP2 capsid polypeptide has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of: relative to SEQ ID The VP1 amino acid sequence of NO:5 consists of E147S, P185G, P166R, G199R, D213A, S162R, and P191N or any combination thereof, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D213A, S162R, and / or P191N. Detailed Implementation

[0016] definition

[0017] As used in the specification and claims, unless the context clearly specifies otherwise, the singular forms “a”, “an”, and “the” include plural indicators. For example, the term “a cell” includes a plurality of cells, including mixtures thereof.

[0018] All numerical expressions (e.g., pH, temperature, time, concentration, and molecular weight) (including ranges) are approximate values, varying in increments of 0.1 (+) or (-). It should be understood that, although not always explicitly stated, all numerical expressions are preceded by the term "about". The term "about" in relation to a numerical value X means, for example, X ± 15%, encompassing all values ​​within this range. It should also be understood that, although not always explicitly stated, the reagents described herein are merely examples, and their equivalents are known in the art.

[0019] Throughout this specification and the following claims, unless the context otherwise requires or otherwise states otherwise, the word “comprise” and variations such as “comprises” and “comprising” are used herein in their open-ended and non-limiting sense.

[0020] When used herein, "consisting of" excludes any element, step, or component not specified in the aspects, embodiments, and / or claims. When used herein, "consisting substantially of" does not exclude materials or steps that do not substantially affect the essential and novel features of the aspects, embodiments, and / or claims.

[0021] The terms “peptide,” “polypeptide,” and “protein” are used interchangeably and refer to compounds composed of amino acid residues covalently linked by peptide bonds. Proteins or peptides typically contain at least two amino acids or amino acid variants, and there is no limit to the maximum number of amino acids that can be included in a protein or polypeptide sequence. Polypeptides include any peptide or protein containing two or more amino acids or variants linked together by peptide bonds. These terms include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, etc. Polypeptides include natural peptides, recombinant peptides, or combinations thereof.

[0022] The terms “polynucleotide” and “nucleic acid” are used interchangeably herein and refer to polymers of nucleotides of any length. They may contain one or more of ribonucleotides or deoxyribonucleotides. Thus, this term includes, but is not limited to, single-stranded, double-stranded, or multi-stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA), genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derived nucleotide bases (e.g., analogs of natural nucleotides that have similar binding properties to a reference nucleic acid and are metabolized in a manner similar to that of naturally occurring nucleotides), locked nucleic acids (LNAs), and peptide nucleic acids (PNAs). Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses its conserved variants (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences, as well as explicitly indicated sequences. Specifically, degenerate codon substitution can be achieved by generating sequences in which the third position of one or more selected (or all) codons is replaced by a mixture of bases and / or deoxyinosine residues (Batzer et al., Nucleic Acid Res. 19:5081 (1991); Ohtsuka et al., J. Biol. Chem. 260:2605-2608 (1985); and Rossolini et al., Mol. Cell. Probes 8:91-98 (1994)).

[0023] The terms “sequence identity” and “sequence homology” are used interchangeably herein and, as in the context of polynucleotides or polypeptides, refer to the percentage of bases or amino acids that are identical and located at the same relative positions when comparing or aligning two sequences of a polynucleotide or polypeptide. Thus, when subunit positions in two molecules are occupied by the same monomeric subunits—for example, if a position in each of two DNA molecules is occupied by adenine—they are homologous or identical at that position. Homology between two sequences is a direct function of the number of matched or homologous positions; for example, if half the positions in two sequences (e.g., five positions in a polymer of ten subunits in length) are homologous, the two sequences are 50% homologous; if 90% of the positions (e.g., nine out of ten) are matched or homologous, the two sequences are 90% homologous. Sequence identity can be determined in many different ways. For example, the percentage of “sequence identity” can be determined by comparing two best-aligned sequences in a comparison window, where the amino acid sequence fragments in the comparison window may contain additions or deletions (e.g., vacancies or overhangs) compared to a reference sequence (which does not contain additions or deletions) to make the two sequences best-aligned. The percentage can be calculated by determining the number of positions in both sequences where the same amino acid residues occur to produce a number of matching positions, dividing the number of matching positions by the total number of positions in the comparison window, and multiplying the result by 100 to produce the percentage of sequence identity. The output is the percentage identity of the subject sequence relative to the query sequence. Sequences can be aligned using various methods and computer programs (e.g., BLAST, T-COFFEE, MUSCLE, MAFFT, etc.). See, for example, Altschul et al., (1990) J. Mol. Bioi. [Journal of Molecular Biology], 215:403-10.

[0024] As used herein, the terms “naturally occurring” or “unmodified” as applied to, for example, nucleic acids, polypeptides, cells, or organisms, refer to nucleic acids, polypeptides, cells, or organisms found in nature. For example, a polypeptide or polynucleotide sequence present in an organism (such as a virus) is naturally occurring, whether it is present in that organism or isolated from one or more components of that organism.

[0025] The term "variant" in relation to polynucleotides or polypeptides refers to a polynucleotide or polypeptide that differs from its parent polynucleotide or polypeptide (also known as a non-variant polynucleotide or polypeptide sequence) by at least one residue (i.e., at least one nucleotide for polynucleotides and at least one amino acid for polypeptides).

[0026] The term "isolated" as used in connection with the nucleic acids, peptides, or viruses discussed herein refers to a nucleic acid, peptide, or virus that has been separated from one or more of its associated components that are normally present in its natural environment. For example, a nucleic acid or peptide naturally present in a living organism is not "isolated," but the same nucleic acid or peptide that is partially or completely separated from its native coexisting material is "isolated." Separation can include removal from a larger nucleic acid (e.g., from a gene or chromosome) or from other proteins or molecules that normally come into contact with the nucleic acid or protein. The term covers, but does not require, complete separation. Thus, isolated nucleic acids or proteins may exist in a substantially purified form or may exist in non-natural environments (e.g., like host cells).

[0027] As used herein, an isolated nucleic acid containing a “heteronucleotide sequence” refers to an isolated nucleic acid containing a portion (i.e., a heteronucleotide portion) found in the natural environment that is not normally operatively linked to one or more other components of the isolated nucleic acid. For example, a heteronucleotide may contain a nucleic acid sequence not originally found in cells, bacterial cells, viruses, or organisms from which other components (e.g., promoters) of the isolated nucleic acid are naturally derived, or wherein other components (e.g., promoters) of the isolated nucleic acid are found not to be operatively linked to heteronucleotides in cells, bacterial cells, viruses, or organisms. In some embodiments, heteronucleotides include transgenes. As used herein, a “transgene” is a nucleic acid sequence that encodes a target molecule (e.g., a therapeutic protein, a therapeutic RNA molecule, or a reporter protein) that is not originally associated with one or more components of the nucleic acid molecule. In some embodiments, the heteronucleotide sequence encodes a human protein. In some embodiments, the heteronucleotide sequence encodes an RNA sequence, such as shRNA.

[0028] As used herein, the term "reporter sequence" refers to a nucleic acid sequence encoding a reporter protein (such as a fluorescent protein or oxidase), which allows for visualization of infection using an rAAV vector containing such a reporter sequence, i.e., monitoring successful transduction of target cells or tissues based on reporter protein expression. Preferred oxidases are firefly luciferases; exemplary fluorescent proteins include GFP and its variants (such as eGFP) and sfCherry. The reporter sequence may be packaged into rAAV viral particles, in addition to or in place of therapeutic transgenes or nucleic acids encoding the AAV VP2 fusion polypeptide disclosed herein.

[0029] As used herein, the term "barcode sequence" refers to a unique oligonucleotide sequence (e.g., 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 50, 75, or 100 nucleotides) that is used as a means of identifying the nucleic acid sequence in which it is incorporated. For example, barcodes can be used as a means of distinguishing or identifying individual members (e.g., variants) in a library.

[0030] A DNA sequence or DNA polynucleotide sequence that “encodes” a specific RNA is a DNA sequence capable of being transcribed into RNA. DNA polynucleotides can encode RNA (mRNA) that is translated into protein, or they can encode RNA that is not translated into protein (e.g., tRNA, rRNA, or guide RNA; also known as “non-coding” RNA or “ncRNA”). DNA sequences or DNA polynucleotide sequences can also “encode” specific polypeptide or protein sequences, where, for example, DNA directly encodes mRNA that can be translated into a polypeptide or protein sequence. A “protein-coding sequence,” or a sequence that encodes a specific protein or polypeptide, is a nucleic acid sequence capable of being transcribed into mRNA (in the case of DNA) and translated (in the case of mRNA) into a polypeptide in vitro or in vivo when placed under the control of appropriate regulatory sequences. The boundaries of a coding sequence can be determined by a start codon at the 5' end (N-terminus) and a translation-terminating nonsense codon at the 3' end (C-terminus). Coding sequences can include, but are not limited to, cDNA from prokaryotic or eukaryotic mRNA, genomic DNA sequences from prokaryotic or eukaryotic DNA, and synthetic nucleic acids. The transcription termination sequence will typically be located at the 3' end of the coding sequence.

[0031] As used herein, the term "promoter" or "promoter sequence" is a DNA regulatory sequence capable of promoting transcription of operatively linked coding or non-coding sequences (e.g., downstream (3' direction) coding or non-coding sequences) by binding to RNA polymerase (e.g., capable of inducing detectable levels of transcription and / or increasing detectable levels of transcription (relative to levels provided in the absence of a promoter)). In some embodiments, the promoter sequence is bounded at its 3' end to a transcription start site and extends upstream (5' direction) to include a minimum number of bases or elements to initiate detectable levels of transcription above background. In some embodiments, the promoter sequence may include a transcription start site and a protein-binding domain responsible for binding to RNA polymerase. In addition to a sequence sufficient to initiate transcription, a promoter may also include sequences of other regulatory elements (e.g., enhancers, cozak sequences, and introns) involved in regulating transcription. Various promoters, including inducible and constitutive promoters, can be used to drive expression of vectors disclosed herein. Examples of promoters known in the art that can be used in some embodiments (e.g., in the nucleic acid molecules and vectors disclosed herein) include the CMV promoter, 173CMV promoter, HCMV promoter, CBh promoter, CAG promoter, mCCT promoter, CBA promoter, smCBA promoter, and those derived from immunoglobulin genes, SV40, or other tissue-specific genes (e.g., RLBP1, RPE, VMD2). Furthermore, standard techniques for generating functional promoters by mixing and matching known regulatory elements are known in the art. Fragments of promoters, such as those retaining at least a minimum number of bases or elements to initiate transcription at detectable levels above background, may also be used.

[0032] In some embodiments, the promoter may be a constitutively active promoter (i.e., a promoter that is constitutively driven to express in any cell type and / or under any conditions). In other embodiments, the promoter may be a constitutively active promoter in a specific tissue setting (e.g., in neurons, cardiomyocytes, etc.). In other embodiments, the promoter may be an inducible promoter (i.e., a promoter whose activity is controlled by an external stimulus (e.g., the presence of a specific temperature, compound, or protein). In some embodiments, the promoter may be a spatially restricted promoter, which may or may not drive activity depending on the physical environment in which the promoter is located. Non-limiting examples of spatially restricted promoters include tissue-specific promoters, cell-type-specific promoters, etc. In some embodiments, the promoter may be a time-restricted promoter, which drives expression depending on the temporal context in which the promoter is located. For example, a time-restricted promoter may drive expression only during a specific stage of embryonic development or a specific stage of a biological process. Non-limiting examples of time-restricted promoters include the hair follicle cycle promoter in mice.

[0033] In some embodiments, the promoter is tissue-specific, such that in a multicellular organism, the promoter drives expression only in a subset of specific cells. For example, tissue-specific promoters include, but are not limited to, neuron-specific promoters, adipocyte-specific promoters, cardiomyocyte-specific promoters, smooth muscle-specific promoters, photoreceptor-specific promoters, etc. A neuron-specific promoter is one that, when applied, for example, peripherally directly to the central nervous system (CNS) or delivered to neuronal cells (including in vitro, ex vivo, or in vivo), preferentially drives or regulates the expression of heterologous nucleic acids (e.g., heterologous nucleic acids encoding a target protein or peptide or shRNA) operatively linked in neurons, compared to expression in non-neuronal cells.

[0034] The term "operably linked" refers to a functional relationship between two or more segments of a polynucleotide (e.g., DNA). Typically, this term refers to the functional relationship between a transcriptional regulatory sequence and a sequence to be transcribed. For example, if a promoter or enhancer sequence stimulates or regulates the transcription of a coding sequence, for example, in a suitable host cell or other expression system, it is operably linked to the coding sequence. Usually, the promoter transcriptional regulatory sequence operably linked to the sequence is adjacent to or separated from the sequence by short spacer sequences; that is, they are cis-acting. However, some transcriptional regulatory sequences (such as enhancers) do not need to be physically adjacent to or located extremely close to the coding sequence that they enhance the transcription of.

[0035] The terms “DNA regulatory sequence,” “control element,” and “regulatory element,” which may be used interchangeably herein, refer to transcriptional and translational control sequences that provide and / or regulate the transcription of non-coding sequences (e.g., short hairpin RNA) or coding sequences (e.g., transgenes) and / or regulate the translation of encoded polypeptides, such as promoters, enhancers, silencers, polyadenylation signals, terminators, protein degradation signals, etc.

[0036] The terms "polyadenylation (polyA) signal sequence" and "polyadenylation sequence" refer to regulatory elements that provide signaling for transcription termination and the addition of adenosine homopolymers to the 3' end of RNA transcripts. Polyadenylation signals may include termination signals (e.g., AAUAAA sequences or other non-canonical sequences) and optionally side-attached auxiliary elements (e.g., GU-rich elements) and / or other elements associated with efficient cleavage and polyadenylation. Polyadenylation sequences may comprise a series of adenosines attached to the 3' end of mRNA via polyadenylation. Exemplary polyA signal sequences are the BGH and SV40 polyA signal sequences. In some embodiments, the DNA regulatory sequence or control element is a tissue-specific regulatory sequence.

[0037] The term "post-transcriptional regulatory element" ("PRE") refers to one or more regulatory elements that regulate gene expression at the mRNA transcriptional level when transcribed into mRNA. Examples of such PREs may include sequences encoding microRNA binding sites, RNA-binding protein binding sites, etc. Examples of PREs that can be used with the nucleic acid molecules and vectors disclosed herein include the marmot hepatitis virus post-transcriptional regulatory element (WPRE) and the hepatitis virus post-transcriptional regulatory element (HPRE).

[0038] The term "intron" refers to one or more nucleic acid sequences (e.g., those within an open reading frame) that do not encode one or more amino acids of a polypeptide transcript (e.g., a target protein) expressed from the nucleic acid. Intron sequences can be transcribed from DNA into RNA (i.e., can be present in pre-mRNA), but can be removed, for example, by splicing, before the protein is expressed from mature mRNA.

[0039] The term "exon" refers to one or more nucleic acid sequences (e.g., those within an open reading frame (ORF)) that encode one or more amino acids of a transcript (e.g., a target protein) expressed from the nucleic acid. Exon sequences can be transcribed from DNA into RNA (i.e., can be present in pre-mRNA) and can also be present in mature mRNA translated into a polypeptide (i.e., a processed form of RNA (e.g., after splicing)).

[0040] In some embodiments, a “vector” is any genetic element (e.g., DNA, RNA, or a mixture thereof) containing a target nucleic acid (e.g., a transgene) capable of expression in a host cell (e.g., a target nucleic acid within a larger nucleic acid sequence or structure suitable for delivery into a cell, tissue, and / or organism), such as plasmids, bacteriophages, transposons, granules, chromosomes, viruses, viral particles, etc. For example, a vector may contain an insert (e.g., a heterologous nucleic acid containing a transgene encoding a gene to be expressed or an open reading frame of that gene) and one or more additional elements suitable for delivery or controlling the expression of the insert. For example, when associated with appropriate control elements, a vector may be capable of replication and / or expression, and it may be capable of transferring genetic information between cells. In some embodiments, a vector may be a vector suitable for expression in a host cell, such as an AAV vector. In some embodiments, a vector may be a plasmid suitable for expression and / or replication, for example, in a cell or bioreactor. In some embodiments, a vector specifically designed for expressing a heterologous nucleic acid sequence (e.g., a transgene encoding a target protein, shRNA, etc.) in a target cell may be referred to as an expression vector and typically has a promoter sequence driving transgene expression. In other embodiments, vectors (e.g., transcription vectors) may be able to transcribe but not translate, meaning they can replicate but not be expressed in target cells. Transcription vectors can be used to amplify their inserts.

[0041] The term "expression vector" refers to a vector containing a polynucleotide that includes an expression control sequence operatively linked to the nucleotide sequence to be expressed. Expression vectors may contain sufficient cis-acting elements for expression, either alone or in combination with other expression elements provided by a host cell or in an in vitro expression system. Expression vectors include, for example, clomids, plasmids (e.g., naked or contained in liposomes) and viruses (e.g., lentiviruses, retroviruses, adenoviruses, and adeno-associated viruses) incorporating recombinant polynucleotides.

[0042] The term "plasmid" refers to a non-chromosomal (and typically double-stranded) DNA sequence containing a complete "replicon" that allows the plasmid to replicate within a host cell. Plasmids can be circular nucleic acids. When a plasmid is placed in a single-celled organism, the organism's characteristics are altered or transformed due to the plasmid's DNA. For example, a plasmid carrying a tetracycline resistance (TcR) gene can convert previously tetracycline-sensitive cells into cells resistant to it.

[0043] As used herein, the term "recombinant virus" is intended to refer to a non-wild-type and / or artificially generated recombinant virus (e.g., parvovirus, adenovirus, lentivirus, or adeno-associated virus, etc.) containing a transgene or other heterologous nucleic acid. A recombinant virus may contain a recombinant viral vector (e.g., containing a transgene) packaged within a viral (e.g., AAV) capsid. A specific type of recombinant virus may be "recombinant adeno-associated virus" or "rAAV". The recombinant viral genome packaged within the viral capsid may be a viral vector. In some embodiments, the recombinant viruses disclosed herein contain a viral vector (e.g., containing a target transgene, such as as described herein). Examples of viral vectors include, but are not limited to, adeno-associated virus (AAV) vectors, chimeric AAV vectors, adenovirus vectors, retroviral vectors, lentiviral vectors, DNA viral vectors, herpes simplex virus vectors, baculovirus vectors, or any mutants or derivatives thereof.

[0044] "AAV" is an abbreviation for adeno-associated virus and can be used to refer to the virus itself or its derivatives. Unless otherwise explicitly stated, the term covers all subtypes as well as both naturally occurring and recombinant forms. The term "rAAV" refers to recombinant adeno-associated virus or recombinant AAV vector.

[0045] As used herein, the term "AAV vector" refers to a vector derived from an adeno-associated virus serotype or a vector containing one or more nucleic acid sequences derived from an adeno-associated virus serotype, including, but not limited to, AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV.5 virus vectors. An AAV vector may have one or more AAV wild-type genes, such as the rep and / or cap genes, either wholly or partially deleted, while retaining, for example, functional inverted terminal repeat ("ITR") sequences. In some embodiments, the AAV vector may be packaged in a protein coat or "capsid," for example, containing one or more AAV capsid proteins, which can provide a medium for delivering the vector nucleic acid to the nucleus of a target cell. In some embodiments, the AAV vector contains one or more AAV ITR sequences (e.g., AAV2 ITR sequences). In some embodiments, the AAV vector contains one or more AAV ITR sequences (e.g., AAV2 ITR sequences) but does not contain any other viral nucleic acid sequences. In some embodiments, the AAV vector component (e.g., ITR) is derived from a serotype of virus different from the rAAV capsid (e.g., the AAV vector may contain an ITR derived from AAV2, and the AAV vector may be packaged into an AAV9 capsid). Examples of these vector constructs are provided, for example, in WO 2019 / 094253 (PCT / US2018 / 058744), which is incorporated herein by reference in its entirety.

[0046] rAAV vectors include single-stranded AAV vectors and self-complementary AAV vectors (scAAV). scAAV is referred to as "self-complementary" because at least a portion of the scAAV vector (e.g., at least a portion of the coding region) forms an intramolecular double-stranded DNA. In some embodiments, rAAV is scAAV. In other embodiments, rAAV is single-stranded AAV. In some embodiments, viral vectors are engineered from naturally occurring adeno-associated virus (AAV) to provide scAAV for gene therapy. Examples of these vector constructs and methods for their preparation and purification are provided, for example, in WO 2019 / 094253 (PCT / US2018 / 058744), which is incorporated herein by reference in its entirety.

[0047] As used herein, "virus" or "viral particle" refers to a viral particle that contains a viral vector (e.g., alone or in combination with one or more other components, such as one or more viral capsids). For example, an AAV virus may contain, for example, a linear single-stranded AAV nucleic acid genome associated with an AAV capsid protein shell.

[0048] In some embodiments, terms such as “virus,” “viral particle,” “AAV virus,” “recombinant AAV viral particle,” “rAAV viral particle,” “AAV vector particle,” “intact capsid,” “intact particle,” etc., refer to infectious, replication-defective viruses, such as those containing an AAV protein coat that encapsulates a target heteronucleotide sequence in a viral vector, for example, with an AAV ITR attached to one or both sides. rAAV viral particles can be generated in suitable host cells and contain a sequence of a designated AAV vector, such as one or more plasmids, either alone or in combination with nucleic acids encoding AAV auxiliary and accessory functions (such as rep and cap genes). In some embodiments, the host cell is enabled to encode an AAV polypeptide for packaging an AAV vector (containing the target recombinant nucleotide sequence) into an infectious recombinant viral particle for subsequent gene delivery.

[0049] "Packaging" refers to a series of intracellular events that lead to the assembly of AAV viral particles or AAV particles that encapsulate a nucleic acid sequence. Packaging can also refer to the encapsulation of a nucleic acid sequence into a capsid containing the AAV VP2 fusion polypeptide disclosed herein.

[0050] "Infectious" viral particles, viruses, or viral particles are viral particles, viruses, or viral particles that contain a polynucleotide component that can be delivered to cells tropism for a viral species. This term does not necessarily preclude any conclusions regarding the viral replication capacity. As used herein, an "infectious" virus or viral particle is a virus or viral particle that, upon approaching a target cell, can infect the target cell and can express heterologous nucleic acids within the target cell. Therefore, "infectivity" refers to the ability of a viral particle to approach a target cell, infect the target cell, and express heterologous nucleic acids within the target cell. Infectivity can refer to in vitro or in vivo infectivity. Assays for counting infectious viral particles are well known in the art. Viral infectivity can be expressed as the ratio of infectious viral particles to total viral particles. Total viral particles can be expressed as the viral genome copy number. The ability of viral particles to express heterologous nucleic acids in cells can be referred to as "transduction." Many techniques can be used to determine the ability of viral particles to express heterologous nucleic acids in cells. These techniques include assessing marker genes, such as green fluorescent protein (GFP) assays (e.g., where the virus contains a nucleotide sequence encoding GFP), where GFP is produced in cells infected with viral particles and is detected and / or measured; or measuring the produced proteins, for example by enzyme-linked immunosorbent assay (ELISA) or fluorescence-activated cell sorting (FACS).

[0051] A “replicating” viral particle or virus (e.g., a replicating AAV) is an infectious virus that can replicate in infected cells (i.e., in the presence of helper viruses or helper virus function). In the case of AAV, replication capability typically requires the presence of functional AAV packaging genes, namely the cap and rep genes. In some embodiments, as described herein, the AAV vector lacks one or more AAV packaging genes and is non-replicating in mammalian cells (such as human cells). In some embodiments, the AAV vector lacks any AAV packaging gene sequence to minimize the possibility of generating a replicating AAV through recombination between the AAV packaging genes and the AAV vector.

[0052] The term "inverted terminal repeat" or "ITR" refers to a nucleotide sequence that can form a T-shaped palindrome, for example, in adeno-associated virus (AAV) and / or recombinant adeno-associated virus vectors (rAAV). (Muzyczka et al., (2001) Fields Virology, Chapter 29, Lippincott Williams & Wilkins). In recombinant AAV vectors, these sequences can play a functional role in genome packaging and second-strand synthesis. In some embodiments, the AAV vector contains one or more mutated or truncated ITRs.

[0053] The term "cap gene" or "capsid gene" refers to a nucleic acid sequence that encodes or contributes to the formation of the viral capsid or protein coat. In the case of AAV, the capsid proteins are typically VP1, VP2, and VP3. For other parvoviruses, the names and numbers of capsid proteins may differ. As used herein, the terms "AAV VP1 capsid polypeptide," "AAV VP2 capsid polypeptide," and "AAV VP3 capsid polypeptide" include wild-type AAV capsid polypeptides and their variants and fragments, particularly their functional variants and fragments. Functional AAV capsid polypeptide variants and fragments can be used in AAV capsid assembly.

[0054] The term "rep gene" refers to the nucleic acid sequence that encodes the non-structural proteins (rep78, rep68, rep52, and rep40) required for AAV replication and production.

[0055] The term "AAV helper function" refers to an AAV-derived coding sequence that can be expressed to provide an AAV gene product, such as those that function in trans form for productive AAV replication. For example, AAV helper functions can include two main AAV open reading frames (ORFs): rep and cap. Rep expression products have been shown to have numerous functions, including, in particular: recognition, binding, and cleavage of AAV DNA replication origins; DNA helicase activity; and regulation of transcription from AAV (or other heterologous) promoters. Cap expression products provide essential packaging functions. In this paper, AAV helper functions can be used to trans-complement AAV functions missing in AAV vectors.

[0056] The term "AAV helper construct" generally refers to a nucleic acid molecule containing nucleotide sequences that provide or encode proteins or nucleic acids that provide AAV functionality missing from AAV vectors (e.g., vectors used to deliver target nucleotide sequences into target cells or tissues). AAV helpers are typically used to provide transient expression of the AAV rep and / or cap genes to complement the AAV functionality missing during AAV replication. Typically, helpers lack AAV ITRs and cannot replicate or package themselves. AAV helpers can be in the form of plasmids, phages, transposons, granules, viruses, or viral particles. Many AAV helpers have been disclosed, such as the commonly used plasmids pAAV / Ad and plM29+45, which encode both Rep and Cap expression products. See, for example, Samulski et al., (1989) J. Virol. [Journal of Virology], 63:3822-3828; McCarty et al., (1991) J. Virol. [Journal of Virology], 65:2936-2945. Many other vectors encoding Rep and / or Cap expression products have been disclosed. See, for example, U.S. Patent Nos. 5,139,941 and 6,376,237. Examples of these vector constructs and methods for their preparation and purification are provided, for example, in WO 2019 / 094253 (PCT / US 2018 / 058744), which is incorporated herein by reference in its entirety.

[0057] The term "helper virus" for AAV refers to a virus that allows AAV to replicate and be packaged in mammalian cells. Many such helper viruses for AAV are known in the art, including adenoviruses, herpesviruses, and poxviruses (such as cowpox). Adenoviruses encompass many different subgroups, although subgroup C5 adenovirus is the most commonly used as a helper virus.

[0058] The term "one or more helper viral functions" refers to one or more functions encoded in the helper virus genome that allow AAV to replicate and be packaged in mammalian cells. Helper viral functions include, for example, adenovirus helper functions. Such helper viral functions can be provided in a number of ways, including by providing a helper virus or by providing, during AAV manufacturing, a nucleic acid sequence encoding one or more desired functions to the producer host cell.

[0059] The terms “tropism” and “transduction” are related but distinct. As used herein, “tropism” refers to the ability of an AAV vector or viral particle to infect one or more specified cell types, but can also encompass how the vector functions to transduce cells in one or more specified cell types; that is, tropism refers to the preferential entry of an AAV vector or viral particle into one or more cell or tissue types and / or preferential interaction with the cell surface, which facilitates entry into certain cell or tissue types, optionally and preferably subsequently expressed (e.g., transcribed and optionally translated) in the cell of a sequence carried by the AAV vector or viral particle, such as, for recombinant viruses, expression of one or more heterologous nucleotide sequences. As used herein, the term “transduction” refers to the ability of an AAV vector or viral particle to infect one or more specific cell types; that is, transduction refers to the entry of an AAV vector or viral particle into a cell and the transfer of the genetic material contained within the AAV vector or viral particle into the cell to achieve expression of the vector genome. In some, but not all, cases, transduction and tropism may be related.

[0060] As used herein, the term "tropism spectrum" refers to the transduction pattern of one or more target cells, tissues, and / or organs. Different AAV serotypes exhibit deviated tropism spectra, and tropism can be altered, for example, through capsid engineering.

[0061] The term "host cell" refers to a cell containing the target exogenous nucleic acid, such as one or more microbial, yeast, insect, or mammalian cells. For example, a host cell may contain AAV helper constructs, AAV vector plasmids, accompanying functional vectors, and / or other transfer DNA. The term includes the progeny of a transfected original cell. Due to natural, accidental, or intentional mutations, the progeny of a single parent cell may not necessarily be identical to the original parent in terms of morphology, genome, or total DNA complementarity.

[0062] As used herein, the term "cell line" refers to a population of cells capable of continuing or prolonging growth and division in vitro. In some cases, spontaneous or induced changes in karyotype may occur during the storage or transfer of such clonal populations. Therefore, cells derived from the cell lines mentioned may not be identical to the ancestral cells or cultures, and the cell lines mentioned may contain such variants.

[0063] The term "transfection" is used to refer to the uptake of foreign DNA by cells, meaning that once the foreign DNA has been introduced into the inner cell membrane, the cell is considered "transfected." See, for example, Graham et al., (1973) Virology, 52:456; Sambrook et al., (1989) Molecular Cloning, a laboratory manual, Cold Spring Harbor Laboratories, New York; Davis et al., (1986) Basic Methods in Molecular Biology, Elsevier; Chu et al., (1981) Gene, 13:197. Such techniques can be used to introduce one or more portions of foreign DNA into a suitable host cell. In some embodiments, the term "transduction" is used to refer to the uptake of foreign DNA by cells, where the foreign DNA is provided by a virus or viral vector. Thus, the cell is considered "transduced" once the foreign DNA has been introduced into the inner cell membrane. In some embodiments, the term "conversion" is used to refer to the uptake of foreign DNA by bacterial cells.

[0064] As used herein, the term "antibody" refers to a protein or polypeptide sequence derived from an immunoglobulin molecule that specifically binds to an antigen. Antibodies can be polyclonal or monoclonal, multi-chain or single-chain, or intact immunoglobulins, and can be derived from natural or recombinant sources. Naturally occurring "antibodies" are glycoproteins comprising at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds. Each heavy chain consists of a heavy chain variable region (abbreviated as VH) and a heavy chain constant region. The heavy chain constant region consists of three domains (CH1, CH2, and CH3). Each light chain consists of a light chain variable region (abbreviated as VL) and a light chain constant region. The light chain constant region consists of one domain (CL). The VH and VL regions can be further subdivided into hypervariable regions called complementarity-determining regions (CDRs), and scattered with more conserved regions called framework regions (FRs). Each VH and VL consists of three CDRs and four FRs arranged in the following order from the amino terminus to the carboxyl terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain binding domains that interact with the antigen. The constant regions of the antibody can mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. Antibodies can be, but are not limited to, monoclonal antibodies, human antibodies, humanized antibodies, camel-derived antibodies, or chimeric antibodies. Antibodies can belong to any isotype (e.g., IgG, IgE, IgM, IgD, IgA, and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2), or subclass. Throughout this document, unless the context otherwise indicates, the term "antibody" or "antibody molecule" also includes any fragment thereof and any derivative thereof.

[0065] The term "antibody fragment" or "antigen-binding fragment" refers to at least a portion of an antibody that retains the ability to specifically interact with an antigenic epitope (e.g., through binding, steric hindrance, stabilization / destabilization, spatial distribution). Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv fragments, scFv antibody fragments, disulfide-linked Fv (sdFv), Fd fragments consisting of VH and CH1 domains, linear antibodies, single-domain antibodies such as sdAb (VL or VH), Camelidae VHH domains, multispecific antibodies formed from antibody fragments (such as bivalent fragments containing two Fab fragments linked by a disulfide bridge in the hinge region), and isolated CDRs or other epitope-binding fragments of antibodies. Antigen-binding fragments can also be incorporated into single-domain antibodies, macrobodies, minibodies, nanobodies, intracellular antibodies, bisomal antibodies, tripoisome antibodies, tetrasomal antibodies, v-NARs, and bis-scFvs (see, for example, Hollinger and Hudson, Nature Biotechnology 23:1126-1136, 2005). Antigen-binding fragments can also be grafted into peptide-based scaffolds such as fibronectin type III (Fn3) (see U.S. Patent No. 6,703,199, which describes fibronectin peptide microantibodies). The term "scFv" refers to a fusion protein comprising at least one antibody fragment containing a light chain variable region and at least one antibody fragment containing a heavy chain variable region, wherein the light and heavy chain variable regions are sequentially linked, for example, via a synthetic linker (e.g., a short flexible peptide linker) and are capable of being expressed as a single-chain peptide, and wherein the scFv retains the specificity of the complete antibody from which it is derived. Unless otherwise stated, as used herein, scFv may have VL and VH variable regions in any order relative to the N-terminus and C-terminus of the polypeptide, and scFv may contain VL-connector-VH or may contain VH-connector-VL.

[0066] As used herein, the term “complementarity-determining region” or “CDR” refers to the amino acid sequence within the variable region of an antibody that confers antigen specificity and binding affinity. For example, generally, there are three CDRs (e.g., HCDR1, HCDR2, and HCDR3) in each heavy chain variable region and three CDRs (LCDR1, LCDR2, and LCDR3) in each light chain variable region. The precise amino acid sequence boundaries of a given CDR can be determined using any of many well-known schemes, including those described in the following literature: Kabat et al. (1991), “Sequences of Proteins of Immunological Interest”, 5th edition, Public Health Service, National Institutes of Health, Bethesda, Maryland (“Kabat” numbering scheme); Al-Lazikani et al. (1997) JMB (Journal of Microbiology and Biotechnology) 273, 927-948 (“Chothia” numbering scheme), or combinations thereof, and Immunogenetics (IMGT) numbering (Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol., 27, 55-77 (2003); Lefranc et al., (2015) Nucleic Acids Res., 43, D413-422 (“IMGT” numbering scheme). In the combined Kabat and Josiah numbering schemes for a given CDR region (e.g., HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, or LCDR3), in some embodiments, the CDR corresponds to amino acid residues defined as part of a Kabat CDR and amino acid residues defined as part of a Josiah CDR. As used herein, a CDR defined according to the “Josiah” numbering scheme is sometimes also referred to as a “hypervariant ring”. According to IMGT, the CDR region of an antibody can be determined using the procedure IMGT / DomainGap Align. Generally, unless otherwise specified, antibody molecules may contain any combination of one or more Cabart CDRs and / or Josiah CDRs.

[0067] The term "epitope" refers to any protein determinant capable of specifically binding to immunoglobulins or otherwise interacting with molecules. Epitope determinants typically consist of chemically active surface groups of a molecule (such as amino acids or carbohydrate or sugar side chains) and may possess specific three-dimensional structural features as well as specific charge characteristics. Epitopes can be "linear" or "conformal." The difference between conformational and linear epitopes lies, for example, in the loss of binding to the former (rather than the latter) in the presence of denaturing solvents.

[0068] As used herein, the phrase "monoclonal antibody" or "monoclonal antibody composition" refers to polypeptides having substantially the same amino acid sequence or originating from the same genetic source, including antibodies, bispecific antibodies, etc. This term also includes formulations of antibody molecules having a single molecular composition. Monoclonal antibody compositions exhibit single binding specificity and affinity for a specific epitope.

[0069] As used herein, the phrase “human antibody” includes antibodies with variable regions, wherein both the frame region and the CDR region are derived from human-derived sequences. Constant regions are also derived from human sequences (e.g., human germline sequences or mutant forms of human germline sequences), or antibodies containing common frame sequences derived from human frame sequence analysis, such as those described in Knappik et al. (2000. J MolBiol [Journal of Molecular Biology] 296, 57-86). The structure and location of immunoglobulin variable domains (e.g., CDRs) can be defined using well-known numbering schemes, such as the Kabat numbering scheme, the Josiah numbering scheme, or a combination of Kabat and Josiah, and immunogenetic (IMGT) numbering (see, for example, Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services (1991), edited by Kabat et al.; Al Lazikani et al., (1997) J. Mol. Bio. 273:927-948; Kabat et al., (1991) Sequences of Proteins of Immunological Interest, 5th edition, NIH Publication No. 91-3242 U.S. Department of Health and Human Services). Services [US Department of Health and Human Services]; Chothia et al., (1987) J. Mol. Biol. [Journal of Molecular Biology] 196:901-917; Chothia et al., (1989) Nature [Nature] 342:877-883; and Al-Lazikani et al., (1997) J. Mal. Biol. [Journal of Molecular Biology] 273:927-948; Lefranc, M.-P., The Immunologist, 7, 132-136 (1999); Lefranc, M.-P. et al., Dev. Comp. Immunol. [Developmental and Comparative Immunology], 27, 55-77 (2003); Lefranc et al., (2015) Nucleic Acids Res. [Nucleic Acids Research] 43, D413-422).

[0070] Human antibodies may contain amino acid residues that are not encoded by human sequences (e.g., mutations introduced through random or site-specific mutagenesis in vitro or through somatic mutations or conserved substitutions in vivo to promote stability or manufacture). However, as used herein, the term "human antibody" is not intended to include antibodies whose CDR sequences derived from a lineage of another mammalian species, such as mice, have been grafted onto human frame sequences.

[0071] As used herein, the phrase "recombinant antibody" includes all antibodies prepared, expressed, generated, or isolated by recombinant means, and includes recombinant human antibodies, such as antibodies isolated from transgenic or transchromosomally modified animals (e.g., mice) or hybridomas prepared therefrom; antibodies isolated from host cells transformed to express human antibodies (e.g., from transfected tumors); antibodies isolated from recombinant, combined human antibody libraries; and antibodies prepared, expressed, generated, or isolated by any other means involving splicing all or part of the human immunoglobulin gene or sequence into other DNA sequences. Such recombinant human antibodies have variable regions, wherein the framework region and CDR region are derived from human germline immunoglobulin sequences. However, in some embodiments, such recombinant human antibodies may be mutagenized in vitro (or in vivo somatic cell mutagenized when using animals transgenic for human Ig sequences), and therefore the amino acid sequences of the VH and VL regions of the recombinant antibody are sequences that, although derived from and associated with human germline VH and VL sequences, may not naturally exist in an in vivo human antibody germline library.

[0072] As used herein, the term "affinity" refers to the strength of the interaction between an antibody and an antigen at a single antigenic site. Within each antigenic site, the variable region of the antibody interacts with the antigen at many sites via weak non-covalent forces; the more interactions, the stronger the affinity. As used herein, the term "high affinity" for IgG antibodies or fragments thereof (e.g., Fab fragments) refers to an antibody having an affinity of 10⁻⁸ M or less, 10⁻⁹ M or less, or 10⁻¹⁰ M, or 10⁻¹¹ M or less, or 10⁻¹² M or less, or 10⁻¹³ M or less for the target antigen. However, high affinity binding can vary for other antibody isotypes. For example, "high affinity" binding for IgM isotypes refers to an antibody having an affinity of 10⁻⁷ M or less, or 10⁻⁸ M or less.

[0073] As used herein, the terms "binding specificity" or "specific binding" refer to the ability of a single antibody binding site to react with one antigenic determinant and not with different antigenic determinants. The antibody binding site is located in the Fab portion of the molecule and is constructed from hypervariable regions of the heavy and light chains. Antibody binding affinity is the intensity of the reaction between a single antigenic determinant and a single binding site on the antibody. It is the sum of attractive and repulsive forces acting between the antigenic determinant and the antibody binding site.

[0074] The terms "treat" and "treatment" refer to therapeutic treatment in which the aim is to alleviate undesirable physiological changes or impairments. For the purposes of this invention, beneficial or desired clinical outcomes include, but are not limited to, relief of symptoms, reduction of disease severity, stabilization of the disease state (i.e., no worsening), delay or slowing of disease progression, improvement or mitigation of the disease state, and remission (whether partial or complete), whether detectable or undetectable. "Treatment" can also mean extended survival compared to expected survival without treatment.

[0075] The terms “prevention,” “prevent,” and “preventing” for any particular disease or disorder refer to prophylactic or preventive measures, such as administering the compound of the invention to a subject prior to the onset of any symptoms of the disease or disorder.

[0076] The term "subject" refers to an animal (human or non-human) to which the treatment according to the method of the invention is provided. Both veterinary and non-veterinary applications are considered. The term includes, but is not limited to, mammals such as humans, other primates, pigs, rodents (such as mice and rats), rabbits, guinea pigs, hamsters, cattle, horses, cats, dogs, sheep, and goats. Typical subjects include humans, farm animals, and domestic pets (such as cats and dogs). In some preferred embodiments, the subject is a human.

[0077] The terms “pharmaceutically acceptable” and “physiologically acceptable” are used interchangeably herein and refer to a biologically acceptable formulation (gas, liquid, or solid) suitable for one or more routes of administration, in vivo delivery, or contact. A “pharmaceutically acceptable” or “physiologically acceptable” composition is a material that is not biologically or otherwise undesirable, for example, a material that can be administered to a subject without causing substantially undesirable biological effects. Therefore, such a pharmaceutical composition can be used, for example, to administer to a subject rAAV viral particles as disclosed herein.

[0078] "Effective amount" refers to an amount sufficient to achieve a beneficial or desired outcome. For example, a therapeutic amount is an amount that achieves the desired therapeutic effect. This amount may be the same as or different from a preventive effective amount, which is the amount required to prevent the onset of disease or disease symptoms. An effective amount may be administered in one or more applications, by application, or by one or more doses. The "therapeutic effective amount" (i.e., effective dose) of a therapeutic compound depends on the therapeutic compound selected. The composition may be administered once or more daily to once or more weekly; including every other day. Those skilled in the art will understand that certain factors may affect the dose and duration required to effectively treat a subject, including but not limited to the severity of the disease or disorder, prior treatment, the subject's general health condition and / or age, and any other pre-existing conditions. Furthermore, treatment of a subject with a therapeutically effective amount of the therapeutic compound described herein may include a single treatment or a series of treatments.

[0079] As used herein, “in vitro” processes refer to processes performed outside of normal biological environments, such as studies conducted in test tubes, flasks, petri dishes, or artificial culture media. “In vivo” processes refer to processes performed within living organisms or cells, such as studies conducted in cell cultures or mice. “Ex vivo” studies refer to studies conducted in or on tissues derived from an organism in an external environment (e.g., with minimal alteration to natural conditions), such as studies that allow manipulation of the organism’s cells or tissues under more controlled conditions than in vivo experiments.

[0080] As used in this article, the term "library" refers to multiple (i.e., at least two) different variants of linear nucleic acids, plasmids, viral particles, or viral vectors.

[0081] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains. While similar or equivalent methods and materials may be used to practice this invention, suitable methods and materials are described below. All publications, patent applications, patents, and other references mentioned herein are incorporated herein by reference in their entirety. In case of conflict, this specification, including the definitions, shall prevail. Furthermore, materials, methods, and examples are illustrative only and not intended to be limiting.

[0082] Details of one or more embodiments of the present invention are set forth in the accompanying drawings and the description below. Other features, objectives, and advantages of the invention will become apparent from the specification, the drawings, and the claims.

[0083] AAV VP2 fusion peptide

[0084] This article provides AAV VP2 fusion peptides comprising a peptide ligand, optionally a peptide linker, and an AAV VP2 capsid peptide from the N-terminus to the C-terminus. rAAV viral particles containing said AAV VP2 fusion peptides and exhibiting the peptide ligand on their surface can be used for cell-type-specific gene delivery during both therapeutic and basic research applications because they provide high cell-type selectivity and / or high targeting specificity, allowing for efficient biodistribution and safe gene transfer.

[0085] When typically used in conjunction with AAV VP1 and / or VP3 capsid peptides for rAAV virus particle assembly, AAV VP2 fusion peptides exhibit good levels of decoration, meaning that a satisfactory number of AAV VP2 fusion peptides are incorporated into rAAV virus particles. Surprisingly, good levels of decoration were found to be achieved by fusing peptide ligands with N-terminus of the AAV VP2 capsid peptide to a peptide with a molecular weight up to 10 kDa. AAV VP2 fusion peptides containing N-terminally targeted peptide ligands with molecular weights higher than 10 kDa showed reduced levels of decoration. AAV VP2 fusion peptides containing N-terminally targeted peptide ligands with molecular weights higher than 15 kDa (such as darpin with a molecular weight of approximately 18 kDa) showed little or no decoration. Unwilling to be bound by theory, it is believed that since the AAV VP2 capsid peptide is not essential for capsid assembly, providing an AAV VP2 capsid peptide with an unfavorable structure (such as an AAV VP2 fusion peptide containing a large polypeptide ligand) may result in the AAV VP2 capsid peptide not being used for capsid assembly, leading to rAAV virus particles having no or very low AAV VP2 fusion peptide decoration, consisting solely or primarily of AAV VP1 and VP3 capsid peptides.

[0086] Compared to an AAV VP2 capsid polypeptide that is not fused with the stated polypeptide ligand but is otherwise identical to the VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide, the AAV VP2 fusion polypeptide described herein can mediate improved transduction and / or increased tropism in at least one tissue or cell type. This improved transduction and / or increased tropism in at least one tissue or cell type can be mediated by a polypeptide ligand that has the ability to bind to a cell surface molecule expressed on at least one tissue or cell type. Suitable polypeptide ligands with a molecular weight below 10 kDa include, but are not limited to, GP2 and Sso7d ligands and their affinity derivatives.

[0087] This invention is based in part on incorporating highly diverse peptide ligand libraries (e.g., highly diverse Sso7d libraries) into rAAV viral particles by fusing them to the N-terminus of an AAV VP2 capsid peptide. This produces AAV libraries containing multiple rAAV viral particles, each containing an AAV VP2 fusion peptide within its capsid, and containing nucleic acids encoding the AAV VP2 fusion peptide encapsulated within the capsid. The AAV libraries exhibit high diversity and functional titers and can be used for in vivo selection of AAV VP2 fusion peptides with desired characteristics. This document provides AAV VP2 fusion peptides obtained by in vivo selective enrichment of highly transductive AAV capsids with specific cell types.

[0088] The AAV VP2 fusion peptides described in this article can be used to generate recombinant AAV vectors. These recombinant AAV vectors are suitable for delivering heterologous nucleic acids (such as therapeutic transgenes) into target cells.

[0089] Therefore, in one respect, this article provides adeno-associated virus (AAV) VP2 fusion peptides comprising an AAV VP2 capsid peptide and a peptide ligand. The peptide ligand is fused directly to or via a linker to the N-terminus of the AAV VP2 capsid peptide. The molecular weight of the peptide ligand is up to 10 kDa, including up to 9 kDa, up to 8 kDa, up to 6 kDa, or up to 5 kDa, for example from 3 to 10 kDa, from 4 to 8 kDa, or from 5 to 7 kDa.

[0090] In one aspect, this document provides an AAV VP2 fusion polypeptide comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide; and wherein the AAV VP2 capsid polypeptide contains one or more mutations that eliminate or reduce binding to heparan sulfate proteoglycan (HSPG) and / or sialic acid (SIA). In some embodiments, the polypeptide ligand has a molecular weight up to 10 kDa.

[0091] “AAV” is an abbreviation for adeno-associated virus and can be used to refer to the virus itself or its derivatives. Unless otherwise required, the term covers all subtypes, as well as both naturally occurring and recombinant forms. The term “AAV” includes, for example, AAV 1 (AAV1), AAV 2 (AAV2), AAV 3 (AAV3), AAV 4 (AAV4), AAV 5 (AAV5), AAV 6 (AAV6), AAV 7 (AAV7), AAV 8 (AAV8), AAV 9 (AAV9), AAV 10 (AAV10, including AAVrh10), AAV 12 (AAV12), avian AAV, bovine AAV, canine AAV, equine AAV, primate AAV, non-primate AAV, and sheep AAV. "Primate AAV" refers to AAV that infects primates, "Non-primate AAV" refers to AAV that infects non-primate mammals, "Bovine AAV" refers to AAV that infects bovine mammals, and so on.

[0092] The genomic sequences of various serotypes of AAV, as well as the sequences of the native inverted terminal repeats (ITRs), Rep protein, and capsid subunits, are known in the art. Such sequences are available in the literature or in public databases such as GenBank. See, for example, GenBank accession numbers NC-002077 (AAV1), AF063497 (AAV1), NC-001401 (AAV2), AF043303 (AAV2), NC-001729 (AAV3), NC-001829 (AAV4), U89790 (AAV4), NC-006152 (AAV5), AF513851 (AAV7), AF513852 (AAV8), and NC-006261 (AAV8); or disclosures such as WO 2005033321 (AAV1-9), the contents of which are incorporated herein by reference. See also, for example, Srivitava et al. (1983) J. Virology 45:555; Chiorini et al. (1998) J. Virology 71:6823; Chiorini et al. (1999) J. Virology 73:1309; Bantel-Schaal et al. (1999) J. Virology 73:939; Xiao et al. (1999) J. Virology Virology 73:3994; Muramatsu et al. (1996) Virology 221:208; Shade et al. (1986) J. Virol. 58:921; Gao et al. (2002) Proc. Nat. Acad. Sci. USA 99:11854; Moris et al. (2004) Virology 33:375-383; International Patent Publications WO 00 / 28061, WO 99 / 61601, WO 98 / 11244; and US Patent No. 6,156,303.

[0093] In some embodiments, the polypeptide ligand specifically binds to a cell surface molecule expressed on at least one tissue or cell type. In some embodiments, the AAV VP2 fusion polypeptide mediates increased transduction and / or increased tropism in at least one tissue or cell type, relative to an AAV VP2 capsid polypeptide that does not contain the polypeptide ligand but is otherwise identical to the VP2 capsid polypeptide contained in the AAVVP2 fusion polypeptide.

[0094] In some embodiments, transduction in at least one tissue or cell type is increased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%. In some embodiments, relative to an AAV VP2 capsid polypeptide that does not contain the peptide ligand but is otherwise identical to the VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide, the AAV VP2 fusion polypeptide mediates a transduction increase of at least 2-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 1000-fold, or more than 1000-fold in at least one tissue or cell type. In some embodiments, tropism in at least one tissue or cell type increases by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%.

[0095] In some embodiments, the AAV VP2 fusion peptide mediates increased transduction and / or increased tropism of the following cells: whole blood cells, brain cells, hepatocytes, spleen cells, kidney cells, skeletal muscle cells, heart cells, lung cells or bone marrow cells, or pluripotent progenitor cells (MPPs) (such as pluripotent hematopoietic progenitor cells), or hematopoietic stem cells (HSCs) (such as long-term hematopoietic stem cells (LT-HSCs)).

[0096] In one respect, this article provides AAV VP2 fusion peptides comprising an AAV VP2 capsid peptide and a peptide ligand, wherein the peptide ligand is fused directly or via a linker to the N-terminus of the AAV VP2 capsid peptide, and is selected from the group consisting of GP2 peptides, Sso7d peptides, and affinity peptides.

[0097] As used herein, the term "GP2 polypeptide" refers to a polypeptide scaffold derived from the 45-residue T7 phage gene 2 protein (GP2). This polypeptide contains an α-helix opposite the β-sheet and two adjacent loops suitable for mutation. Mutagenesis of this scaffold can produce high-affinity target-specific binders.

[0098] As used herein, the term "Sso7d polypeptide" refers to a polypeptide derived from the Sso7d protein of the hyperthermophilic archaea *Sulphozoa sulforaphata*. This protein is an attractive binding scaffold due to its small size (7 kDa), high thermal stability (Tm of 98 °C), and the absence of cysteine ​​and glycosylation sites. In some embodiments, the Sso7d polypeptide is derived from a charge-neutralized variant of the *Sulphozoa sulforaphata* Sso7d protein, particularly from the charge-reduced Sso7d (rcSso7d) variant described by Traxlmayr et al. (DOI 10.1074 / jbc.M116.741314). As used herein, Sso7d peptides also encompass peptides that have at least about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity in their full length with wild-type Sso7d or the rcSso7d variant described by Traxlmayr et al. (DOI 10.1074 / jbc.M116.741314).

[0099] In some embodiments, the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1 and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0100] In some embodiments, the polypeptide ligand is selected from the Sso7d polypeptide of SEQ ID NO:1, which optionally has up to 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions.

[0101] In some embodiments, the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y and W; and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0102] In some embodiments, the polypeptide ligand is selected from the Sso7d polypeptide of SEQ ID NO:1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y, W and amino acid substitutions, and wherein SEQ ID NO:1 optionally has up to 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitution.

[0103] In some embodiments, the AAV VP2 fusion peptide further comprises a peptide linker located between the peptide ligand and the AAV VP2 capsid peptide. In some embodiments, the peptide linker is selected from the group consisting of glycine-serine (GS) linkers and alanine-proline-serine (APS) linkers. The GS linker may, for example, have the formula [GGGGS]n, where n is an integer in the range of 1 to 10, for example where n is 1, 2, 3, 4, 5, or 6, particularly where n is 1, 2, 3, or 4. The APS linker may, for example, have the formula [APS]n, where n is an integer in the range of 1 to 10, for example where n is 1, 2, 3, 4, 5, or 6, particularly where n is 2, 3, 4, or 5.

[0104] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide has an AAV serotype selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV.5. In a specific embodiment, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide has an AAV serotype selected from the group consisting of: AAV1, AAV6, AAV8, and AAV9.

[0105] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide contains at least one mutation at at least one binding site of its natural receptor present on the target cell of the AAV viral particle containing the AAV VP2 capsid polypeptide. As used herein, the term “natural receptor” refers to, for example, heparan sulfate proteoglycan (HSPG), which has been shown to be the major cellular receptor for serotype 2 AAV; N-linked sialic acid proteoglycans, which have been shown to be the major cellular receptors for serotypes 1, 5, and 6 AAV; O-linked sialic acid proteoglycans, which have been shown to be the major cellular receptors for serotypes 4 and 9 AAV; αVβ5 integrin, α5β1 integrin, CD9, and hepatocyte growth factor receptors, which act as secondary receptors or more precisely co-receptors for serotype 2 AAV; basic fibroblast growth factor receptor and 37 / 67kDa laminin receptor (LamR), which act as secondary receptors or more precisely co-receptors for serotypes 2, 3, 8, and 9 AAV; and / or platelet-derived growth factor receptor (PDGFR), which act as a secondary receptor or more precisely co-receptor for serotype 5 AAV. In some embodiments, at least one essential binding site of the native receptor of the AAV VP2 capsid polypeptide is mutated. In some embodiments, the at least one binding site of the native receptor of the AAV VP2 capsid polypeptide is located within the VP3 region of the AAV VP2 capsid polypeptide, i.e., within a region shared by the VP1, VP2, and VP3 capsid polypeptides. The regions encoding the VP1 and VP2 proteins represent the N-terminal extension of the region encoding the VP3 protein. Thus, the reading frames encoding the regions of VP1, VP2, and VP3 overlap, such that the mutation in the VP3 region is present in all three capsid proteins. In some embodiments, the AAV VP2 fusion polypeptide has the AAV serotype AAV6 and contains at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q, and D590A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:3. In some embodiments, the AAV VP2 fusion peptide has AAV serotype AAV6 and comprises the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:3: i) K531E and V473D; ii) K531E, K459S, V473D and N500E; iii) G266A and N269Q; iv) G266A, N269Q and D590A; v) K531E, V473D, G266A and N269Q; or vi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A.

[0106] In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV8 and contains at least one amino acid substitution selected from the group consisting of: G268E, N271Q, S387A, A592Q, and A592D, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:4. In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV8 and contains one or more of the following amino acid substitutions: i) G268E and N271Q; ii) S387A; iii) G268E, N271Q, and S387A; iv) A592Q; or v) A592D, relative to the VP1 amino acid sequence of SEQ ID NO:4.

[0107] In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV9 and contains at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV9 and contains one or more of the following amino acid substitutions: i) W503A; ii) N562A and E563A; iii) Q590A and W503A; or iv) Q590A, W503A, N562A, and E563A, relative to the VP1 amino acid sequence of SEQ ID NO:5.

[0108] In some embodiments, the AAV VP2 fusion peptide has AAV serotype AAV2 and contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO:6 in its VP3 region.

[0109] In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV1 and contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:7. In some embodiments, the AAV VP2 fusion polypeptide has AAV serotype AAV1 and contains one or more of the following amino acid substitutions: i) V473D and N500E; ii) R514A; or iii) V473D, N500E, and R514A, relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0110] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide comprises at least one amino acid substitution relative to its corresponding wild-type AAV VP2 capsid polypeptide. The inventors have demonstrated that certain amino acid substitutions in the AAV VP2 capsid polypeptide can lead to improved receptor binding, for example, improved binding of the AAV VP2 fusion polypeptide containing a mutated AAV VP2 capsid polypeptide to a receptor containing a ligand in the AAV VP2 fusion polypeptide. Amino acid substitutions in the AAV VP2 capsid polypeptide can also lead to improved transduction. Without wishing to be bound by theory, it is assumed that amino acid substitutions identified by the inventors as improving receptor binding and / or transduction result in the higher portion of the VP2 N-terminus present in the AAV viral particle facing outwards. Under natural conditions, the majority of the VP2 N-terminus present in the AAV viral particle faces inwards towards the AAV capsid, thereby limiting the level of decoration of the AAV viral particle having a ligand fused to the VP2 N-terminus. Increasing the level of decoration of ligands fused to the N-terminus of VP2 in AAV viruses by increasing the portion of the VP2 N-terminus facing the outside of the viral particle (i.e., by increasing VP2 exposure of AAV viral particles) can lead to improved receptor binding and transduction levels.

[0111] Therefore, in some embodiments, the AAV VP2 fusion peptide has AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:7. In particular, the AAV VP2 fusion peptide comprises one or more of the following amino acid substitutions: D213A, T162R, and / or P191N; specifically, the AAV VP2 fusion peptide comprises all three of the following amino acid substitutions: D213A, T162R, and P191N.

[0112] In some embodiments, the AAV VP2 fusion polypeptide of AAV serotype AAV1 further comprises amino acid substitutions V473D and N500E relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0113] In other embodiments, the AAV VP2 fusion polypeptide has an AAV serotype other than AAV1 and contains at least one amino acid substitution corresponding to at least one of the amino acid substitutions selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N relative to the VP1 amino acid sequence of SEQ ID NO:7. In a particular such embodiment, the AAV VP2 fusion polypeptide has an AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:4. Specifically, the AAV VP2 fusion peptide contains one or more of the following amino acid substitutions: D214A, K163R and / or P192N, particularly all three of the following amino acid substitutions: D214A, K163R and P192N.

[0114] In other such embodiments, the AAV VP2 fusion polypeptide has AAV serotype 9 and comprises at least one amino acid substitution selected from the group consisting of E147S, P185G, P166R, G199R, D213A, S162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. In specific such embodiments, the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: D213A, S162R, and / or P191N, particularly all three of the following amino acid substitutions: D213A, S162R, and P191N.

[0115] In some embodiments, the nucleic acid encoding the AAV VP2 fusion polypeptide does not contain the natural start codon of the AAV VP2 capsid polypeptide. The natural start codon of the AAV VP2 capsid polypeptide can be mutated (e.g., deleted) to prevent the expression of the natural VP2 polypeptide by inhibiting transcription of the VP2 open reading frame. Preferably, the mutation does not alter the reading frame. In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide lacks its first natural amino acid, such as the first threonine of the corresponding wild-type AAV VP2 capsid polypeptide.

[0116] In some embodiments, the peptide ligand contained in the AAV VP2 fusion peptide contains up to 3 cysteine ​​residues, up to 2 cysteine ​​residues, up to 1 cysteine ​​residue, or no cysteine ​​residue.

[0117] Nucleic acid encoding the AAV VP2 fusion peptide and AAV cargo nucleic acid sequences

[0118] In one respect, this document provides nucleic acids encoding the AAV VP2 fusion polypeptide described herein. The nucleic acid encoding the AAV VP2 fusion polypeptide may be RNA, such as mRNA; or DNA, such as cDNA, linear DNA, or circular DNA (e.g., plasmid DNA).

[0119] This document also provides nucleic acids that can be encapsulated with an AAV capsid containing the AAV VP2 fusion peptide described herein, and rAAV viral particles containing such nucleic acids. These nucleic acids are referred to herein as “AAV genome,” “AAV vector genome,” “AAV vector,” “AAV vector nucleic acid,” “AAV cargo,” or “cargo particle,” and these terms are used interchangeably herein. Such AAV cargo or AAV vector genome typically contains two AAV inverted terminal repeat sequences. AAV cargo may encode the AAV VP2 fusion peptide described herein and / or may contain a reporter sequence and / or a barcode sequence, or AAV cargo may encode a therapeutic RNA or protein (including a therapeutic antibody or fragment thereof).

[0120] AAV vector genomes can be single-stranded or self-complementary. "Self-complementary AAV" or "scAAV" refers to a construct in which the coding region carried by the recombinant AAV nucleic acid sequence has been engineered to form an intramolecular double-stranded DNA template. Unbound by theory, at infection, instead of waiting for cell-mediated synthesis of the second strand, two complementary half-scAAVs can associate to form a single double-stranded DNA (dsDNA) unit that is readily replicated and transcribed. See, for example, DM McCarty et al., "Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis," Gene Therapy, (August 2001), Vol. 8, No. 16, pp. 1248-1254 (incorporated in full by reference). Self-complementary AAVs are described in, for example, the following U.S. Patent Nos.: 6,596,535; 7,125,717; and 7,456,683, each of which is incorporated herein by reference in its entirety. For example, the 5' ITR can be mutated, for instance, by deleting the end resolution site to allow hairpin formation in the genome.

[0121] In some embodiments, the rAAV vectors disclosed herein lack one or more (e.g., all) AAV rep and / or cap genes. AAV vectors may (e.g., in their ITRs) contain nucleic acid sequences (e.g., DNA) from any suitable AAV serotype. Suitable AAV serotypes include, but are not limited to, AAV serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV.5. For example, an AAV vector (e.g., a scAAV vector) may contain nucleic acid sequences from AAV-2, such as the ITR sequence from AAV-2. AAV vectors (e.g., scAAV vectors) may also contain nucleic acids from more than one serotype. The nucleotide sequences of the genomes of AAV serotypes are known in the art. For example, the complete genome of AAV-1 is provided in GenBank accession NC_002077; the complete genome of AAV-2 is provided in GenBank accession NC 001401 and Srivastava et al., Virol. [Virology], 45:555-564 (1983); the complete genome of AAV-3 is provided in GenBank accession NC_1829; the complete genome of AAV-4 is provided in GenBank accession NC_001829; the genome of AAV-5 is provided in GenBank accession AF085716; the complete genome of AAV-6 is provided in GenBank accession NC_001862; and at least partial genomes of AAV-7 and AAV-8 are also provided. The genomes are available in GenBank accessions AX753246 and AX753249, respectively; the AAV-9 genome is available in Gao et al., J.Virol., 78:6381-6388 (2004); the AAV-10 genome is available in Williams, (2006) Mol.Ther., 13(1):67-76; and the AAV-11 genome is available in Mori et al., (2004) Virology, 330(2):375-383.

[0122] In some embodiments, a functional inverted terminal repeat (ITR) sequence can be used to support, for example, the rescue, replication, and packaging of AAV viral particles. Therefore, the AAV vectors disclosed herein may contain cis-form sequences (e.g., functional ITRs) for enabling viral replication and packaging. The ITR may, but need not, be a wild-type nucleotide sequence and may be altered, for example by the insertion, deletion, or substitution of nucleotides, as long as the sequence enables functional rescue, replication, and packaging. The ITR may be derived from any AAV serotype from which recombinant viruses can be derived, including but not limited to AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV.5.

[0123] In some embodiments, the rAAV vectors disclosed herein comprise one or more ITRs (e.g., two ITRs, one upstream of a heterologous nucleic acid (e.g., encoding the AAV VP2 fusion peptide and / or reporter protein or therapeutic RNA or protein described herein) and / or other nucleic acid elements discussed above. In some embodiments, the nucleic acid disclosed herein (e.g., in scAAV vectors) comprises a first ITR disposed at the 5' of another vector element and a second ITR disposed at the 3' of another vector element, wherein the ITRs are independently 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 50, 100, 150, 200, or 250 nucleotides at the 5' and / or 3' of the other elements. The ITR sequence may be wild-type, or it may contain one or more mutations, for example, as long as it retains one or more functions of the wild-type ITR. In some embodiments, the wild-type ITR may be modified to include the deletion of a terminal resolution site. In some embodiments, the scAAV disclosed herein may comprise two ITR sequences, both of which are independently wild-type, variant, or modified AAV ITR sequences. In some embodiments, at least one ITR sequence is a wild-type, variant, or modified AAV ITR sequence. In some embodiments, both ITR sequences are wild-type, variant, or modified AAV ITR sequences. In some embodiments, the “left” or 5’-ITR is a modified AAV ITR sequence that allows for the generation of a self-complementary genome, and the “right” or 3’-ITR is a wild-type AAV ITR sequence. In some embodiments, the “right” or 3’-ITR is a modified AAV ITR sequence that allows for the generation of a self-complementary genome, and the “left” or 5’-ITR is a wild-type AAV ITR sequence. In some embodiments, both ITRs are AAV2ITRs (optionally, one is wild-type and the other is modified to remove terminal resolution sites, or both are wild-type). The embodiments of AAV ITR provided in WO / 2019 / 094253 (PCT / US 2018 / 058744) (which is incorporated herein by reference in its entirety) may also be used with any AAV ITR disclosed herein.

[0124] Polynucleotide sequences can be generated by de novo synthesis (e.g., solid-phase DNA synthesis) or by PCR using existing sequences as templates. Direct chemical synthesis of nucleic acids can be accomplished by methods known in the art, such as the phosphotriester method of Narang et al., 1979, Meth. Enzymol. [Enzymological Methods] 68:90; the phosphodiester method of Brown et al., Meth. Enzymol. [Enzymological Methods] 68:109, 1979; the diethylphosphite method of Beaucage et al., Tetra. Lett. [Tetrahedral Letters] 22:1859, 1981; and the solid-phase support method of U.S. Patent No. 4,458,066. Introducing mutations into polynucleotide sequences via PCR can be performed as described in, for example, the following literature: PCR Technology: Principles and Applications for DNA Amplification, HAErlich (ed.), Freeman Press, New York, NY, 1992; PCR Protocols: A Guide to Methods and Applications, Innis et al. (ed.), Academic Press, San Diego, CA, 1990; Mattila et al., Nucleic Acids Res. 19:967, 1991; and Eckert et al., PCR Methods and Applications 1:17, 1991.

[0125] This article also provides vectors (e.g., expression vectors) that contain nucleic acids encoding the AAV VP2 fusion peptide described herein and / or contain reporter sequences and / or barcode sequences or nucleic acids encoding therapeutic RNA or proteins (including therapeutic antibodies or fragments thereof). Such vectors can be used to express and / or generate target RNA or proteins (such as the AAV VP2 fusion peptide) in cells, such as in vitro, ex vivo, or in vivo, or in one or more target tissues of an organism. Various expression vectors can be used to express target RNA or proteins (such as the AAV VP2 fusion peptide described herein). Both virus-based and non-viral expression vectors can be used to generate target RNA or proteins in cells (e.g., mammalian cells). Non-viral vectors and systems include plasmids, augmentation vectors (typically having expression cassettes for expressing proteins or RNA), and human artificial chromosomes (see, for example, Harrington et al., Nat Genet. [Nature Genetics] 15:345, 1997). Such nonviral vectors can be delivered to target cells using transfection or transduction methods known in the art (e.g., using lipids (e.g., lipofectamine), electroporation, mechanical cell membrane deformation, etc.). The term "expression vector" refers to a vector nucleic acid molecule in which a desired coding sequence can be inserted to introduce it into cells in which it can be expressed. Vectors can be DNA vectors, RNA vectors, plasmids, granules, or viral vectors, or artificial chromosomes (see, for example, Harrington et al., Nat Genet [Nature Genetics] 15:345, 1997). For example, nonviral vectors that can be used to express target RNA and proteins (such as the AAV VP2 fusion polypeptide described herein) in mammalian (e.g., human) cells include pThioHis A, B, and C; pcDNA3.1 / His; pEBVHis A, B, and C (Invitrogen, San Diego, CA); MPSV vectors; and many other vectors known in the art for protein expression. For example, one type of vector utilizes DNA elements derived from animal viruses, such as bovine papillomavirus, polyomavirus, adenovirus, vaccinia virus, baculovirus, retrotranscriptovirus (Rouse sarcoma virus, MMTV, or MOMLV), or SV40 virus. Another type of vector utilizes RNA elements derived from RNA viruses, such as Semlikie Forest virus, Eastern Equine Encephalitis Virus, and Flavivirosis.Useful viral vectors include those based on any of the following viruses: retrotranscriptoviruses (e.g., lentiviruses), lentiviruses, adenoviruses, adeno-associated viruses, herpesviruses (e.g., herpes simplex virus (HSV)), SV40-based vectors, papillomaviruses, HBP / EBV, vaccinia virus, Sindbis virus, influenza virus, reovirus, Newcastle disease virus (NDV), measles virus, vesicular stomatitis virus (VSV), parvovirus, poliovirus, poxvirus, Seneca Valley virus, Coxsackie virus, enterovirus, myxoma virus, maraba virus, or Semlee Forest virus (SFV). See Brent et al., ibid.; Smith, Annu. Rev. Microbiol. [Annual Review of Microbiology] 49:807, 1995; and Rosenfeld et al., Cell [Cell] 68:143, 1992. In some embodiments, the vector is an adeno-associated virus (AAV) vector, such as a recombinant AAV (rAAV) vector.

[0126] In some embodiments, the vector may be a recombinant DNA molecule comprising a nucleic acid encoding an AAV VP2 fusion polypeptide as described herein and / or a reporter sequence and / or a barcode sequence, or a nucleic acid encoding a therapeutic RNA or protein (including a therapeutic antibody or fragment thereof). As used herein, “recombinant” means that the vector, polynucleotide, polypeptide, or cell is the product of various combinations of cloning, restriction, or ligation steps (e.g., involving the polynucleotide or polypeptide contained therein) and / or other procedures that produce a construct different from those found in nature. A recombinant virus or vector is a viral particle containing a recombinant polynucleotide. This term includes both replication of the original polynucleotide construct and progeny of the original viral construct.

[0127] Recombinant vectors typically contain one or more regulatory sequences operatively linked to the nucleic acid sequence to be expressed. The term "regulatory sequence" includes promoters, enhancers, and other expression control elements (e.g., polyadenylation signals). Those skilled in the art will readily recognize that expression of one or more components of the vector in target cells may require regulatory sequences. Regulatory sequences include those that direct constitutive expression of the nucleotide sequence, as well as tissue-specific regulatory and / or inducible sequences. Expression vectors may also contain elements designed to optimize the stability and translational properties of the messenger RNA in host cells and / or drug-selective markers for establishing permanently stable cell clones expressing the AAV VP2 fusion polypeptide as described herein. The design of expression vectors can depend on factors such as the selection of host cells to be transformed, the desired protein expression level, etc. General methods for generating such recombinant expression vectors can be found in the following literature: Sambrook and Russell, eds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; the series Ausubel et al., eds. (2007-2010) Current Protocols in Molecular Biology; and other methods known in the art.

[0128] Efficient translation of the coding sequence may also require specific start signals. These signals include the ATG start codon and adjacent sequences. Exogenous translation control signals, including the ATG start codon, may need to be provided. Those skilled in the art will be able to readily determine this and provide the necessary signals. It is well known that the start codon must be "in-frame" with the desired coding sequence to ensure the translation of the entire insert. Exogenous translation control signals and start codons can be natural or synthetic. Expression efficiency can be improved by including appropriate transcriptional enhancer elements.

[0129] Expression can be performed using any suitable host cell known in the art, such as mammalian host cells, bacterial host cells, yeast host cells, insect host cells, etc. Both prokaryotic and eukaryotic expression systems are widely available. In some embodiments, the expression system is a mammalian cell expression system (such as HEK293 expression). In some embodiments, the nucleic acid can be codon-optimized to facilitate expression in the desired host cell. It will be important to employ promoters and / or enhancers that effectively guide the expression of DNA segments in the selected cell type, organelle, and organism for expression. Those skilled in the art of molecular biology are generally familiar with the use of combinations of promoters, enhancers, and cell types for protein expression; see, for example, Sambrook et al. (2001).

[0130] Eukaryotic RNA molecules can undergo RNA splicing to remove introns from primary transcripts. Vectors containing eukaryotic genomic sequences may require donor and / or recipient splicing sites to ensure proper handling of transcripts used for protein expression (see Chandler et al., 1997, Proc. Natl. Acad. Sci. USA, 94(8):3596-601).

[0131] The vectors or constructs disclosed herein will typically contain at least one termination signal. A “termination signal” or “terminator” consists of a DNA sequence involved in the specific termination of an RNA transcript by an RNA polymerase. Therefore, in some embodiments, a termination signal for terminating RNA transcript production is considered. In vivo, a terminator may be necessary to achieve a desired level of information. In eukaryotic systems, the terminator region may also contain a specific DNA sequence that allows for site-specific cleavage of the new transcript to expose a polyadenylation site. This means that a specialized endogenous polymerase adds a length of approximately 200 Å residues (poly-A) to the 3' end of the transcript. RNA molecules modified with this poly-A tail appear to be more stable and translate more efficiently. Therefore, in other embodiments involving eukaryotes, it is preferred that the terminator contains a signal for cleaving RNA, and more preferably, the terminator signal promotes polyadenylation of mRNA. The terminator and / or polyadenylation site element can be used to increase mRNA levels and / or minimize read-through from the cassette to other sequences. Terminators considered for use in this disclosure include any known transcription terminators described herein or known to those skilled in the art, including but not limited to, gene termination sequences (e.g., bovine growth hormone terminators) or viral termination sequences (e.g., SV40 terminators). In some embodiments, the termination signal may be due to the lack of a transcribed or translatable sequence, such as due to sequence truncation.

[0132] In expression, particularly eukaryotic expression, polyadenylation signals are typically included to achieve proper polyadenylation of the transcript. The nature of the polyadenylation signal is not considered critical to successful implementation of this disclosure, and / or any such sequence may be employed. Preferred embodiments include SV40 polyadenylation signals and / or bovine growth hormone polyadenylation signals, which are convenient and / or known to function well in a variety of target cells. Polyadenylation can increase transcript stability or promote cytoplasmic transport.

[0133] To propagate the vector within a host cell, it can contain one or more origins of replication (often called "ori"), which are specific nucleic acid sequences that initiate replication. Alternatively, if the host cell is yeast, an autonomous replication sequence (ARS) can be used.

[0134] In some embodiments of this disclosure, cells containing the nucleic acid constructs of this disclosure can be identified in vitro or in vivo by including markers in the expression vector. Such markers confer identifiable variations on the cells, allowing for easy identification of cells containing the expression vector. Typically, selectable markers are markers that confer the property of allowing selection. Positive selectable markers are those whose presence allows selection, while negative selectable markers are those whose presence prevents selection. An example of a positive selectable marker is a drug resistance marker.

[0135] Typically, drug-selective markers are helpful for cloning and identifying transformants; for example, genes conferring resistance to kanamycin, neomycin, puromycin, hygromycin, DHFR, GPT, giomycin, and histamine are useful selectable markers. In addition to markers that confer resistance allowing for condition-based differentiation of transformant phenotypes, other types of markers are considered, including selectable markers (such as GFP), which are based on colorimetric analysis. Alternatively, selectable enzymes, such as herpes simplex virus thymidine kinase (HSV-tk) or chloramphenicol acetyltransferase (CAT), can be used. Those skilled in the art will also know how immunomarkers can be used in conjunction with FACS analysis. The marker used is not considered critical, as long as it can be co-expressed with the nucleic acid encoding the gene product. Further examples of selectable and selectable markers are well known to those skilled in the art.

[0136] The choice of expression vector depends on the intended cells for one or more components of the vector to be expressed. Typically, the vector contains one or more regulatory sequences, such as promoters and other regulatory sequences (e.g., enhancers), which are operatively linked to the open reading frame of the AAV VP2 fusion peptide.

[0137] A promoter is a control sequence located within a region of a nucleic acid sequence that controls the initiation and rate of transcription. It may contain genetic elements on which proteins and molecules, such as RNA polymerases and other transcription factors, can bind. The phrases "operably positioned," "operably linked," "controlled," and "transcriptionally controlled" mean that the promoter is in the correct functional location and / or orientation associated with the nucleic acid sequence to control the initiation and / or expression of that sequence. Promoters can be used in conjunction with or without "enhancers," which are cis-regulatory sequences involved in the transcriptional activation of a nucleic acid sequence.

[0138] Promoters can be promoters naturally associated with a gene or sequence, such as those obtained by isolating a 5' non-coding sequence located upstream of a coding region and / or exon. Such promoters can be referred to as "endogenous." Similarly, enhancers can be enhancers naturally associated with a nucleic acid sequence, located downstream or upstream of that sequence. Alternatively, certain advantages can be gained by positioning the coding nucleic acid segment under the control of recombinant or heterologous promoters, which are promoters that are not normally associated with a nucleic acid sequence in their natural environment. Recombinant or heterologous enhancers also refer to enhancers that are not normally associated with a nucleic acid sequence in their natural environment. Such promoters or enhancers can include promoters or enhancers of other genes, and promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cells, and promoters or enhancers that are not "naturally present" (i.e., containing different elements of different transcriptional regulatory regions and / or mutations that alter expression). In addition to synthetically generating nucleic acid sequences for promoters and enhancers, sequences can be generated using recombinant cloning and / or nucleic acid amplification techniques (e.g., PCR) in combination with the compositions disclosed herein (see US 4683202, US 5928906). Furthermore, control sequences guiding transcription and / or expression in non-nuclear organelles (such as mitochondria, chloroplasts, etc.) can also be considered.

[0139] The promoters used can be constitutive, inducible, synthetic, tissue- or cell-specific, and / or, under appropriate conditions, can be used to guide high-level expression of the introduced DNA segment, such as facilitating large-scale production of recombinant proteins and / or peptides. Furthermore, other regulatory elements can be incorporated to improve the expression of nucleic acids encoding the AAV VP2 fusion polypeptide described herein, such as enhancers, ribosome binding sites, transcription termination sequences, etc.

[0140] In some embodiments, constitutive promoters are employed to provide constant expression of the AAV VP2 fusion peptide or reporter sequence described herein, or of therapeutic RNA or protein encoded by nucleic acids contained in the rAAV viral particles described herein. Examples of constitutive promoters include, but are not limited to, the Immediate Early Cytomegalovirus (CMV) promoter, the Simian Virus 40 (SV40) Early promoter, the Mouse Mammary Tumor Virus (MMTV) promoter, the Human Immunodeficiency Virus (HIV) Long Terminal Repeat (LTR) promoter, the MoMuLV promoter, the Avian Leukosis Virus promoter, the Epstein-Barr Virus (EBV) Immediate Early promoter, the Rous sarcoma virus promoter, and human gene promoters (such as, but not limited to, the actin promoter, myosin promoter, elongation factor-1 promoter, hemoglobin promoter, and creatine kinase promoter).

[0141] In some embodiments, a ubiquitous promoter is employed. Non-limiting examples of ubiquitous promoters include CMV, CBA (including derivatives CAG, CBh, etc.), EF-1a, PGK, UBC, GUSB (hGBp), and UCOE (the promoter of HNRPA2B1-CBX3).

[0142] In some embodiments, an inducible promoter is employed to prevent the inserted sequence from being expressed under conditions other than induction conditions. The use of an inducible promoter provides a molecular switch that can initiate expression when expression of the polynucleotide sequence to which it is operatively linked is required, or shut down expression when expression is not required. Examples of inducible promoters include, but are not limited to, arabinose promoters, lacZ promoters, tetracycline promoters, metallothionein promoters, glucocorticoid promoters, progesterone promoters, or heat shock promoters.

[0143] In some embodiments, tissue- or cell-specific promoters are employed to provide the AAV VP2 fusion polypeptide or reporter protein described herein, therapeutic RNA or protein encoded by nucleic acids contained in the rAAV viral particles described herein, expressed only in specific tissues or cells. The characteristics of tissue- or cell-specific promoters or elements, and the assays for characterizing their activity, are well known to those skilled in the art. Examples include the human LIMK2 gene (Nomoto et al. 1999, Gene, 236(2):259-271), the somatostatin receptor 2 gene (Kraus et al. 1998, FEES... Lett. [FEES Letters], 428(3):165-170), mouse epididymal retinoic acid binding gene (Lareyre et al., 1999, J. Biol. Chem., 274(12):8282-8290), human CD4 (Zhao-Emonet et al., 1998, Biochirn. Biophys. Acta, 1442(2-3):109-119), mouse α2(XI) collagen (Tsumaki et al., 1998, J. Biol. Chem., 273(36):22861-22864) D1A dopamine receptor gene (Lee et al., 1997, J. Auton. Nerv. Syst. [Journal of Autonomic Nervous System], 74(2-3):86-90), insulin-like growth factor II (Wu et al., 1997, Biochem. Biophys. Res. Commun. [Biochemistry and Biophysics Research Communications], 233(1):221-226), human platelet endothelial cell adhesion molecule-1 (Almendro et al., 1996, J. Immunol. [Journal of Immunology], 157(12):5411-5421), muscle creatine kinase (MCK) promoter (Wang et al., Gene Ther. [Gene Therapy] November 2008; 15(22):1489-99).

[0144] In some embodiments, non-cell-specific promoters are employed. In some embodiments, strong promoters or weak promoters are employed (classified according to their affinity for RNA polymerase and / or σ factor and the affinity of other promoters for RNA polymerase and / or σ factor).

[0145] In some embodiments, synthetic promoters are employed to provide expression of the AAV VP2 fusion polypeptide described herein or therapeutic RNA or protein encoded by nucleic acids contained in the rAAV viral particles described herein. Synthetic promoters can significantly exceed the transcriptional efficiency of natural promoters. For example, synthetic promoters that are not shut down or deactivated by endogenous cellular machinery or factors can be selected. Other elements, including trans-acting factor binding sites and enhancers, can be inserted into synthetic promoters to improve transcriptional efficiency. Synthetic promoters can be rationally designed and chemically synthesized to combine the best characteristics of both synthetic and biological promoters. Synthetic oligonucleotides are annealed and ligated through several processes to produce a full-length chemically synthesized promoter. Synthetic promoters can be inducible or cell-type specific promoters.

[0146] In some embodiments, the promoter operatively linked to the AAV VP2 fusion peptide ORF, or a nucleic acid sequence encoding a therapeutic nucleic acid or protein, or a reporter sequence is selected from the 173CMV promoter, HCMV promoter, CBh promoter, CAG promoter, and mCCT promoter.

[0147] Those skilled in the art will readily recognize that specific promoters are particularly well-suited for expressing, in target cells, AAV VP2 fusion peptides, reporter sequences, or therapeutic RNAs or proteins as described herein, including but not limited to species-specific, inducible, tissue-specific, or cell cycle-specific promoters (Parr et al., Nat. Med. [Nature Medicine] 3:1145-9 (1997); the contents of which are incorporated herein by reference in their entirety).

[0148] In some embodiments, the promoter operatively linked to the AAV VP2 fusion peptide, reporter sequence, or therapeutic RNA or protein encoded by a nucleic acid contained in the rAAV viral particle described herein is less than 1 kb. The promoter length can be 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 5 00, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more than 800bp. The promoter length can be between 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800 bp.

[0149] In one embodiment, the promoter operatively linked to the AAV VP2 fusion peptide, reporter sequence, or therapeutic RNA or protein encoded by a nucleic acid contained in the rAAV viral particle described herein can be a combination of two or more components, regions, or sequences of the same or different promoters (such as, but not limited to, CMV and CBA). The length of each component can be 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 381, 382, ​​383, 384, 385, 386, 387, 388, 389, 390, 400, 410, 420, 430, 440, or 450. 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 or more than 800bp. The length of each component can be between 200-300, 200-400, 200-500, 200-600, 200-700, 200-800, 300-400, 300-500, 300-600, 300-700, 300-800, 400-500, 400-600, 400-700, 400-800, 500-600, 500-700, 500-800, 600-700, 600-800, or 700-800 bp.

[0150] In some embodiments, the promoter operatively linked to the AAV VP2 fusion peptide, reporter sequence, or therapeutic RNA or protein encoded by a nucleic acid contained in the rAAV viral particle described herein is a combination of a CMV enhancer sequence (e.g., an immediate / early CMV enhancer sequence (e.g., a 382-nucleotide CMV enhancer sequence)) and a chicken β-actin (CBA) promoter sequence (e.g., a 260-nucleotide CBA promoter sequence).

[0151] In addition to promoters, efficient expression of the AAV VP2 fusion polypeptide or reporter protein described herein, therapeutic RNA or therapeutic protein encoded by nucleic acids contained in the rAAV viral particles described herein, may require or be desired by other regulatory elements. These elements include the ATG start codon and adjacent ribosome binding sites or other sequences. Furthermore, expression efficiency can be improved by including enhancers suitable for the cellular system in use (see, for example, Scharf et al., Results Probl. Cell Differ. 20:125, 1994; and Bittner et al., Meth. Enzymol. 153:516, 1987). For example, the SV40 enhancer or CMV enhancer can be used to increase expression in mammalian host cells.

[0152] In some embodiments, the AAV vectors provided herein contain introns, optionally arranged between the promoter element and the polynucleotide to be expressed. Without being bound by theory, the inclusion of 5' introns can improve the level and homeostasis of expressed mRNA. Non-limiting examples of introns include SV40-derived introns, CBA-MVM-derived introns, MVM (67-97 bp), FIX-truncated intron 1 (300 bp), β-globin SD / immunoglobulin heavy chain splice acceptor (250 bp), adenovirus splice donor / immunoglobulin splice acceptor (500 bp), SV40 late splice donor / splicing acceptor (19S / 16S) (180 bp), and hybrid adenovirus splice donor / IgG splice acceptor (230 bp).

[0153] In one embodiment, the length of an intron or intronic portion can be 100-500 nucleotides. The length of an intron can be 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 171, 172, 173, 174, 175, 176, 177, 178, 179, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, or 500 nucleotides. The length of introns can be between 80-100, 80-120, 80-140, 80-160, 80-180, 80-200, 80-250, 80-300, 80-350, 80-400, 80-450, 80-500, 200-300, 200-400, 200-500, 300-400, 300-500, or 400-500 nucleotides.

[0154] Expression vectors can also provide a secretion signal sequence location to form a fusion protein with the protein to be expressed. More often, the inserted sequence encoding the protein to be expressed is linked to the signal sequence before being included in the vector.

[0155] Expression vectors can be generated using vectors containing multiple cloning sites (MCS), which are nucleic acid regions containing multiple restriction enzyme sites. Any of these sites can be combined with standard recombinant techniques to digest the vector. See Carbonelli et al., 1999; Levenson et al., 1998; and Cocea, 1997. "Restriction enzyme digestion" refers to the cleavage of nucleic acid molecules using an enzyme that functions only at a specific location within the nucleic acid molecule. Many of these restriction enzymes are commercially available. The uses of such enzymes are widely understood by those skilled in the art. Typically, restriction enzymes that cleave within the MCS are used to linearize or fragment the vector so that a foreign sequence can be ligated to it. "Lie-off" refers to the process of forming a phosphodiester bond between two nucleic acid fragments, which may or may not be adjacent to each other. Techniques involving restriction enzymes and ligation reactions are well known to those skilled in the art of recombinant technology.

[0156] In some embodiments, the nucleic acid encoding the AAV VP2 fusion peptide described herein further includes a regulatory sequence. In some embodiments, the nucleic acid encoding the AAV VP2 fusion peptide described herein further includes a promoter. In some embodiments, the nucleic acid encoding the AAV VP2 fusion peptide described herein includes a regulatory sequence, particularly a promoter, that effectively drives expression in target cells.

[0157] In some embodiments, the open reading frame of the AAV VP2 fusion peptide is operatively linked to the promoter. In some embodiments, the promoter is selected from the HCMV promoter, 173CMV promoter, CAG promoter, CBh promoter, and mCCT promoter. In some embodiments, the nucleic acid further comprises a polyadenylation signal, which may be selected, for example, from the BGH or SV40 polyadenylation signal. In one embodiment, the nucleic acid comprises the sequence of SEQ ID NO:8.

[0158] In some embodiments, the nucleic acid encoding the AAV VP2 fusion polypeptide further comprises a reporter sequence. In some embodiments, the reporter sequence is operatively linked to a promoter (e.g., a second promoter). In some embodiments, the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein. Many reporter proteins are known in the art, including green fluorescent protein (GFP), variants of green fluorescent protein (GFP10), enhanced GFP (eGFP), TurboGFP, GFPS66T, TagGFP2, mUKGEmerald GFP, Superfolder GFP, GFPuv, unstable EGFP (dEGFP), Azami Green, mWasabi, Clover, mClover3, mNeonGreen, NowGFP, Sapphire, T-Sapphire, mAmetrine, photoactivated GFP (PA-GFP), Kaede, Kikume, mKikGR, tdEos, Dendra2, mEosFP2, Dronpa, blue fluorescent protein (BFP), eBFP2, azunte BFP, mTagBFP, mKalamal, mTagBFP2, shBFP, cyan fluorescent protein (CFP), eCFP, Cerulian CFP, SCFP3A, Unstable ECFP (dECFP), CyPet, mTurquoise, mTurquoise2, mTFPI, Optical Switch CFP2 (PS-CFP2), TagCFP, mTFPI, mMidonishi-Cyan, aquamanne, mKeima, mBeRFP, LSS-mKate2, LSS-mKatel, LSS-mOrange, CyOFPI. Sandercyanin, Red Fluorescent Protein (RFP), eRFP, mRaspberry, mRuby, mApple, mCardinal, mStable, mMaroonl, mGarnet2, tdTomato, mTangerine, mStrawberry, TagRFP, TagRFP667, TagRFP675, mKate2, HcRed, t-HcRed, HcRed-Tandem, mPlum, mNeptune, NirFP, Kindling, Far Red Fluorescent Protein, Yellow Fluorescent Protein (YFP), eYFP, Unstable EYFP (dEYFP), TagYFP, Topaz, Venus, SYFP2, mCherry, PA-mCherry, sfCherry, sfCherry2, Citrine, mCitrine, Ypet, IANRFP-AS83, mPapayal, mCyRFPI, mHoneydew, mBanana, mOrange, Kusabira Orange, Kusabira Orange 2, mKusabira Orange, mOrange 2, mKOv, mKO2, mGrapel, mGrape2, zsYellow, eqFP611, Sirius, Sandercyanm, shBFP-N168S / L1731, near-infrared protein, iFP1.4, iRFP713, iRFP670, iRFP682, iRFP702, iRFP720, iFP2.0, mIFP, TDsmURFP, miRFP670, Brilliant Violet (BV)421, BV 605, BV 510, BV 711, BV786, PerCP, PerCP / Cy5.5, DsRed, DsRed2, mRFPI, pocilloporin, Renilla GFP, Monster GFP, paGFP, or Phycobih protein or any of the biologically active variants or fragments thereof. The reporter protein can be selected from, for example, the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase and nanoluciferase, particularly EGFP and sfCherry2.

[0159] In some embodiments, the vector (e.g., an expression vector) is a gland-associated vector (AAV). In some embodiments, the AAV vector comprises an open reading frame encoding the AAV VP2 fusion polypeptide described herein, with inverted terminal repeat (ITR) sequences lateralized to one or both sides. The nucleic acid may additionally comprise one or more other elements, such as promoters, enhancers, one or more intron sequences, poly(A) sequences, filler sequences (e.g., HPRT intron-derived filler sequences), and combinations thereof. In some embodiments, the vector comprises a polynucleotide AAV vector encoding the AAV VP2 fusion polypeptide as described herein, encapsulated in an AAV capsid.

[0160] In some embodiments, the vector comprises an open reading frame encoding the AAV VP2 fusion polypeptide described herein, operatively linked to at least one target cell compatibility regulatory sequence (e.g., a promoter). In some embodiments, the promoter is selected from the 173CMV promoter, HCMV promoter, CBh promoter, CAG promoter, and mCCT promoter.

[0161] In some embodiments, the ITR in the AAV vector is derived from the same AAV serotype. In some embodiments, the ITR in the AAV vector is derived from different AAV serotypes. In some embodiments, the ITR is the same. In some embodiments, the ITR is different.

[0162] In some embodiments, the ITR in the AAV vector is derived from the same AAV serotype as the AAV capsid. In some embodiments, the ITR in the AAV vector is derived from a serotype different from the AAV capsid. In some embodiments, the ITR is derived from AAV2, and the AAV capsid is derived from a serotype other than AAV2, such as AAV9.

[0163] In some embodiments, the nucleic acid encoding the AAV VP2 fusion polypeptide comprises two AAV inverted terminal repeat (ITR) sequences located upstream and downstream of the open reading frame of the AAV VP2 fusion polypeptide. In some embodiments, these two ITR sequences are located at the 5' and 3' ends of the nucleic acid molecule. In some of these embodiments, the nucleic acid further comprises a reporter sequence. The reporter sequence may, for example, encode a fluorescent reporter protein or a luminescent reporter protein. For example, the reporter protein may be selected from the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase, particularly selected from EGFP and sfCherry2. In some embodiments, the reporter sequence is operatively linked to a second promoter. In some embodiments, the nucleic acid encoding the AAV VP2 fusion polypeptide further comprises a posttranscriptional regulatory element, such as WPRE or a derivative thereof. In some embodiments, the nucleic acid further comprises a polyadenylation signal, such as a polyadenylation signal selected from BGH and SV40. In one embodiment, the nucleic acid encoding the AAV VP2 fusion polypeptide comprises the sequence of SEQ ID NO:2.

[0164] In one respect, this article provides a kit containing isolated nucleic acids encoding the AAV VP2 fusion polypeptide.

[0165] Host cells and AAV production

[0166] The methods used to introduce expression vectors containing the target polynucleotide sequence vary depending on the type of cell host. For example, calcium chloride transfection is commonly used for prokaryotic cells, while calcium phosphate treatment or electroporation can be used for other cell hosts (see Sambrook et al., ibid.). Other methods include, for example, electroporation, calcium phosphate treatment, liposome-mediated transformation, injection and microinjection, shock / gene gun, virions, immunoliposomes, polycation:nucleic acid conjugates, naked DNA, artificial viral particles, fusion with the herpesvirus structural protein VP22, drug-enhanced DNA uptake, in vitro transduction, protoplast fusion, retroviral transduction, viral transfection, lipid-based transfection, or other conventional techniques. In the case of protoplast fusion, cells are grown in a culture medium and screened for appropriate activity. For long-term, high-yield production of recombinant proteins, stable expression is usually required. For example, expression vectors containing viral origins of replication or endogenous expression elements and selectable marker genes can be used to prepare cell lines that stably express peptides. After vector introduction, cells can be allowed to grow in enrichment media for 1–2 days and then transferred to selective media. The purpose of the selectable marker is to confer selective resistance, and its presence allows cells that successfully express the introduced sequence to grow in selective media. Resistant, stably transfected cells can be proliferated using tissue culture techniques suitable for the cell type. The methods and conditions used to culture the resulting transfected cells and recover the generated antibodies are known to those skilled in the art and can be varied or optimized based on this specification depending on the specific expression vector and mammalian host cells used.

[0167] In one respect, this document provides cells comprising the AAV VP2 fusion peptide described herein or nucleic acids encoding the AAV VP2 fusion peptide. Such cells may be, for example, host cells or therapeutic cells. The terms “host cell” and “recombinant host cell” are used interchangeably herein and refer not only to the specific test cell but also to the progeny or potential progeny of such cells. Because certain modifications may occur in offspring due to mutations or environmental influences, such progeny may differ in fact from the parent cells but are still included within the scope of the terminology used herein.

[0168] Host cells can be used to generate or express the AAV VP2 fusion peptide and optionally assemble AAV viral particles containing the AAV VP2 fusion peptide. Therefore, this disclosure is also characterized by methods for generating the AAV VP2 fusion peptide and methods for generating AAV viral particles containing the AAV VP2 fusion peptide using host cells. In some embodiments, these methods include culturing host cells in a suitable culture medium (where a recombinant expression vector encoding the AAV VP2 fusion peptide has been introduced) to generate the AAV VP2 fusion peptide. In some embodiments, the method further includes isolating the AAV VP2 fusion peptide or AAV viral particles containing the AAV VP2 fusion peptide from the culture medium or host cells.

[0169] In one embodiment, host cells are genetically engineered to contain nucleic acids encoding an AAV VP2 fusion polypeptide. In another embodiment, host cells are genetically engineered using an expression cassette. The phrase "expression cassette" refers to a nucleotide sequence that can influence gene expression in a host compatible with such a sequence. Such a cassette may contain a promoter, an open reading frame with or without introns, and a termination signal. Additional factors necessary or helpful in achieving expression, such as inducible promoters, may also be used.

[0170] The host cell can be, but is not limited to, eukaryotic or prokaryotic cells, such as bacterial cells, insect cells, or mammalian cells (such as human cells). *Escherichia coli* is a prokaryotic host suitable for cloning and expressing polynucleotides. Other suitable microbial hosts include bacilli (such as *Bacillus subtilis*) and other Enterobacteriaceae (such as *Salmonella* and *Serratia*), as well as various *Pseudomonas* species. Expression vectors can also be replicated in these prokaryotic hosts, typically containing control sequences (e.g., origin of replication) compatible with the host cell. Furthermore, any number of well-known promoters will be available, such as the lactose promoter system, the tryptophan (trp) promoter system, the β-lactamase promoter system, or promoter systems derived from bacteriophage λ. Promoters are typically optionally controlled by operon sequences and have ribosome binding site sequences, etc., for initiating and completing transcription and translation. Other microorganisms (such as yeast) can also be used to express the AAV VP2 fusion polypeptide described herein. Eukaryotic host cell lines capable of secreting complete heterologous proteins have been developed, including CHO cell lines, various Cos cell lines, HeLa cells, myeloma cell lines, transformed B cells, and hybridomas. Suitable eukaryotic host cells include, but are not limited to, Vero cells, HeLa cells, COS cells, CHO cells, HEK293 cells, BHK cells, and MDCKII cells. The use of mammalian tissue cells to culture and express peptides is commonly discussed, for example, in Winnacker, *From Genes to Clones*, VCH Publishers, New York, NY, 1987. Expression vectors from mammalian host cells may contain expression control sequences such as origin of replication, promoters, and enhancers (see, for example, Queen et al., *Immunol. Rev.* 89:49-68, 1986); and necessary processing information sites such as ribosome binding sites, RNA splicing sites, polyadenylation sites, and transcription terminator sequences. These expression vectors typically contain promoters derived from mammalian genes or mammalian viruses. Suitable promoters can be constitutive, cell type-specific, stage-specific, and / or tunable or modulotropic. Useful promoters include, but are not limited to, metallothionein promoters, constitutive adenovirus major late promoters, dexamethasone-inducible MMTV promoters, SV40 promoters, MRP pol III promoters, constitutive MPSV promoters, tetracycline-inducible CMV promoters (such as human immediate early CMV promoters), constitutive CMV promoters, and promoter-enhancer combinations known in the art.

[0171] In some embodiments, the host cell is adapted for the assembly of AAV viral particles. Therefore, a method for generating rAAV viral particles is also disclosed herein.

[0172] Naturally occurring AAVs contain distinct sequences that direct viral DNA replication (rep), encapsulation / packaging, and integration into the host cell chromosome. Typically, three AAV promoters (named p5, p19, and p40 based on their relative map positions) drive the expression of two open reading frames within the AAVs encoding the rep and cap genes in wild-type viruses. Differential splicing of the two rep promoters (p5 and p19) with a single AAV intron (at nucleotides 2107 and 2227) results in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. The rep proteins possess a variety of enzymatic properties ultimately responsible for replicating the viral genome. The cap gene is typically expressed by the p40 promoter. Alternative splicing and non-shared translation initiation sites are responsible for the production of three associated capsid proteins, VP1, VP2, and VP3. A single shared polyadenylation site is located at map position 95 of the AAV genome. A review of the life cycle and genetics of AAV is available in Muzyczka, (1992) Curr. Topics Microbiol. Imm. [Current Topics in Microbiology and Immunology], 158: 97-129.

[0173] In some embodiments, rAAV viral particles are generated using a nucleic acid (e.g., a plasmid) encoding an AAV VP2 fusion polypeptide. In some embodiments, at least one additional nucleic acid (e.g., a plasmid) containing the AAV rep gene and / or the AAV cap gene is used in the preparation of rAAV viral particles. In some embodiments, the VP2 start codon in the cap gene is mutated, thereby making the nucleic acid encoding the AAV VP2 fusion polypeptide the sole source of the VP2 subunit, and thus all VP2 capsid polypeptides in the resulting rAAV viral particles are fused to the polypeptide ligand. Nucleic acid sequences, such as plasmids, containing at least one adenovirus helper gene are also disclosed herein. In some embodiments, the nucleic acids encoding the AAV rep, AAV cap, and / or adenovirus helper genes may be present in the same structure (e.g., a single plasmid), or they may be present in separate structures. In some embodiments, one or more plasmids are co-transfected with cargo nucleic acids (i.e., nucleic acids to be encapsulated within rAAV viral particles) into competent cells, and the cells are then cultured to generate rAAV viral particles. In some cases, a cargo plasmid containing the nucleic acid sequence to be packaged (“AAV genome”) and one or more plasmids containing the AAV rep and / or cap genes are transferred into cells that are permitted to be infected with AAV helper viruses (e.g., adenovirus, E1-deficient adenovirus, or herpesvirus). Techniques for generating rAAV particles (in which the AAV genome to be packaged, the rep and cap genes, and helper viral functions are provided to the cells) are known in the art and may include, for example, electroporation. In some embodiments, the generation of rAAV involves the following components present in a single cell (referred to herein as a packaging cell): the rAAV vector, the AAV rep and cap genes separated from the rAAV vector (i.e., not in the rAAV vector), and the helper viral functions. The generation of pseudotyped rAAV is disclosed, for example, in WO 01 / 83692, which is incorporated herein by reference in its entirety. In various embodiments, the AAV capsid protein may be modified to enhance the delivery of the recombinant vector. Modifications to the capsid protein are generally known in the art. See, for example, US2005 / 0053922 and US2009 / 0202490, the disclosures of which are incorporated herein by reference in their entirety.

[0174] In various embodiments, the general principles for generating viral vectors can be used to generate the vectors and viruses disclosed herein, such as rAAV. Carter, (1992) Curr. Opinions Biotech. [Biotechnology Review], 1533-539; Muzyczka, (1992) Curr. Topics Microbial. Immunol. [Current Topics in Microbiology and Immunology], 158:97-129. Various methods are disclosed in the following literature: Ratschin et al., (1984) Mol. Cell. Biol. [Molecular Cell Biology], 4:2072; Hennonat et al., (1984) Proc. Natl. Acad. Sci. USA [Proceedings of the National Academy of Sciences of the United States of America], 81:6466; Tratschin et al., (1985) Mol. Cell. Biol. [Molecular Cell Biology], 5:3251; McLaughlin et al., (1988) J. Virol. [Journal of Virology], 62:1963; Lebkowski et al., (1988) Mol. Cell. Biol. [Molecular Cell Biology], 7:349; Samulski et al., (1989) J. Virol. [Journal of Virology], 63:3822-3828; US Patent No. 5,173,414; WO WO95 / 13365 and the corresponding US patent number 5,658,776; WO95 / 13392; WO96 / 17947; PCT / US98 / 18600; WO97 / 09441 (PCT / US96 / 14423); WO97 / 08298 (PCT / US96 / 13872); WO97 / 21825 (PCT / US96 / 20777); WO97 / 06243 (PCT / FR96 / 01064); WO99 / 11764; Perrin et al., (1995) Vaccine, 13:1244-1250; Paul et al., (1993) Hum. Gene Ther., 4:609-615; Clark et al., (1996) Gene Therapy, 3:1124-1132; U.S. Patent Nos. 5,786,211, 5,871,982, and 6,258,595. These documents are incorporated herein by reference in their entirety, with particular emphasis on the sections relating to the generation of rAAV.

[0175] An exemplary method for generating packaging cells is to generate cell lines that stably express some or all of the essential components for AAV particle production. For example, this involves integrating an rAAV vector encoding the AAV rep and cap genes (lacking the AAV rep and cap genes), the AAV rep and cap genes separated from the rAAV vector, and a plasmid (or plasmids) with optional markers (such as neomycin resistance genes) into the cell's genome. The AAV genome has been introduced into bacterial plasmids via procedures such as GC tailing (Samulski et al., (1982) Proc. Natl. Acad. Sci. USA, 79:2077-2081), adding synthetic adapters containing restriction endonuclease cleavage sites (Laughlin et al., (1983) Gene, 23:65-73), or direct blunt-end ligation (Senapathy et al., (1984) J. Biol. Chem., 259:4661-4666). The packaging cell lines are then infected with helper viruses (such as adenovirus) and / or plasmids encoding the helper viruses. The advantage of this method is that the cells are selectable and suitable for large-scale production of rAAV. Other examples of suitable methods use adenovirus or baculovirus instead of plasmids to introduce the rAAV vector and / or the rep and cap genes into the packaging cells.

[0176] In some embodiments, a method of generating a recombinant virus includes providing a nucleic acid to be packaged. In some embodiments, the nucleic acid is a plasmid. In other embodiments, the nucleic acid comprises a heterologous nucleic acid sequence inserted between a first AAV terminal repeat and a second AAV terminal repeat. In some embodiments, the heterologous nucleic acid encodes the AAV VP2 fusion polypeptide and / or reporter protein described herein. In some embodiments, the heterologous nucleic acid encodes a therapeutic RNA or a therapeutic protein (including a therapeutic antibody). In some embodiments, where the heterologous nucleic acid does not encode the AAV VP2 fusion polypeptide, a method of generating a recombinant virus includes providing additional nucleic acid encoding the AAV VP2 fusion polypeptide. In some embodiments, a method of generating a recombinant virus includes providing one or more additional nucleic acids. In some embodiments, one or more additional nucleic acids comprise the AAV rep gene and / or the AAV cap gene. In some embodiments, one or more additional nucleic acids comprise the AAVrep gene derived from AAV serotype 1, AAV serotype 2, AAV serotype 3, AAV serotype 4, AAV serotype 5, AAV serotype 6, AAV serotype 7, AAV serotype 8, or AAV serotype 9. In some embodiments, one or more additional nucleic acids comprise an AAV cap gene derived from AAV serotype 1, AAV serotype 2, AAV serotype 3, AAV serotype 4, AAV serotype 5, AAV serotype 6, AAV serotype 7, AAV serotype 8, or AAV serotype 9. In some embodiments, one or more additional nucleic acids comprise one or more adenovirus helper genes.

[0177] In some embodiments, nucleic acids are co-transfected into competent cells or packaging cells. Methods of co-transfection are known in the art and include, but are not limited to, transfection via lipofectamine, electroporation, and polyethyleneimine. Competent cells or packaging cells can be non-adherent or adherent cells in suspension culture. In one embodiment, any suitable packaging cell line can be used, such as HeLa cells, HEK293 cells, and PerC.6 cells (homogeneous 293 line). In one embodiment, the packaging cell is a human cell. In one embodiment, the packaging cell is a HEK293 cell. In one embodiment, the packaging cell is an insect cell. In one embodiment, the packaging cell is an Sf9 cell. In some embodiments, the method includes culturing the transfected cells to produce a recombinant virus. In some embodiments, the method includes recovering the recombinant virus. Methods for recovering the recombinant virus include, for example, those disclosed in U.S. Patent Nos. 6,143,548 and 9,408,904. In some embodiments, the recombinant virus is secreted into a cell culture medium and purified from the medium. In some embodiments, the packaging cells are lysed, and the contents are purified to recover the recombinant virus. In some embodiments, the virus is recovered from the packaging cells by filtration or centrifugation. In some embodiments, the virus is recovered from the packaging cells by chromatography.

[0178] In some embodiments, mammalian host cells are used to express the AAV VP2 fusion polypeptide and incorporate it into AAV viral particles, typically along with the AAV VP1 and VP3 polypeptides. For this purpose, HEK293 cells or derivatives thereof (such as HEK293T / 17 or AAV293 cells) can be transfected with nucleic acids encoding the AAV VP2 fusion polypeptide and nucleic acids encoding the AAV VP1, VP2, and rep polypeptides. In some embodiments, HEK293 cells are further transfected with nucleic acids encoding adenoviral helper functions for AAV replication (such as adenoviral E2, E4, and / or VA gene products). In some embodiments, HEK293 cells are co-transfected with the following nucleic acid molecules: a nucleic acid molecule encoding an AAV VP2 fusion polypeptide; a nucleic acid molecule encoding AAV VP1, VP2, and rep polypeptides, particularly wherein the AAV VP1 and VP2 polypeptides are encoded by the AAV cap gene, and more particularly wherein the AAV VP2 start codon in the AAV cap gene is mutated; a nucleic acid molecule encoding at least one, at least two, at least three, or at least four adenovirus helper functions for AAV replication, particularly wherein the nucleic acid molecule encodes adenovirus E2, E4, and VA gene products; and optionally additional nucleic acid molecules encoding therapeutic RNA or proteins. In some embodiments, the nucleic acid molecule encoding therapeutic RNA or proteins is encapsulated in an AAV capsid composed of the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides. In these embodiments, the nucleic acid molecule encoding therapeutic RNA or proteins typically further comprises a side-joined AAVITR sequence. In other embodiments, a nucleic acid molecule encoding the AAV VP2 fusion peptide is encapsulated in an AAV capsid composed of the AAV VP2 fusion peptide and AAV VP1 and VP3 peptides. In these embodiments, the nucleic acid molecule encoding the AAV VP2 fusion peptide further includes a side-mounted AAV ITR sequence. In other embodiments, a nucleic acid molecule including a barcode sequence and a side-mounted AAV ITR sequence is encapsulated in an AAV capsid composed of the AAV VP2 fusion peptide and AAV VP1 and VP3 peptides.

[0179] In some embodiments, a method for generating rAAV viral particles includes transfecting insect cells. Suitable insect cells include, but are not limited to, Sf9 cells. In some embodiments, the method includes transfecting insect cells with a baculovirus comprising a nucleic acid as disclosed herein. In some embodiments, the method includes transfecting insect cells with a baculovirus comprising a heterologous nucleic acid sequence inserted between a first AAV terminal repeat and a second AAV terminal repeat. In some embodiments, the method includes transfecting insect cells with a baculovirus comprising one or more additional nucleic acids. In some embodiments, the one or more additional nucleic acids comprise an AAV rep gene and / or an AAV cap gene. In some embodiments, the one or more additional nucleic acids comprise one or more adenovirus helper genes. In some embodiments, where the heterologous nucleic acid does not encode the AAV VP2 fusion polypeptide described herein, the method further comprises transfecting insect cells with additional nucleic acids encoding the AAV VP2 fusion polypeptide described herein. In some embodiments, insect cells are cultured under conditions suitable for generating recombinant virus. In some embodiments, virus is recovered from insect cells. In some embodiments, virus is recovered from insect cells by filtration or centrifugation. In some embodiments, virus is recovered from insect cells by chromatography.

[0180] In some embodiments, the cells are selected from mammalian cells, including but not limited to mouse cells, non-human primate cells, or human cells. Mammalian cells may be selected from the group consisting of: hepatocytes, brain cells, spleen cells, kidney cells, blood cells, lung cells, muscle cells, heart cells, bone marrow cells, pluripotent progenitor cells (MPPs) (such as pluripotent hematopoietic progenitor cells), and hematopoietic stem cells (HSCs) (such as long-term hematopoietic stem cells (LT-HSCs)).

[0181] rAAV viral particles containing AAV VP2 fusion peptide

[0182] In one respect, this article provides recombinant AAV (rAAV) viral particles comprising the AAV VP2 fusion peptide described herein.

[0183] The abbreviation "rAAV" refers to recombinant adeno-associated virus. As used herein, "rAAV vector" refers to an AAV vector containing a non-AAV-derived polynucleotide sequence (i.e., a polynucleotide heterologous to AAV), typically a target sequence for cellular genetic transformation. In some embodiments, the heteronucleotide encodes the AAV VP2 fusion polypeptide described herein. In some embodiments, the heteronucleotide encodes a therapeutic nucleic acid, therapeutic protein, or therapeutic antibody or antibody fragment. In some embodiments, the heteronucleotide may be side-joined with at least one (sometimes two) AAV inverted terminal repeat (ITR) sequence. The term rAAV vector encompasses both the rAAV vector particle and the rAAV vector nucleic acid. The rAAV vector can be single-stranded (ssAAV) or self-complementary (scAAV). "AAV virus," "AAV virus particle," or "AAV virus particle" refers to a viral particle consisting of at least one AAV capsid protein (typically composed of all capsid proteins of one or more wild-type AAVs or capsid proteins derived from one or more wild-type AAVs) and an encapsulated polynucleotide rAAV vector. If the particle contains heterologous polynucleotides (i.e., polynucleotides other than the wild-type AAV genome, such as transgenes to be delivered into mammalian cells), it is typically referred to as an "rAAV vector particle," "rAAV virus particle," or simply "rAAV vector."

[0184] In some embodiments, the AAV viral particles disclosed herein comprise one or more AAV capsid proteins. Typically, in AAV, three capsid proteins, VP1, VP2, and VP3, polymerize to form a capsid. The rAAV viral particles disclosed herein comprise an AAV VP2 fusion polypeptide and optionally further comprise AAV VP1 and / or VP3 polypeptides. Typically, the capsid of the rAAV viral particles disclosed herein is composed of VP1, VP3, and VP2 fusion polypeptide subunits. Typically, the capsid of the rAAV viral particles disclosed herein does not contain AAV VP2 capsid polypeptides that are not fused with a polypeptide ligand, meaning that typically, all VP2 subunits are AAV VP2 fusion polypeptides as described herein. The AAV capsid polypeptide contained in the rAAV viral particles disclosed herein can be derived from any AAV serotype from which recombinant viruses can be derived, including but not limited to AAV serotypes AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV or avian AAV.5, or any variant thereof, or variants thereof, having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over the full length of the VP1, VP2, and / or VP3 capsid polypeptide.

[0185] The polypeptide sequences of capsid proteins are known in the art and may also be derived from the genome of AAV. These can be used as exemplary capsids in the AAV viral compositions disclosed herein.

[0186] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 peptide and / or the AAV VP3 peptide contained in the rAAV viral particle described herein may be naturally occurring or mutant / variant capsid peptides independently selected from the group including, but not limited to, AAV1, AAV2, AAV2G9, AAV3, AAV3a, AAV3b, AAV3-3, AAV4, AAV4-4, AAV5, AAV6, AAV6.1, AAV6.2, AAV6.1.2, AAV7, AAV7.2, AAV8, AAV9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV9.9, AAV9.10, AAV9.11, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, AAV9.84, AAV9.9, AAV10, AAV11, AAV9.12, AAV9.13, AAV9.14, AAV9.15, AAV9.16 ...17, AAV9.18, AAV9.19, AAV9.10, AAV11, AAV9.19, AAV9.12, AAV9.13, A 12. AAV16.3, AAV24.1, AAV27.3, AAV42.12, AAV42-lb, AAV42-2, AAV42-3a, AAV42-3b, AAV42-4, AAV42-5a, AAV42-5b, AAV42-6b, A AV42-8, AAV42-10, AAV42-11, AAV42-12, AAV42-13, AAV42-15, AAV42-aa, AAV43-1, AAV43-12, AAV43-20, AAV43-21, AAV43-23, AA V43-25, AAV43-5, AAV44.1, AAV44.2, AAV44.5, AAV223.1, AAV223.2, AAV223.4, AAV223.5, AAV223.6, AAV223.7, AAVl-7 / rh.48, A AVl-8 / rh.49, AAV2-15 / rh.62, AAV2-3 / rh.61, AAV2-4 / rh.50, AAV2-5 / rh.51, AAV3.1 / hu.6, AAV3.1 / hu.9, AAV3-9 / rh.52, AAV3-l l / rh.53, AAV4-8 / r 11.64, AAV4-9 / rh.54, AAV4-19 / rh.55, AAV5-3 / rh.57, AAV5-22 / rh.58, AAV7.3 / hu.7, AAV16.8 / hu.10, AAV16.12 / hu.11, AAV29.3 / bb.1, AAV29.5 / bb.2, AAV106.1 / hu.37, AAV114.3 / hu.40, AAV127.2 / hu.41, AAV127.5 / hu.42, AAV128.3 / hu.44, AAV130.4 / hu.48, AAV145.1 / hu.53、AAV145.5 / hu.54、AAV145.6 / hu.55、AAV161.10 / hu.60、AAV161.6 / hu.61、AAV33.12 / hu.17、AAV33.4 / hu.15、AAV33.8 / hu.16、AAV52 / hu.19、AAV52.1 / hu.20、AAV58.2 / hu.25、AAV A3.3、AAV A3.4、AAV A3.5、AAV A3.7、AAVC1、AAVC2、AAVC5、AAV-DJ、AAV-DJ8、AAVF3、AAVF5、AAVH2、AAVrh.72、AAVhu.8、AAVrh.68、AAVrh.70、AAVpi.1、AAV pi.3、AAVpi.2、AAVrh.60、AAVrh.44、AAVrh.65、AAVrh.55、AAVrh.47、AAVrh.69、AAVrh.45、AAVrh.59、AAVhu.12、AAVh6、AA VLK03, AAVH-1 / hu.1, AAVH-5 / hu.3, AAVLG-10 / rh.40, AAVLG-4 / rh.38, AAVLG-9 / hu.39, AAVN721-8 / rh.43, AAVCh.5, AAVCh.5Rl, AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVCy.5Rl, AAVCy.5R2, AAVCy.5R3, AAVCy.5R4, AAVcy.6, AAVhu.1, AAVhu.2, AA Vhu.3、AAVhu.4、AAVhu.5、AAVhu.6、AAVhu.7、AAVhu.9、AAVhu.10、AAVhu.11、AAVhu.13、AAVhu.15、AAVhu.16、AAVhu.17、AA Vhu.18、AAVhu.20、AAVhu.21、AAVhu.22、AAVhu.23.2、AAVhu.24、AAVhu.25、AAVhu.27、AAVhu.28、AAVhu.29、AAVhu.29R、AA Vhu.31、AAVhu.32、AAVhu.34、AAVhu.35、AAVhu.37、AAVhu.39、AAVhu.40、AAVhu.41、AAVhu.42、AAVhu.43、AAVhu.44、AAVhu .44Rl、AAVhu.44R2、AAVhu.44R3、AAVhu.45、AAVhu.46、AAVhu.47、AAVhu.48、AAVhu.48Rl、AAVhu.48R2、AAVhu.48R3、AAVhu.49, AAVhu.51, AAVhu.52, AAVhu.54, AAVhu.55, AAVhu.56, AAVhu.57, AAVhu.58, AAVhu.60, AAVhu.61, AAVhu.63, AAVhu.64, AAVhu.66, AAVhu.67, AAVhu.14 / 9, AAVhu.t 19, AAVrh.2, AAVrh.2R, AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.12, AAVrh.13, AAVrh.13R, AAVrh.14, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.20, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrh.37R2, AAVrh.38, AAVrh.39, AAVrh.40, AAVrh.46, AAVrh.48, AAVrh.48.1, AAVrh.48.1.2, AAVrh.48.2, AAVrh.49, AAVrh.51, AAVrh.52, AAVrh.53, AAVrh.54, AAVrh.56, AAVrh.57, AAVrh.58, AAVrh.61, AAVrh.64, AAVrh.64Rl, AAVrh.64R2, AAVrh.67, AAVrh.73, AAVrh.74, AAVrh8R, AAVrh8R A586R mutant, AAVrh8R R533A mutant, AAAV, BAAV, goat AAV, bovine AAV, AAVhE1.1, AAVhEr1.5, AAVhER1.14, AAVhEr1.8, AAVhEr1.16, AAVhEr1.18, AAVhEr1.35, AAVhEr1.7, AAVhEr1.36, AAVhEr2.29, AAVhEr2.4, AAVhEr2.16, AAVhEr2.30, AAVhEr2.31, AAVhEr2.36, AAVhER1.23, AAVhEr3.1, AAV2.5T, AAV-PAEC, AAV-LK01, AAV-LK02, AAV-LK03, AAV-LK04, AAV-LK05, AAV-LK06, AAV-LK07, AAV-LK08, AAV-LK09, AAV-LK10, AAV-LK11, AAV-LK12, AAV-LK13, AAV-LK14, AAV-LK15, AAV -LK16, AAV-LK17, AAV-LK18, AAV-LK19, AAV-PAEC2, AAV-PAEC4, AAV-PAEC6, AAV-PAEC7, AAV-PAEC8, AAV-PAEC11, AAV-PAEC12, AAV-2-pre-miRNA-lOl, AAV-8h, AAV-8b, AAV-h, AAV-b, AAV SM 10-2, AAV Shuffle 100-1, AAV Shuffle 100-3, AAV Shuffle 100-7, AAV Shuffle 10-2, AAV Shuffle 10-6, AAV Shuffle10-8, AAV Shuffle100-2, AAV SM 10-1, AAV SM 10-8, AAV SM 100-3, AAV SM 100-10, BNP61 AAV, BNP62 AAV, BNP63 AAV, AAVrh.50, AAVrh.43, AAVrh.62, AAVrh.48, AAVhu.19, AAVhu.l, AAVhu.53, AAV4-8 / rh.64, AAVLG-9 / hu.39, AAV54.5 / hu.23, AAV54 .2 / hu.22, AAV54.7 / hu.24, AAV54.1 / hu.21, AAV54.4R / hu.27, AAV46.2 / hu.28, AAV46.6 / hu.29, AAV128.1 / hu.43, true AAV (ttAAV), UPEN AAV 10 and / or Japanese AAV 10. A capsid polypeptide, or a variant thereof, having at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% sequence identity over the full length of the VP1, VP2, and / or VP3 capsid polypeptides.

[0187] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or AAV VP3 polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotypes described in U.S. Publication No. US20030138772 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV1 (SEQ ID NO: 6 and 64 of US20030138772), AAV2 (SEQ ID NO: 7 and 70 of US20030138772), AAV3 (SEQ ID NO: 8 and 71 of US20030138772), AAV4 (SEQ ID NO: 63 of US20030138772), AAV5 (SEQ ID NO: 114 of US20030138772), AAV6 (SEQ ID NO: 114 of US20030138772), AAV4 (SEQ ID NO: 63 of US20030138772), AAV5 (SEQ ID NO: 114 of US20030138772), AAV6 (SEQ ID NO: 6 ... AAV7 (SEQ ID NO: 1-3 of US20030138772), AAV8 (SEQ ID NO: 4 and 95 of US20030138772), AAV9 (SEQ ID NO: 5 and 100 of US20030138772), AAV10 (SEQ ID NO: 117 of US20030138772), AAV11 (SEQ ID NO: 118 of US20030138772), AAV12 (SEQ ID NO: 119 of US20030138772), AAVrh10 (amino acids 1 to 738 of SEQ ID NO: 81 of US20030138772), AAV16.3 (SEQ ID NO: 65 of US20030138772), AAV7 (SEQ ID NO: 1-3 of US20030138772), AAV8 (SEQ ID NO: 4 and 95 of US20030138772), AAV9 (SEQ ID NO: 5 and 100 of US20030138772), AAV10 (SEQ ID NO: 117 of US20030138772), AAV11 (SEQ ID NO: 118 of US20030138772), AAV12 (SEQ ID NO: 119 of US20030138772), AAV16.3 (SEQ ID NO: 65 of US20030138772), AAV16.3 (SEQ ID NO: 65 of US20030138772), AAV17 (SEQ ID NO: 65 of US20030138772), AAV18 (SEQ ID NO: 65 of US20030138772), AAV19 (SEQ ID NO NO:10), AAV29.3 / bb.l(US20030138772 SEQ ID NO:11), AAV29.4(US 20030138772SEQ ID NO:12), AAV29.5 / bb.2(US20030138772 SEQ ID NO:13), AAV1.3(US 20030138772 SEQ ID NO:14), AAV13.3 (US 20030138772 SEQ ID NO:15), AAV24.1 (US 20030138772 SEQ ID NO:16), AAV27.3 (US 20030138772 SEQ ID NO:17), AAV7.2 (US 20030138772 SEQ ID NO:18), AAVC1 (US 20030138772 SEQ ID NO:19), AAVC3 (US 20030138772SEQ ID NO:20)、AAVC5(US 20030138772 SEQ ID NO:21)、AAVF1(US 20030138772 SEQ ID NO:22)、AAVF3(US20030138772 SEQ ID NO:23)、AAVF5(US 20030138772 SEQ ID NO:24)、AAVH6(US20030138772 SEQ ID NO:25)、AAVH2(US 20030138772 SEQ ID NO:26)、AAV42-8(US20030138772 SEQ ID NO:27)、AAV42-15(US 20030138772 SEQ ID NO:28)、AAV42-5b(US20030138772 SEQ ID NO:29)、AAV42-lb(US 20030138772 SEQ ID NO:30)、AAV42-13(US20030138772 SEQ ID NO:31)、AAV42-3a(US 20030138772 SEQ ID NO:32)、AAV42-4(US20030138772 SEQ ID NO:33)、AAV42-5a(US 20030138772 SEQ ID NO:34)、AAV42-10(US20030138772 SEQ ID NO:35)、AAV42-3b(US 20030138772 SEQ ID NO:36)、AAV42-11(US20030138772 SEQ ID NO:37)、AAV42-6b(US 20030138772 SEQ ID NO:38)、AAV43-1(US20030138772 SEQ ID NO:39)、AAV43-5(US 20030138772 SEQ ID NO:40)、AAV43-12(US20030138772 SEQ ID NO:41)、AAV43-20(US 20030138772 SEQ ID NO:42)、AAV43-21(US20030138772 SEQ ID NO:43)、AAV43-23(US 20030138772 SEQ ID NO:44)、AAV43-25(US20030138772 SEQ ID NO:45)、AAV44.1(US 20030138772 SEQ ID NO:46)、AAV44.5(US20030138772 SEQ IDNO: 47), AAV223.1 (US 20030138772 SEQ ID NO: 48), AAV223.2 (US 20030138772 SEQ ID NO: 49), AAV223.4 (US 20030138772 SEQ ID NO: 50), AAV223.5 (US 20030138772 SEQ ID NO: 51), AAV223.6 (US 20030138772 SEQ ID NO: 52), AAV223.7 (US 20030138772 SEQ ID NO: 53), AAV A3.4 (US 20030138772 SEQ ID NO: 54), AAV A3.5 (US 20030138772 SEQ ID NO: 55), AAV A3.7 (US 20030138772 SEQ ID NO: 56), AAV A3.3 (US 20030138772 SEQ ID NO: 57), AAV42.12 (US 20030138772 SEQ ID NO: 58), AAV44.2 (US 20030138772 SEQ ID NO: 59), AAV42-2 (US 20030138772 SEQ ID NO: 9) or variants thereof.

[0188] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or AAV VP3 polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotypes described in U.S. Publication No. US20150159173 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV2 (SEQ ID NO:7 and 23 of US20150159173), rh20 (SEQ ID NO:1 of US20150159173), rh32 / 33 (SEQ ID NO:2 of US20150159173), rh39 (SEQ ID NO:3, 20 and 36 of US20150159173), rh46 (SEQ ID NO:4 and 22 of US20150159173), rh73 (SEQ ID NO:3 of US20150159173), rh46 (SEQ ID NO:4 and 22 of US20150159173), and rh73 (SEQ ID NO:3 of US20150159173). NO: 5), rh74 (SEQ ID NO: 6 of US20150159173), AAV6.1 (SEQ ID NO: 29 of US 20150159173), rh.8 (SEQ ID NO: 41 of US20150159173), rh.48.1 (SEQ ID NO. of US20150159173) NO: 44), hu.44 (SEQ ID NO: 45 of US20150159173), hu.29 (SEQ ID NO: 42 of US20150159173), hu.48 (SEQ ID NO: 38 of US20150159173), rh54 (SEQ ID of US20150159173 NO:49), AAV2 (SEQ ID NO:7 of US20150159173), cy.5 (US The following are related to the SEQ ID NOs of US20150159173: SEQ ID NOs 8 and 24, rh.10 (SEQ ID NOs 9 and 25), rh.13 (SEQ ID NOs 10 and 26), AAV1 (SEQ ID NOs 11 and 27), AAV3 (SEQ ID NOs 12 and 28), AAV6 (SEQ ID NOs 13 and 29), AAV7 (SEQ ID NOs 14 and 30), AAV8 (SEQ ID NOs 15 and 31), hu.13 (SEQ ID NOs 16 and 32), and hu.26 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NO: 18 and 34 of US20150159173), hu.53 (SEQ ID NO: 19 and 35 of US20150159173), rh.43 (SEQ ID NO: 21 and 37 of US20150159173), rh2 (SEQ ID NO: 39 of US20150159173), rh.37 (SEQ ID NO: 40 of US20150159173), rh.64 (SEQ ID NO: 43 of US20150159173), rh.48 (SEQ ID NO: 44 of US20150159173), ch.5 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NO: 18 and 34 of US20150159173), hu.53 (SEQ ID NO: 19 and 35 of US20150159173), rh.43 (SEQ ID NO: 21 and 37 of US20150159173), rh2 (SEQ ID NO: 39 of US20150159173), rh.37 (SEQ ID NO: 40 of US20150159173), ch.5 (SEQ ID NO: 17 and 33 of US20150159173), hu.37 (SEQ ID NO: 18 and 34 of US20150159173), hu.53 (SEQ ID NO: 19 and 35 of US20150159173), hu.53 (SEQ ID NO: 19 and 3 (SEQ ID NO:46), rh.67 (SEQ ID NO:47 of US20150159173), rh.58 (SEQ ID NO:48 of US20150159173), or variants thereof, including but not limited to Cy5R1, Cy5R2, Cy5R3, Cy5R4, rh.13R, rh.37R2, rh.2R, rh.8R, rh.48.1, rh.48.2, rh.48.1.2, hu.44R1, hu.44R2, hu.44R3, hu.29R, ch.5R1, rh64R1, rh64R2, AAV6.2, AAV6.1, AAV6.12, hu.48R1, hu.48R2, and hu.48R3.

[0189] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or the AAV VP3 polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotypes described in U.S. Patent No. US 7198951 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV9 (SEQ ID NO:1-3 of US 7198951), AAV2 (SEQ ID NO:4 of US 7198951), AAV1 (SEQ ID NO:5 of US 7198951), AAV3 (SEQ ID NO:6 of US 7198951), and AAV8 (SEQ ID NO:7 of US 7198951).

[0190] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or the AAV VP3 polypeptide contained in the rAAV viral particles described herein may be derived from an AAV serotype that may be or has mutations in the AAV9 sequence as described by N Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), which is incorporated herein by reference in its entirety), such as, but not limited to, AAV9.9, AAV9.11, AAV9.13, AAV9.16, AAV9.24, AAV9.45, AAV9.47, AAV9.61, AAV9.68, and AAV9.84. In some embodiments, the AAV capsid comprises one or more sequences engineered to deliver a vector across the blood-brain barrier (see, for example, BEDeverman et al., Nature Biotech, Vol. 34, No. 2, pp. 204-211 (published online February 1, 2016); and Caltech Press Release, A. Wetherston, www.neurology-cenfrd.com / 2016 / 02 / 10 / successfd / brain-barrier; see also WO 2016 / 0492301 and US 8,734,809 (the contents of each of these are incorporated herein by reference in their entirety)).

[0191] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or the AAV VP3 polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent No. US 6156303 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV3B (SEQ ID NO:1 and 10 of US 6156303), AAV6 (SEQ ID NO:2, 7 and 11 of US 6156303), AAV2 (SEQ ID NO:3 and 8 of US 6156303), AAV3A (SEQ ID NO:4 and 9 of US 6156303), or derivatives thereof.

[0192] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 polypeptide and / or AAV VP3 polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Publication No. US20140359799 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV 8 (SEQ ID NO:1 of US20140359799), AAVDJ (SEQ ID NO:2 and 3 of US20140359799), or variants thereof.

[0193] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from an AAV serotype selected from AAVDJ or variants thereof, such as AAVDJ8 (or AAV-DJ8), as described by Grimm et al. (Journal of Virology 82(12):5887-5911(2008), incorporated herein by reference in its entirety). The amino acid sequence of AAVDJ8 may contain two or more mutations to remove the heparin-binding domain (HBD). As a non-limiting example, the AAV-DJ sequence described as SEQ ID NO:1 in U.S. Patent No. 7,588,772 (the contents of which are incorporated herein by reference in their entirety) may contain the following two mutations: (1) R587Q, wherein arginine at amino acid 587 (R; Arg) is changed to glutamine (Q; Gln); and (2) R590T, wherein arginine at amino acid 590 (R; Arg) is changed to threonine (T; Thr). As another non-limiting example, it may contain the following three mutations: (1) K406R, wherein lysine at amino acid 406 (K; Lys) is changed to arginine (R; Arg); (2) R587Q, wherein arginine at amino acid 587 (R; Arg) is changed to glutamine (Q; Gln); and (3) R590T, wherein arginine at amino acid 590 (R; Arg) is changed to threonine (T; Thr).

[0194] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in International Publication No. WO 1998011244 (the contents of which are incorporated herein by reference in their entirety), such as but not limited to AAV4 (SEQ ID NO:1-20 of WO 1998011244).

[0195] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from an AAV serotype that may be or have mutations in the AAV2 sequence as described in International Publication No. WO 2014144229 (which is incorporated herein by reference in its entirety) to produce AAV2G9.

[0196] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in International Publication No. WO 2005033321 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV3-3 (SEQ ID NO: 217 of WO 2005033321), AAV1 (SEQ ID NO: 219 and 202 of WO 2005033321), AAV106.1 / hu.37 (SEQ ID No: 10 of WO 2005033321), AAV114.3 / hu.40 (SEQ ID No: 11 of WO 2005033321), AAV127.2 / hu.41 (SEQ ID No: 10 of WO 2005033321), AAV114.3 / hu.40 (SEQ ID No: 11 of WO 2005033321), and AAV127.2 / hu.41 (SEQ ID No: 10 of WO 2005033321). NO:6 and 8), AAV128.3 / hu.44 (SEQ ID No:81 of WO 2005033321), AAV130.4 / hu.48 (SEQ ID NO:78 of WO 2005033321), AAV145.1 / hu.53 (SEQ ID No:176 and 177 of WO 2005033321), AAV145.6 / hu.56 (SEQ ID NO:168 and 192 of WO 2005033321), AAV16.12 / hu.11 (SEQ ID NO:153 and 57 of WO 2005033321), AAV16.8 / hu.10 (SEQ ID NO:156 and 56 of WO 2005033321), AAV161.10 / hu.60 (WO SEQ ID No: 170 of WO 2005033321), AAV161.6 / hu.61 (SEQ ID No: 174 of WO 2005033321), AAV1-7 / rh.48 (SEQ ID NO: 32 of WO 2005033321), AAV1-8 / rh.49 (SEQ ID NO: 103 and 25 of WO 2005033321), AAV2 (SEQ ID NO: 211 and 221 of WO 2005033321), AAV2-15 / rh.62 (SEQ ID No: 33 and 114 of WO 2005033321), AAV2-3 / rh.61 (SEQ ID NO: 21 of WO 2005033321), AAV2-4 / rh.50 (SEQ ID No: 170 of WO 2005033321). No:23 and 108), AAV2-5 / rh.51 (SEQ ID NO: 104 and 22 of WO 2005033321), AAV3.1 / hu.6 (SEQ ID NO: 5 and 84 of WO 2005033321), AAV3.1 / hu.9 (SEQ ID NO: 155 and 58 of WO 2005033321), AAV3-11 / rh.53 (SEQ ID NO: 186 and 176 of WO 2005033321), AAV3-3 (SEQ ID NO: 200 of WO 2005033321), AAV33.12 / hu.17 (SEQ ID NO: 4 of WO 2005033321), AAV33.4 / hu.15 (SEQ ID NO: 51 ... No:50), AAV33.8 / hu.16 (SEQ ID No:51 of WO2005033321), AAV3-9 / rh.52 (SEQ ID NO:96 and 18 of WO 2005033321), AAV4-19 / rh.55 (SEQ ID NO:117 of WO 2005033321), AAV4-4 (SEQ ID NO:201 and 218 of WO 2005033321), AAV4-9 / rh.54 (SEQ ID NO:116 of WO 2005033321), AAV5 (SEQ ID NO:199 and 216 of WO 2005033321), AAV52.1 / hu.20 (SEQ ID NO:50 of WO 2005033321) NO:63), AAV52 / hu.l9 (SEQ ID NO:133 of WO2005033321), AAV5-22 / rh.58 (SEQ ID No:27 of WO 2005033321), AAV5-3 / rh.57 (SEQ ID NO:105 of WO 2005033321), AAV5-3 / rh.57 (SEQ ID No:26 of WO 2005033321), AAV58.2 / hu.25 (SEQ ID No:49 of WO 2005033321), AAV6 (SEQ ID NO:203 and 220 of WO 2005033321), AAV7 (SEQ ID NO:222 and 213 of WO 2005033321), AAV7.3 / hu.7 (WO SEQ ID No: 55 of WO2005033321), AAV 8 (SEQ ID NO: 223 and 214 of WO2005033321), AAVH-l / hu.1 (SEQ ID No: 46 of WO2005033321), AAVH-5 / hu.3 (SEQ ID No:44 of WO 2005033321), AAVhu.1 (SEQ ID NO:144 of WO2005033321), AAVhu.10 (SEQ ID NO:156 of WO 2005033321), AAVhu.11 (SEQ ID NO:153 of WO2005033321), AAVhu.12 (SEQ ID NO:59 of WO 2005033321), AAVhu.13 (SEQ ID NO:129 of WO2005033321), AAVhu.14 / AAV9 (SEQ ID NO:123 and 3 of WO 2005033321), AAVhu.15 (SEQ ID NO:147 of WO 2005033321), AAVhu.16 (SEQ ID NO:148 of WO 2005033321), AAVhu.17 (SEQ ID NO:83 of WO 2005033321), AAVhu.18 (SEQ ID NO:149 of WO 2005033321), AAVhu.19 (SEQ ID NO:133 of WO 2005033321), AAVhu.2 (SEQ ID NO:143 of WO 2005037 (SEQ ID NO:88 of WO 2005033321), AAVhu.39 (SEQ ID NO:102 of WO 2005033321), AAVhu.4 (SEQ ID NO:141 of WO 2005033321), AAVhu.40 (SEQ ID NO:87 of WO 2005033321), AAVhu.41 (SEQ ID NO:91 of WO 2005033321), AAVhu.42 (SEQ ID NO:85 of WO 2005033321), AAVhu.43 (SEQ ID NO:160 of WO 2005033321), AAVhu.44 (SEQ ID NO:144 of WO 2005033321), AAVhu.45 (SEQ ID NO:127 of WO 2005033321), AAVhu.46 (SEQ ID NO:159 of WO 2005033321), AAVhu.47 (SEQ ID NO:128 of WO 2005033321), AAVhu.48 (SEQ ID NO:157 of WO 2005033321), AAVhu.49 (SEQ ID NO:189 of WO 2066 (SEQ ID NO:197 of WO 2005033321), AAVhu.67 (SEQ ID NO:198 of WO 2005033321), AAVhu.7 (SEQ ID NO:150 of WO 2005033321), AAVhu.8 (SEQ ID NO:12 of WO 2005033321), AAVhu.9 (SEQ ID NO:155 of WO 2005033321), AAVLG-10 / rh.40 (SEQ ID No:14 of WO 2005033321), AAVLG-4 / rh.38 (SEQ ID NO:86 of WO 2005033321), AAVLG-4 / rh.38 (SEQ ID No:7 of WO 2005033321), AAVN721-8 / rh.43 (SEQ ID NO:163 of WO 2005033321), AAVN721-8 / rh.43 (SEQ ID No:43 of WO 2005033321), AAVpi.l (SEQ ID NO:28 of WO 2005033321), AAVpi.2 (SEQ ID NO:30 of WO 20050333‘21), AAVpi.3 (SEQ ID NO:29 of WO 2005033321), AAVrh.38 (SEQ ID NO:86 of WO 2005033321), AAVrh.40 (SEQ ID NO:92 of WO 2005033321), AAVrh.43 (SEQ ID NO:163 of WO 2005033321), AAVrh.44 (SEQ ID NO:34 of WO 2005033321), AAVrh.45 (SEQ ID NO:41 of WO 2005033321), AAVrh.47 (SEQ ID NO:38 of WO 2005033321), AAVrh.48 (SEQ ID NO:115 of WO 2005033321), AAVrh.49 (SEQ ID NO:103 of WO 2005033321), AAVrh.50 (SEQ ID NO:108 of WO 2005033321), AAVrh.51 (SEQ ID NO:104 of WO 2005033321), AAVrh.52 (SEQ ID NO:96 of WO 2005033321), AAVrh.53 (SEQ ID NO:97 of WO 2005033321), AAVrh.55 (SEQ ID NO:37 of WO 2005033321), AAVrh.56 (SEQ ID NO: 152 of WO 2005033321), AAVrh.57 (SEQ ID NO: 105 of WO 2005033321), AAVrh.58 (SEQ ID NO: 106 of WO 2005033321), AAVrh.59 (SEQ ID NO: WO 2005033321 IDNO:42), AAVrh.60 (SEQ ID NO:31 of WO 2005033321), AAVrh.61 (SEQ ID NO:107 of WO 2005033321), AAVrh.62 (SEQ ID NO:114 of WO 2005033321), AAVrh.64 (WO SEQ IDNO:99 of 2005033321), AAVrh.65 (WO 2005033321 SEQ AAVrh.68 (WO 2005033321 SEQ ID NO:16), AAVrh.69 (WO 2005033321 SEQ ID NO:39), AAVrh.70 (WO 2005033321 SEQ ID NO:20), AAVrh.72 (WO2005033321 SEQ ID NO:9), or variants thereof, including but not limited to AAVcy.2, AAVcy.3, AAVcy.4, AAVcy.5, AAVcy.6, AAVrh.12, AAVrh.17, AAVrh.18, AAVrh.19, AAVrh.21, AAVrh.22, AAVrh.23, AAVrh.24, AAVrh.25, AAVrh.25 / 42 15. AAVrh.31, AAVrh.32, AAVrh.33, AAVrh.34, AAVrh.35, AAVrh.36, AAVrh.37, AAVrhl4. Non-limiting examples of variations include SEQ ID NOs: 13, 15, 17, 19, 24, 36, 40, 45, 47, 48, 51-54, 60-62, 64-77, 79, 80, 82, 89, 90, 93-95, 98, 100, 101, 109-113, 118-120, 124, 126, 131, 139, 142, 151, 154, 158, 161, 162, 165-183, 202, 204-212, 215, 219, 224-236 of WO2005033321 (the contents of which are incorporated herein by reference in their entirety).

[0197] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in International Publication No. WO 2015168666 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVrh8R (SEQ ID NO:9 of WO 2015168666), AAVrh8R A586R mutant (SEQ ID NO:10 of WO 2015168666), AAVrh8R R533A mutant (SEQ ID NO:11 of WO 2015168666), or variants thereof.

[0198] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in International Publication No. WO2018 / 160582 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVhu68 (e.g., SEQ ID NO:2 of WO 2018160582) or variants thereof.

[0199] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent No. US 9233131 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVhE1.1 (SEQ ID NO: 44 of US 9233131), AAVhEr1.5 (SEQ ID NO: 45 of US 9233131), AAVhER1.14 (SEQ ID NO: 46 of US 9233131), AAVhEr1.8 (SEQ ID NO: 47 of US 9233131), AAVhEr1.16 (SEQ ID NO: 48 of US 9233131), AAVhEr1.18 (SEQ ID NO: 47 of US 9233131), AAVhEr1.16 (SEQ ID NO: 48 of US 9233131), and AAVhEr1.18 (SEQ ID NO: 48 of US 9233131). NO: 49), AAVhEr1.35 (SEQ ID NO: 50 of US 9233131), AAVhEr1.7 (SEQ ID NO: 51 of US 9233131), AAVhEr1.36 (SEQ ID NO: 52 of US 9233131), AAVhEr2.29 (SEQ ID of US 9233131 NO: 53), AAVhEr2.4 (SEQ ID NO: 54 of US 9233131), AAVhEr2.16 (SEQ ID NO: 55 of US 9233131), AAVhEr2.30 (SEQ ID NO: 56 of US 9233131), AAVhEr2.31 (SEQ ID of US 9233131 NO:58), AAVhEr2.36 (SEQ ID of US 9233131 (NO:57), AAVhER1.23 (SEQ ID NO:53 of US 9233131), AAVhEr3.1 (SEQ ID NO:59 of US 9233131), AAV2.5T (SEQ ID NO:42 of US 9233131), or variants thereof.

[0200] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent Publication No. US 20150376607 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV-PAEC (SEQ ID NO:1 of US20150376607), AAV-LKO1 (SEQ ID NO:2 of US20150376607), AAV-LK02 (SEQ ID NO:3 of US20150376607), AAV-LK03 (SEQ ID NO:4 of US20150376607), AAV-LK04 (SEQ ID NO:4 of US20150376607), and AAV-LK04 (SEQ ID NO:3 of US20150376607). NO:5), AAV-LK05 (SEQ ID NO:6 of US20150376607), AAV-LK06 (SEQ ID NO:7 of US20150376607), AAV-LK07 (SEQ ID NO:8 of US20150376607), AAV-LK08 (SEQ ID of US20150376607 NO: 9), AAV-LK09 (SEQ ID NO: 10 of US20150376607), AAV-LK10 (SEQ ID NO: 1 of US20150376607), AAV-LK11 (SEQ ID NO: 12 of US20150376607), AAV-LK12 (SEQ ID of US20150376607 NO:13), AAV-LK13 (SEQ ID of US20150376607 NO:14), AAV-LK14 (SEQ ID NO:15 of US20150376607), AAV-LK15 (SEQ ID NO:16 of US20150376607), AAV-LK16 (SEQ ID NO:17 of US20150376607), AAV-LK17 (SEQ ID of US20150376607 NO: 18), AAV-LK18 (SEQ ID NO: 19 of US20150376607), AAV-LK19 (SEQ ID NO: 20 of US20150376607), AAV-PAEC2 (SEQ ID NO: 21 of US 20150376607), AAV-PAEC 4 (SEQ ID of US20150376607) NO:22), AAV-PAEC6 (SEQ ID of US20150376607(NO:23), AAV-PAEC7 (SEQ ID NO:24 of US20150376607), AAV-PAEC8 (SEQ ID NO:25 of US20150376607), AAV-PAEC11 (SEQ ID NO:26 of US20150376607), AAV-PAEC12 (SEQ ID NO:27 of US20150376607), or variants thereof.

[0201] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent No. US9163261 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV-2-premiRNA-101 (SEQ ID NO:1 of US 9163261) or variants thereof.

[0202] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent Publication No. 20150376240 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV-8h (SEQ ID NO:6 of US20150376240), AAV-8b (SEQ ID NO:5 of US20150376240), AAV-h (SEQ ID NO:2 of US20150376240), AAV-b (SEQ ID NO:1 of US20150376240), or variants thereof.

[0203] In some embodiments, the AAV particles of the present invention may comprise or be derived from such AAV serotypes, which may be or have sequences as described in U.S. Patent Publication No. US20160017295 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAV SM 10-2 (SEQ ID NO:22 of US20160017295), AAV Shuffle 100-1 (SEQ ID NO:23 of US20160017295), AAV Shuffle 100-3 (SEQ ID NO:24 of US20160017295), AAV Shuffle 100-7 (SEQ ID NO:25 of US20160017295), AAV Shuffle 10-2 (SEQ ID NO:34 of US20160017295), AAV Shuffle 10-6 (SEQ ID NO:35 of US20160017295), AAV Shuffle AAV SM 10-8 (SEQ ID NO:36 of US 20160017295), AAV Shuffle 100-2 (SEQ ID NO:37 of US20160017295), AAV SM 10-1 (SEQ ID NO:38 of US20160017295), AAV SM10-8 (SEQ ID NO:39 of US20160017295), AAV SM 100-3 (SEQ ID NO:40 of US20160017295), AAV SM 100-10 (SEQ ID NO:41 of US 20160017295), or variations thereof.

[0204] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent Publication No. 20150238550 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, BNP61 AAV (SEQ ID NO:1 of US20150238550), BNP62 AAV (SEQ ID NO:3 of US20150238550), BNP63 AAV (SEQ ID NO:4 of US20150238550), or variants thereof.

[0205] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in U.S. Patent Publication No. US 20150315612 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAVrh.50 (SEQ ID NO: 108 of US20150315612), AAVrh.43 (SEQ ID NO: 163 of US20150315612), AAVrh.62 (SEQ ID NO: 114 of US20150315612), AAVrh.48 (SEQ ID NO: 115 of US20150315612), AAVhu.19 ...5 of US20150315612), AAVhu.19 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO: 115 of US20150315612), AAVhu.19 (SEQ ID NO:133), AAVhu.ll (SEQ ID NO:153 of US20150315612), AAVhu.53 (SEQ ID NO:186 of US20150315612), AAV4-8 / rh.64 (SEQ ID No:15 of US20150315612), AAVLG-9 / hu.39 (SEQ ID No:24 of US20150315612), AAV54.5 / hu.23 (SEQ ID No:60 of US20150315612), AAV54.2 / hu.22 (SEQ ID No:67 of US20150315612), AAV54.7 / hu.24 (SEQ ID No:66 of US20150315612), AAV54.1 / hu.21 (SEQ ID No:133 of US20150315612), AAVhu.11 (SEQ ID No:153 of US20150315612), AAVhu.23 (SEQ ID No:186 of US20150315612), AAV4-8 / rh.64 (SEQ ID No:15 of US20150315612), AAVLG-9 / hu.39 (SEQ ID No:24 of US20150315612), AAV54.5 / hu.23 (SEQ ID No:60 of US20150315612), AAV54.1 / hu.21 (SEQ ID No:133 of US20150315612), AAV4-8 / rh.64 (SEQ ID No:15 ... (SEQ ID No: 65), AAV54.4R / hu.27 (SEQ ID No: 64 of US20150315612), AAV46.2 / hu.28 (SEQ ID No: 68 of US20150315612), AAV46.6 / hu.29 (SEQ ID No: 69 of US20150315612), AAV128.1 / hu.43 (SEQ ID No: 80 of US20150315612) or variants thereof.

[0206] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 capsid polypeptide and / or the AAV VP3 capsid polypeptide contained in the rAAV viral particles described herein may have or be derived from the AAV serotype described in International Publication No. WO 2015121501 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, true AAV (ttAAV) (SEQ ID NO:2 of WO 2015121501), “UPenn AAV10” (SEQ ID NO:8 of WO 2015121501), “Japanese AAV10” (SEQ ID NO:9 of WO 2015121501), or variants thereof.

[0207] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 capsid peptide and / or the AAV VP3 capsid peptide contained in the rAAV viral particles described herein may be selected from the capsid peptides disclosed in International Publication No. WO 2015191508 (the contents of which are incorporated herein by reference in their entirety).

[0208] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 and / or VP3 peptides contained in the rAAV viral particles described herein may have a heterozygous serotype, which has enhanced transduction or tropism in a specific target cell type, prolonged transgene expression, and / or improved safety profile. The heterozygous serotype can be generated by capsid transformation, bispecific antibody adsorption to the capsid surface, inlay capsids and chimeric capsids, and / or other capsid protein modifications.

[0209] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 and / or VP3 peptides contained in the rAAV viral particles described herein may be further modified to produce new AAV variants through reasonable mutagenesis of the capsid protein (see, for example, Pulicherla et al., Mol Ther [Molecular Therapy], 2011, 19:1070-1078), peptide ligand incorporation into the capsid, and directed evolution for specific therapeutic applications.

[0210] The AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptides contained in the rAAV viral particles described herein may have an AAV serotype that may be selected from or derived from a variety of species, including but not limited to humans, non-human primates, birds, and cattle. In one embodiment, the AAV may be avian AAV (AAAV). The AAAV serotype may be or have a sequence as described in U.S. Patent No. US 9,238,800 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, AAAV (SEQ ID NOs: 1, 2, 4, 6, 8, 10, 12, and 14 of US 9,238,800) or variants thereof.

[0211] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may have an AAV serotype that may be or is derived from bovine AAV (BAAV). The BAAV serotype may be or have a sequence as described in U.S. Patent No. 9,193,769 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, BAAV (SEQ ID NO: 1 and 6 of US 9,193,769) or variants thereof. The BAAV serotype may be or have a sequence as described in U.S. Patent No. 7,427,396 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, BAAV (SEQ ID NO: 5 and 6 of US 7,427,396) or variants thereof.

[0212] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptides contained in the rAAV viral particles described herein may have an AAV serotype that may be or is derived from goat AAV. The goat AAV serotype may be or have a sequence as described in U.S. Patent No. US7427396 (the contents of which are incorporated herein by reference in their entirety), such as, but not limited to, goat AAV (SEQ ID NO: 3 of US 7427396) or variants thereof.

[0213] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptides contained in the rAAV viral particles described herein may have an AAV serotype that can be engineered as a hybrid AAV derived from two or more parental serotypes. In some embodiments, the serotype may be AAV2G9, comprising sequences from AAV2 and AAV9. The AAV2G9 AAV serotype may be or have the sequences described in U.S. Patent Publication No. US20160017005 (the contents of which are incorporated herein by reference in their entirety).

[0214] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 and / or VP3 peptide contained in the rAAV viral particles described herein may have an AAV serotype that can be generated from an AAV9 capsid library having a mutation in amino acids 390-627 (VP1 number) as described by Pulicherla et al. (Molecular Therapy 19(6):1070-1078 (2011), the contents of which are incorporated herein by reference in their entirety). The serotype and corresponding nucleotide and amino acid substitutions can be, but are not limited to, AAV9.1 (G1594C; D532H), AAV6.2 (T1418A and T1436X; V473D and I479K), AAV9.3 (T1238A; F413Y), AAV9.4 (T1250C and A1617T; F417S), AAV9.5 (A1235G, A1314T, A1642G, C1760T; Q412R, T548A, A587V), AAV9.6 (T12... 31A; F411I), AAV9.9 (G1203A, G1785T; W595C), AAV9.10 (A1500G, T1676C; M559T), AAV9.11 (A1425T, A1702C, A1769T ; T568P, Q590L), AAV9.13 (A1369C, A1720T; N457H, T574S), AAV9.14 (T1340A, T1362C, T1560C, G1713A; L447H), AAV9 .16(A1775T; Q592L), AAV9.24(T1507C, T1521G; W503R), AAV9.26(A1337G, A1769C; Y446C, Q590P), AAV9.33(A1667C ; D556A), AAV9.34 (A1534G, C1794T; N512D), AAV9.35 (A1289T, T1450A, C1494T, A1515T, C1794A, G1816A; Q430L, Y48 4N, N98K, V606I), AAV9.40 (A1694T, E565V), AAV9.41 (A1348T, T1362C; T450S), AAV9.44 (A1684C, A1701T, A1737G; N 562H, K567N), AAV9.45 (A1492T, C1804T; N498Y, L602F), AAV9.46 (G1441C, T1525C, T1549G; G481R, W509R, L517V), 9.47(G1241A, G1358A, A1669G, C1745T; S414N, G453D, K557E, T582I), AAV9.48 (C1445T, A1736T; P482L, Q579L ), AAV9.50 (A1638T, C1683T, T1805A; Q546H, L602H), AAV9.53 (G1301A, A1405C, C1664T, G1811T; R134Q, S469 R, A555V, G604V), AAV9.54 (C1531A, T1609A; L511I, L537M), AAV9.55 (T1605A; F535L), AAV9.58 (C1475T, C1 579A; T492I, H527N), AAV.59 (T1336C; Y446H), AAV9.61 (A1493T; N498I), AAV9.64 (C1531A, A1617T; L511I), AAV9.65 (C1335T, T1530C, C1568A; A523D), AAV9.68 (C1510A; P504T), AAV9.80 (G1441A; G481R), AAV9.83 (C 1402A, A1500T; P468T, E500D), AAV9.87 (T1464C, T1468C; S490P), AAV9.90 (A1196T; Y399F), AAV9.91 (T1316 G, A1583T, C1782G, T1806C; L439R, K528I), AAV9.93 (A1273G, A1421G, A1638C, C1712T, G1732A, A1744T, A1832T; S425G, Q474R, Q546H, P571L, G578R, T582S, D611V), AAV9.94 (A1675T; M559L) and AAV9.95 (T1605A; F535L).

[0215] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may contain the capsid sequences of SEQ ID NO:1 and 3 of International Publication No. WO2014160092 (the contents of which are incorporated herein by reference in their entirety).

[0216] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may contain the AAV capsid sequence of SEQ ID NO:1 or SEQ ID NO:2 to 4 of International Publication No. WO2014052789 (the contents of which are incorporated herein by reference in their entirety).

[0217] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 and / or VP3 peptides contained in the rAAV viral particles described herein may have an increased ability to cross the blood-brain barrier in the CNS, as disclosed in U.S. Patent No. 8,927,514 (the contents of which are incorporated herein by reference in their entirety). The amino acid and nucleic acid sequences of such capsid proteins may include, but are not limited to, SEQ ID NO:2-17 and SEQ ID NO:25-33 of U.S. Patent No. 8,927,514, respectively.

[0218] In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide described herein and / or the AAV VP1 and / or VP3 peptides contained in the rAAV viral particles described herein are AAV5 capsid proteins or variants thereof, such as those capsid proteins or variants thereof of U.S. Patent No. 7,056,502 (the contents of which are incorporated herein by reference in their entirety).

[0219] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be the AAV6 capsid protein or a variant thereof.

[0220] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be the AAV8 capsid protein or a variant thereof, such as containing the amino acid sequence of SEQ ID NO:2 of U.S. Patent No. 8,318,480 (the contents of which are incorporated herein by reference in their entirety).

[0221] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be the AAV9 capsid protein or a variant thereof, such as containing the amino acid sequence of SEQ ID NO:2 of U.S. Patent No. 7,198,951 (the contents of which are incorporated herein by reference in their entirety), or the sequence of SEQ ID NO:2, 4, or 6 disclosed in U.S. Patent Publication No. US20130224836 (the contents of which are incorporated herein by reference in their entirety), wherein at least one surface-exposed tyrosine residue in the amino acid sequence is replaced by another amino acid residue.

[0222] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be variant capsid proteins engineered to obtain specific properties. Such methods for obtaining engineered capsids are described, for example, in patent publication WO2011038187, the contents of which are incorporated herein by reference in their entirety. Such methods and vectors are also described, for example, in patent publication WO 2012112832 and patent application publication WO 2015054653, the contents of which are incorporated herein by reference in their entirety. Such variant capsids comprise, for example, SEQ ID NO:23 or a variant thereof of WO 2015054653. Further variant capsids comprise, for example, those capsid sequences described in patent publication WO2017 / 019994 (the contents of which are incorporated herein by reference in their entirety). In the embodiments, the AAV capsid polypeptide may comprise the Anc80 AAV capsid sequence (e.g., SEQ ID NO:1 of WO 2017019994), such as Anc80L65 (e.g., SEQ ID NO:23 of WO 2017019994); or such as Anc110 (e.g., SEQ ID NO:42 of WO2017019994).

[0223] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be the AAVrh10 capsid protein or a variant thereof, for example, containing the amino acid sequence of SEQ ID NO:81 of European Patent No. 2341068.

[0224] In some embodiments, the AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide described herein and / or the AAV VP1 and / or VP3 polypeptide contained in the rAAV viral particles described herein may be the AAVDJ capsid protein, the AAVDJ / 8 capsid protein, or variants thereof. In some embodiments, the AAVDJ capsid protein and / or the AAVDJ / 8 capsid protein may comprise an amino acid sequence comprising a first region derived from a first AAV serotype (e.g., AAV2), a second region derived from a second AAV serotype (e.g., AAV8), and a third region derived from a third AAV serotype (e.g., AAV9), wherein the first, second, and third regions may comprise any amino acid sequence disclosed herein.

[0225] In some embodiments, the serotype of the AAV capsid peptide can be determined based on the desired distribution, transduction efficiency, and required cell targeting. As described by Sorrentino et al. (comprehensive map of CNS transduction by eightadeno-associated virus serotypes upon cerebrospinal fluid administration inpigs, Molecular Therapy, December 7, 2015, online preview); doi:10.1038 / mt.2015.212; the contents of which are incorporated herein by reference in their entirety), AAV serotypes offer different distributions, transduction efficiencies, and cell targeting. To provide the desired efficacy, it is necessary to select an AAV serotype that not only optimally matches the cells to be targeted but also matches the desired transduction efficiency and distribution.

[0226] In some embodiments, rAAV viral particles exhibit increased transduction and / or increased tropism in at least one tissue or cell type, relative to rAAV viral particles containing the same but not fused AAV VP2 capsid polypeptide.

[0227] In some embodiments, transduction in at least one tissue or cell type is increased by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%. In some embodiments, relative to rAAV viral particles comprising the same but not fused to the polypeptide ligand AAV VP2 capsid polypeptide, rAAV viral particles exhibit at least a 2-fold, at least 5-fold, at least 10-fold, at least 15-fold, at least 20-fold, at least 25-fold, at least 30-fold, at least 40-fold, at least 50-fold, at least 100-fold, at least 1000-fold, or more than 1000-fold increase in transduction in at least one tissue or cell type. In some embodiments, tropism in at least one tissue or cell type increases by about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%, 150%, 200%, 300%, 400%, 500%, 600%, 700%, 800%, 900%, or 1000%.

[0228] In some embodiments, all AAV VP2 capsid peptides contained in the rAAV viral particles are fused directly to a peptide ligand or via a linker.

[0229] In some embodiments, the rAAV viral particle further comprises a nucleic acid sequence selected from the group consisting of: non-coding nucleic acids, protein or RNA coding sequences, expression cassettes, multiple expression cassettes, sequences for homologous recombination, and genomic gene targeting cassettes.

[0230] In some embodiments, the rAAV viral particle further comprises a nucleic acid sequence encoding the AAV VP2 fusion polypeptide described herein. In some of these embodiments, the AAV VP2 fusion polypeptide contained in the rAAV viral particle is the same as the AAV VP2 fusion polypeptide encoded by the nucleic acid sequence contained in the rAAV viral particle.

[0231] In some embodiments, rAAV viral particles contain a nucleic acid sequence encoding a therapeutic nucleic acid, a therapeutic protein, or a therapeutic antibody or antibody fragment.

[0232] Therapeutic nucleic acids can be selected from the following groups: mRNA, siRNA, miRNA, shRNA, and antisense oligonucleotides.

[0233] Antibody fragments can be selected from, for example, the following groups: Fab, Fab′, F(ab′)2, Fv, single-domain antibodies (dAb), and single-chain variable fragments (scFv).

[0234] In some embodiments, the rAAV viral particle comprising the AAV VP2 fusion polypeptide further comprises AAV VP1 and VP3 polypeptides. In some embodiments, the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have an AAV serotype independently selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV. In some embodiments, the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have an AAV serotype selected from the group consisting of: AAV1, AAV6, AAV8, and AAV9. In some of these embodiments, the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the same AAV serotype.

[0235] In some embodiments, the AAV VP1, VP2, and VP3 peptides contained in the rAAV viral particle contain at least one mutation at at least one binding site of their natural receptor present on the target cell of the AAV viral particle composed of the AAV VP1, VP2, and VP3 peptides. In certain embodiments, at least one essential binding site of the natural receptor is mutated in the AAV VP1, VP2, and VP3 peptides. In some embodiments, the AAV VP1, VP2, and VP3 peptides contain the same at least one mutation in a shared VP3 region of each AAV capsid peptide. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV6 and each contains at least one amino acid substitution selected from the group consisting of K531E, V473D, K459S, N500E, G266A, N269Q, and D590A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:3. In some of these embodiments, the AAV VP2 fusion peptide and the AAVVP1 and VP3 peptides each comprise the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:3: i) K531E and V473D; ii) K531E, K459S, V473D and N500E; iii) G266A and N269Q; iv) G266A, N269Q and D590A; v) K531E, V473D, G266A and N269Q; or vi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A.

[0236] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV8, and each comprises at least one amino acid substitution selected from the group consisting of G268E, N271Q, S387A, A592Q, and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each comprise one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:4: i) G268E and N271Q; ii) S387A; iii) G268E, N271Q, and S387A; iv) A592Q; or v) A592D.

[0237] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV9, and each comprises at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each comprise one or more of the following amino acid substitutions: i) W503A; ii) N562A and E563A; iii) Q590A and W503A; or iv) Q590A, W503A, N562A, and E563A, relative to the VP1 amino acid sequence of SEQ ID NO:5.

[0238] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have AAV serotype AAV2, and each contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO:6 within a shared VP3 region.

[0239] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have AAV serotype AAV1, and each contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain one or more of the following amino acid substitutions: i) V473D and N500E; ii) R514A; or iii) V473D, N500E, and R514A relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0240] In one respect, this article provides cells containing the rAAV viral particles described herein.

[0241] In some embodiments, the cell is a host cell. In some embodiments, rAAV viral particles are assembled in the host cell. The host cell may be selected from the group consisting of insect cells (e.g., Sf9 cells) and HEK293 cells or derivatives thereof (such as HEK293T / 17 cells or AAV293 cells).

[0242] In some embodiments, the cells are selected from mammalian cells, including but not limited to mouse cells, non-human primate cells, or human cells. In some embodiments, the mammalian cells are selected from the group consisting of: hepatocytes, brain cells, spleen cells, kidney cells, blood cells, lung cells, muscle cells, heart cells, bone marrow cells, pluripotent progenitor cells (MPPs) (such as pluripotent hematopoietic progenitor cells), and hematopoietic stem cells (HSCs) (such as long-term hematopoietic stem cells (LT-HSCs)).

[0243] Pharmaceutical compositions and treatment methods

[0244] In one respect, this article provides pharmaceutical compositions comprising the rAAV viral particles described herein and pharmaceutically acceptable excipients.

[0245] The rAAV viral particles described herein can be formulated to prepare pharmaceutically useful compositions. Exemplary formulations include, for example, those disclosed in U.S. Patent Nos. 9,051,542 and 6,703,237 (which are incorporated herein by reference in their entirety). The compositions disclosed herein can be formulated for administration to mammalian subjects (e.g., humans). In some embodiments, delivery systems can be formulated for intramuscular, intradermal, mucosal, subcutaneous, intravenous, intrathecal, injectable reservoir-type devices, or topical administration.

[0246] In some embodiments, when the delivery system is formulated as a solution or suspension, the delivery system is contained in an acceptable carrier (e.g., an aqueous carrier). Various aqueous carriers can be used, such as water, buffered water, 0.8% physiological saline, 0.3% glycine, hyaluronic acid, etc. These compositions can be sterilized and / or aseptically filtered. The resulting aqueous solution can be packaged for use as is or lyophilized. In some embodiments, the lyophilized formulation is combined with a sterile solution prior to administration.

[0247] In some embodiments, the composition (e.g., a pharmaceutical composition) may contain pharmaceutically acceptable excipients to mimic physiological conditions, such as pH adjusters and buffers, tension modifiers, humectants, etc., for example, sodium acetate, sodium lactate, sodium chloride, potassium chloride, calcium chloride, sorbitol monolaurate, triethanolamine oleate, etc. In some embodiments, the pharmaceutical composition contains a preservative. In some other embodiments, the pharmaceutical composition does not contain a preservative.

[0248] Typically, pharmaceutical compositions are formulated to be compatible with the intended route of administration. Non-limiting examples of routes of administration include parenteral, such as intravenous, intra-arterial, subcutaneous, intraperitoneal, intrathecal, intramuscular, or injection or infusion administration. Methods for formulating suitable pharmaceutical compositions are known in the art, see, for example, Remington: The Science and Practice of Pharmacy, 21st edition, 2005; and books in the series Drugs and the Pharmaceutical Sciences: a Series of Textbooks and Monographs (Dekker, NY).

[0249] This document also provides rAAV viral particles or pharmaceutical compositions comprising such rAAV viral particles for use as medicines. For example, the rAAV viral particles disclosed herein can be administered to deliver heterologous nucleic acids encoding therapeutic RNA or proteins into target cells. Therefore, the terms “therapeutic application” or “treatment” as used herein include gene therapy for the treatment or prevention of disease, wherein the term “gene therapy” can be broadly defined as the concept of the directed introduction of foreign genetic material into cells, tissues, or organs to correct defective genes with the aim of improving the clinical condition of a patient. For example, heterologous nucleic acids can replace genes in target cells that have been mutated or lost, resulting in a genetic disease. Administration of the rAAV viral particles disclosed herein can be used to treat, prevent, delay, mitigate, or improve such genetic diseases. In some embodiments, “gene therapy” refers only to “somatic cell therapy” and not to “germ therapy” that induces genetic changes passed down through generations, where somatic cell therapy limits the therapeutic effect to the individual being treated. The rAAV viral particles described herein can be administered in vivo or ex vivo. As used herein, the terms “treat” and “treatment” include the step of administering an effective dose or multiple effective doses of a composition comprising the rAAV viral particles disclosed herein to an animal (including a human) in need. If the dose is administered before the onset of the disorder / disease, the administration is prophylactic. If the dose is administered after the onset of the disorder / disease, the administration is therapeutic. In some embodiments, an effective dose is a dose that detectably reduces (eliminates or reduces) at least one symptom associated with the treated disorder / disease state, slows or prevents progression to the disorder / disease state, slows or prevents the progression of the disorder / disease state, reduces the severity of the disease, results in partial or complete remission of the disease, and / or prolongs survival. The term encompasses, but does not require, complete treatment (i.e., cure) and / or prevention.

[0250] In one respect, this article provides a method for delivering transgenic material into cells, the method comprising contacting the cells with rAAV viral particles as described herein or a pharmaceutical composition containing the rAAV viral particles.

[0251] In one respect, this article provides a method for delivering transgenes into cells, wherein the cells express cell surface molecules that specifically bind to the polypeptide ligand.

[0252] In some embodiments, the cells are in a live subject. In some embodiments, the subject is a mammalian subject, such as a human.

[0253] In one aspect, this document provides methods for using the rAAV viral particles described herein or pharmaceutical compositions containing the rAAV viral particles in therapeutic treatment regimens, or methods for using the rAAV viral particles described herein or pharmaceutical compositions containing the rAAV viral particles as vaccines.

[0254] In one aspect, this article provides a method for using the rAAV viral particles described herein or a pharmaceutical composition containing the rAAV viral particles in a method of reducing the amount of total rAAV viral particles administered to a subject in a treatment method, the method comprising administering to a subject a reduced amount of total rAAV viral particles compared to the amount of rAAV containing the same but not fused to the peptide ligand AAV VP2 capsid peptide, which enables similar therapeutic effects.

[0255] In one aspect, this article provides a method for using the rAAV viral particles described herein or a pharmaceutical composition containing the rAAV viral particles in a method of increasing the transduction efficiency of rAAV viral particles administered to a subject in a treatment therapy, the method comprising administering a certain amount of rAAV viral particles to a subject, wherein the rAAV viral particles containing the AAV VP2 fusion polypeptide are able to transduce cell types or tissues at a higher rate than rAAV viral particles containing the same but not fused to the polypeptide ligand.

[0256] AAV VP2 fusion peptide library

[0257] In one respect, this paper provides a library construct containing a nucleic acid sequence encoding an AAV VP2 fusion peptide comprising an AAV VP2 capsid peptide and a peptide ligand, for example, composed thereof, wherein the peptide ligand is fused to the N-terminus of the AAV VP2 capsid peptide, and wherein the molecular weight of the peptide ligand is up to 10 kDa.

[0258] In some embodiments, the polypeptide ligand encoded by the library construct contains randomized amino acids at at least 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid positions.

[0259] In one respect, this paper provides a library construct containing a nucleic acid sequence encoding an AAV VP2 fusion peptide comprising an AAV VP2 capsid peptide and a peptide ligand, for example, composed thereof, wherein the peptide ligand is fused to the N-terminus of the AAV VP2 capsid peptide, and wherein the peptide ligand is selected from the group consisting of GP2 peptide, Sso7d peptide, and affinity peptide.

[0260] In some embodiments, the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1 and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0261] In some embodiments, the polypeptide ligand is selected from the Sso7d polypeptide of SEQ ID NO:1, which optionally has up to 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions.

[0262] In some embodiments, the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y and W; and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0263] In some embodiments, the polypeptide ligand is selected from the Sso7d polypeptide of SEQ ID NO:1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y, W and amino acid substitutions, and wherein SEQ ID NO:1 optionally has up to 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitution.

[0264] In some embodiments, the encoded AAV VP2 fusion further comprises a peptide linker between the polypeptide ligand and the AAV VP2 capsid polypeptide. In some of these embodiments, the peptide linker is selected from the group consisting of glycine-serine (GS) linkers and alanine-proline-serine (APS) linkers. In some of these embodiments, the GS linker has the formula [GGGGS]n, where n is an integer in the range of 1 to 10, for example, where n is 1, 2, 3, 4, 5, or 6, particularly where n is 1, 2, 3, or 4. In some embodiments, the APS linker has the formula [APS]n, where n is an integer in the range of 1 to 10, for example, where n is 1, 2, 3, 4, 5, or 6, particularly where n is 2, 3, 4, or 5.

[0265] In some embodiments, the nucleic acid encoding the AAV VP2 fusion peptide does not contain the natural start codon of the AAV VP2 capsid peptide. The natural start codon of the AAV VP2 capsid peptide may be mutated, for example, deleted. In some embodiments, the AAV VP2 capsid peptide contained in the AAV VP2 fusion peptide is missing its first natural amino acid, for example, the first threonine of the corresponding wild-type AAV VP2 capsid peptide.

[0266] In one respect, this document provides libraries comprising multiple library constructs described herein. In some embodiments, the library comprises at least two different library constructs described herein. In some embodiments, the at least two different library constructs contained in the library differ in the nucleic acid sequences encoding polypeptide ligands.

[0267] In some embodiments, the library contains at least 10 2 10 3 10 4 10 5 10 6 10 7 10 8 Or 10 9 A unique library structure. In some embodiments, the library contains 10... 2 -10 3 10 3 -10 4 10 4 -10 5 10 5 -10 6 10 6 -10 7 10 7 -10 8 Or 10 8 -10 9 A unique library structure.

[0268] In some embodiments, the library contains at least 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 Or 10 10 10 members. In some embodiments, the library contains 10 members. 2 -10 3 10 3 -10 4 10 4 -10 5 10 5 -10 6 10 6 -10 7 10 7 -10 8 10 8 -10 9 Or 10 9 -10 10 One member.

[0269] In some embodiments, the library contains a library construct encoding all possible variants of a polypeptide ligand.

[0270] In some embodiments, the library construct is an RNA molecule, such as an mRNA molecule; or a DNA molecule, such as a cDNA molecule, a linear DNA molecule, or a circular DNA molecule (e.g., a plasmid DNA molecule). In some embodiments, the library construct further includes a promoter. In some embodiments, an open reading frame of the AAV VP2 fusion peptide is operatively linked to the promoter.

[0271] In some embodiments, the library construct is a plasmid DNA molecule containing the nucleic acid sequence encoding the AAV VP2 fusion polypeptide operably linked to a promoter. In some embodiments, the library construct further includes a reporter sequence. In some embodiments, the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein. In some embodiments, the reporter protein is selected from the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase.

[0272] In some embodiments, the library construct further includes a barcode sequence. In some of these embodiments, each specific AAV VP2 fusion peptide sequence is assigned a specific barcode sequence, meaning that each specific barcode sequence corresponds to a specific AAV VP2 fusion peptide sequence.

[0273] In some embodiments, the library is an AAV library, which means that each library construct exists within rAAV virus particles.

[0274] In some embodiments, rAAV viral particles contain, for example, the AAV VP2 fusion polypeptide described herein in their capsid. In some embodiments, the AAV VP2 fusion polypeptide contained in a given rAAV viral particle (e.g., in its capsid) is the same as the AAV VP2 fusion polypeptide encoded by a library construct present in the given rAAV viral particle. In some embodiments, most rAAV viral particles contain a library construct encoding the AAV VP2 fusion polypeptide, which is the same as the AAV VP2 fusion polypeptide contained in a given rAAV viral particle. This is referred to as genotype-phenotype association or capsid-genome correlation in the AAV library.

[0275] In some embodiments, the AAV library contains at least 10 2 10 3 104 10 5 10 6 10 7 10 8 Or 10 9 10 unique AAV variants. In some embodiments, the AAV library contains 10 2 -10 3 10 3 -10 4 10 4 -10 5 10 5 -10 6 10 6 -10 7 10 7 -10 8 Or 10 8 -10 9 A unique AAV variant.

[0276] In some embodiments, the AAV library contains at least 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 Or 10 10 10 AAV members. In some embodiments, the AAV library contains 10 2 -10 3 10 3 -10 4 10 4 -10 5 10 5 -10 6 10 6 -10 7 10 7 -10 8 10 8 -10 9 Or 10 9 -10 10 One AAV member.

[0277] The AAV library described herein can be used for phenotypic selection of capsid peptides (e.g., AAV VP2 fusion peptides) with desired characteristics. The AAV VP2 fusion peptide is cis-encoded from the replicated AAV genome. This allows for the recovery of capsid DNA after phenotypic selection. Therefore, it is necessary to minimize random mixing of capsomeres and the encapsulation of non-matching viral genomes during viral library production. This can be achieved, for example, by selecting appropriate conditions for rAAV viral particle production (e.g., by using an appropriate ratio of nucleic acid molecules encoding the AAV VP2 fusion peptide and nucleic acid molecules encoding the AAV VP1 and VP3 capsid peptides for transfection into host cells used for rAAV viral particle production). Typically, VP1 and VP3 encoded nucleic acids are used in excess relative to the AAV VP2 fusion peptide-encoded nucleic acid in the transfection reaction. The AAV VP2 fusion peptide-encoded nucleic acid is used in such an amount that, on average, only a single AAV VP2 fusion peptide-encoded nucleic acid is used to transfect each host cell.

[0278] In some embodiments, all AAV VP2 capsid peptides contained in the rAAV viral particles of the AAV library are fused directly to a peptide ligand or via a linker.

[0279] In some embodiments, each library construct of the AAV library contains two AAV inverted terminal repeat (ITR) sequences located upstream and downstream of the AAV VP2 fusion peptide open reading frame, for example, at the 5' and 3' ends of the library construct. In some embodiments, the AAV VP2 fusion peptide open reading frame is operatively linked to a promoter. In some embodiments, the library construct further contains a reporter sequence. In some embodiments, the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein. In some embodiments, the reporter protein is selected from the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase. In some embodiments, the reporter sequence is operatively linked to a promoter (e.g., a second promoter contained in the library construct).

[0280] In some embodiments, the rAAV viral particles of the AAV library comprise the AAV VP2 fusion polypeptide described herein and further comprise AAV VP1 and VP3 polypeptides. In some embodiments, the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides contained in the rAAV viral particles have AAV serotypes independently selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV, or avian AAV.5. In some embodiments, the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides contained in the rAAV viral particles have AAV serotypes independently selected from the group consisting of: AAV1, AAV6, AAV8, and AAV9. In some embodiments, the AAV VP2 fusion peptide contained in the rAAV viral particles, as well as the AAVVP1 and VP3 peptides, have the same AAV serotype.

[0281] In some embodiments, the AAV VP1, VP2, and VP3 peptides contained in the rAAV viral particles of the AAV library contain at least one mutation at at least one binding site of their natural receptor present on the target cell of the AAV viral particles composed of said AAV VP1, VP2, and VP3 peptides. In a particular embodiment, at least one essential binding site of the natural receptor is mutated in the AAV VP1, VP2, and VP3 peptides. In some embodiments, the AAV VP1, VP2, and VP3 peptides contain the same at least one mutation in the shared VP3 region of each AAV capsid peptide.

[0282] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have AAV serotype AAV6, and each contains at least one amino acid substitution selected from the group consisting of K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:3. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each comprise the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:3: i) K531E and V473D; ii) K531E, K459S, V473D and N500E; iii) G266A and N269Q; iv) G266A, N269Q and D590A; v) K531E, V473D, G266A and N269Q; or vi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A.

[0283] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV8, and each comprises at least one amino acid substitution selected from the group consisting of G268E, N271Q, S387A, A592Q, and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each comprise one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:4: i) G268E and N271Q; ii) S387A; iii) G268E, N271Q, and S387A; iv) A592Q; or v) A592D.

[0284] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV9, and each comprises at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each comprise one or more of the following amino acid substitutions: i) W503A; ii) N562A and E563A; iii) Q590A and W503A; or iv) Q590A, W503A, N562A, and E563A, relative to the VP1 amino acid sequence of SEQ ID NO:5.

[0285] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have AAV serotype AAV2, and each contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO:6 within a shared VP3 region.

[0286] In some embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have AAV serotype AAV1, and each contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7. In some of these embodiments, the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain one or more of the following amino acid substitutions: i) V473D and N500E; ii) R514A; or iii) V473D, N500E, and R514A relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0287] In some embodiments, the AAV VP2 fusion polypeptide contained in rAAV viral particles of an AAV library has AAV serotype AAV1 and contains at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:7. Specifically, the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, particularly all three of the following amino acid substitutions: D213A, T162R, and P191N.

[0288] In other embodiments, the AAV VP2 fusion polypeptide contained in rAAV viral particles of the AAV library has an AAV serotype other than AAV1 and contains at least one amino acid substitution corresponding to at least one of the amino acid substitutions selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0289] In certain embodiments of this kind, the AAV VP2 fusion polypeptide contained in the rAAV viral particles has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:4. Specifically, the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, particularly all three of the following substitutions: D214A, K163R, and P192N.

[0290] In other such embodiments, the AAV VP2 fusion polypeptide contained in the rAAV viral particles has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of E147S, P185G, P166R, G199R, D213A, S162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. Specifically, the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D213A, S162R, and / or P191N, particularly all three of the following amino acid substitutions: D213A, S162R, and P191N.

[0291] On one hand, this paper provides a library containing multiple rAAV viral particles, each containing a variant AAV VP2 fusion peptide as described herein.

[0292] In some embodiments, the library contains at least two distinct rAAV viral particles, each containing a variant AAV VP2 fusion polypeptide as described herein. In some embodiments, the at least two distinct rAAV viral particles differ in the polypeptide ligands contained in the AAV VP2 fusion polypeptide.

[0293] In some embodiments, the AAV library contains at least 10 2 10 3 10 4 10 5 10 6 10 7 10 8 Or 10 9 Each rAAV virus particle is unique. In some embodiments, the AAV library contains 10... 2 -10 3 10 3 -10 4 10 4 -10 5 105 -10 6 10 6 -10 7 10 7 -10 8 Or 10 8 -10 9 A unique rAAV virus particle.

[0294] In some embodiments, the AAV library contains at least 10 2 10 3 10 4 10 5 10 6 10 7 10 8 10 9 Or 10 10 One rAAV viral particle member. In some embodiments, the AAV library contains 10 2 -10 3 10 3 -10 4 10 4 -10 5 10 5 -10 6 10 6 -10 7 10 7 -10 8 10 8 -10 9 Or 10 9 -10 10 One rAAV virus particle member.

[0295] In some embodiments, the rAAV viral particles contained in the library comprise nucleic acids containing barcode sequences. In some embodiments, each specific AAV VP2 fusion peptide is assigned a specific barcode sequence, meaning that rAAV viral particles containing an AAV VP2 fusion peptide with a given amino acid sequence comprise nucleic acids containing the corresponding barcode sequence. The barcode sequence may, for example, comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or more nucleotides.

[0296] Methods for identifying AAV VP2 fusion peptide variants

[0297] In one aspect, this document provides a method for generating an AAV VP2 fusion peptide having at least one desired feature, the method comprising screening a library described herein for an AAV VP2 fusion peptide having said at least one desired feature.

[0298] In some embodiments, the at least one desired feature is increased transduction and / or increased tropism in at least one tissue or cell type mediated by the AAV VP2 fusion polypeptide, relative to an AAV VP2 capsid polypeptide that does not contain the polypeptide ligand but is otherwise identical to an AAV VP2 capsid polypeptide contained in the AAV VP2 fusion polypeptide.

[0299] In one aspect, this document provides methods for generating AAV VP2 fusion peptides having at least one desired characteristic, methods comprising the steps of: b) contacting a library described herein with a plurality of cells, c) isolating nucleic acid molecules from at least a portion of the cells, and d) determining at least a portion of the sequence of the at least one nucleic acid molecule isolated in step b) encoding a polypeptide ligand or a fragment thereof. In some embodiments, the plurality of cells in step b) are present in a non-human model animal (e.g., a mouse model or a non-human primate model).

[0300] In some embodiments, the method further includes step a) of providing an AAV library as described herein prior to step b). In some embodiments, the library is packaged in HEK293 cells or HEK293-derived cells, wherein helper functions (e.g., E2A, E4, VA, E1A, and E1B) are provided in trans configuration. In some embodiments, the AAV rep function comprises the rep78, rep68, rep52, and rep40 gene products. In some embodiments, the rep gene is provided in trans configuration. In some embodiments, the start codon of the open reading frame of rep78 and / or rep68 is changed from ACG to ATG to increase the replication of capsid library constructs containing inverted terminal repeats (ITRs), thereby improving AAV library manufacturing yield. In some embodiments, the cap gene is provided in trans configuration. In some embodiments, the cap gene is controlled by the p40 promoter such that it is expressed in HEK293 cells only during manufacturing in the presence of helper viral functions. In some embodiments, the start codon of the VP2 open reading frame in the cap gene provided in trans configuration is mutated. In some embodiments, during AAV manufacturing, a nucleic acid encoding an AAV VP2 fusion peptide is provided as a payload to the production cell line.

[0301] In some embodiments, the step of providing an AAV library a) includes ai) transfecting cells with a nucleic acid library encoding an AAV rep, a nucleic acid sequence encoding an AAV VP1 capsid polypeptide, a nucleic acid sequence encoding an AAV VP3 capsid polypeptide, and a nucleic acid library encoding the AAV VP2 fusion polypeptide described herein, wherein each library construct further includes two AAV inverted terminal repeat (ITR) sequences at its 5' and 3' ends, and aii) incubating the cells under conditions suitable for AAV virus particle formation, optionally wherein the cells are mammalian cells, particularly HEK293 cells, or insect cells, particularly Sf9 cells.

[0302] In some embodiments, the AAV VP1 capsid polypeptide and the AAV VP3 capsid polypeptide are encoded by the same nucleic acid sequence containing the AAV cap gene, particularly wherein the start codon of VP2 in the cap gene is mutated.

[0303] In some embodiments, the multiple cells in step b) are present in a non-human model animal. In some embodiments, the animal is treated with an AAV library via intravenous, intracranial, or intrathecal injection, or via other routes (e.g., nasal, liver, ventricles, cisterns, vitreous humor, cochlea, etc.). After sufficient time (e.g., 7, 10, 14, 18, 21, 24, 28, 30 days or longer) since AAV transport to the desired tissue or organ, the animal is euthanized and the target tissue / organ is harvested. In some embodiments, the harvested target tissue / organ is selected from the CNS, brain, heart, lungs, trachea, esophagus, muscle, bone, cartilage, bone marrow, stomach, pancreas, intestine, liver, spleen, bladder, kidney, ureter, urethra, uterus, fallopian tubes, ovary, testis, prostate, eye, blood, lymph, and oral mucosa. In some embodiments, the harvested target tissue / organ is selected from whole blood, brain, liver, spleen, kidney, skeletal muscle, heart, lungs, and bone marrow.

[0304] In some embodiments, the expression of a reporter sequence in cells within a tissue is monitored in the cytoplasm of the cells or in a target organelle. In some embodiments, the target organelle is the cell nucleus. In some embodiments, organelles containing an AAV payload (as demonstrated by the expression of the reporter sequence) are isolated from the tissue. In some embodiments, the organelle is the cell nucleus. In some embodiments, the method further includes the step of selecting cells in which the reporter sequence is expressed.

[0305] In some embodiments, in step c), nucleic acids from cells of a predefined tissue or cell type are isolated. In some embodiments, the cells of the predefined tissue are selected from cells of the CNS, brain, heart, lungs, trachea, esophagus, muscle, bone, cartilage, bone marrow, stomach, pancreas, intestine, liver, spleen, bladder, kidney, ureter, urethra, uterus, fallopian tubes, ovary, testis, prostate, eye, blood, lymph, and oral mucosa. In some embodiments, the cells of the predefined tissue are selected from whole blood, brain, liver, spleen, kidney, skeletal muscle, heart, lungs, and bone marrow. In some embodiments, the cells of the predefined cell type are selected from pluripotent progenitor cells (MPPs) (such as pluripotent hematopoietic progenitor cells) and hematopoietic stem cells (HSCs) (such as long-term hematopoietic stem cells (LT-HSCs)). In some embodiments, the cells of the predefined tissue or cell type are isolated 1-21 days, 1-14 days, 7-21 days, 2-10 days, and 2-5 days after contacting the library with multiple cells.

[0306] In some embodiments, nucleic acids are extracted from organelles (e.g., the cell nucleus). In some embodiments, the extracted nucleic acid is RNA, while in some embodiments, the extracted nucleic acid is DNA. In some embodiments, the extracted RNA is subjected to reverse transcription to produce cDNA, which is then amplified. In some embodiments, primers specific to the barcoded region are used in the amplification. In some embodiments, at least a portion of the sequence encoding a variable polypeptide ligand is amplified. In some embodiments, the amplified cDNA is sequenced. In some embodiments, enrichment of a specific AAV variant in a specific tissue / organ is observed after in vivo selection.

[0307] In some embodiments, step c) includes isolating RNA from at least a portion of the cell, and step d) includes substep di) reverse transcription of the isolated RNA, dii) PCR amplification of at least a portion of the sequence encoding a polypeptide ligand or a fragment thereof from the cDNA generated in step di), and diii) sequencing at least a portion of the polypeptide ligand sequence, for example by next-generation sequencing.

[0308] In some embodiments, the method further includes step e): determining the relative occurrence of a specific polypeptide ligand sequence in a tissue or cell type relative to the total number of polypeptide ligand sequences in the tissue or cell type.

[0309] In some embodiments, in vivo selection of AAV VP2 fusion peptide variants can be performed in rounds 1, 2, 3, 4, 5 or more, in each case, a subset of AAV variants or synthetically enriched variants obtained from the previous round are combined and reselected in vitro or in vivo.

[0310] In some embodiments, the method further includes step f): generating a second library encoding a nucleic acid sequence of an AAV VP2 fusion polypeptide from the nucleic acid molecules isolated in step c), and repeating steps b), c), d), and optionally a) and e) with the second library.

[0311] In some embodiments, the obtained variants are analyzed after a desired number of selection rounds. In some embodiments, a single variant is used in vivo to deliver a transgene (such as a reporter gene) to a desired cell or organ. After analyzing the delivery capability of the variants, the best candidate is selected for future use.

[0312] In some embodiments, selected candidates are subjected to functional maturation through random mutagenesis and in vivo or in vitro selection of variants with improved characteristics, such as improved transduction of cells of a particular cell type or tissue.

[0313] In one respect, this article provides an AAV VP2 fusion peptide generated by the methods described herein.

[0314] This document also provides rAAV viral particles comprising an AAV VP2 fusion polypeptide produced by the methods described herein, and pharmaceutical compositions comprising these rAAV viral particles. The rAAV viral particles and pharmaceutical compositions can be used as pharmaceuticals.

[0315] AAV VP2 capsid peptide with improved receptor binding and / or transduction levels

[0316] In one aspect, this document provides AAV VP2 capsid polypeptides having AAV serotype AAV1, wherein these AAV VP2 capsid polypeptides comprise at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:7. In some embodiments, the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, particularly all three of the following amino acid substitutions: D213A, T162R, and P191N.

[0317] On the other hand, this article provides AAV VP2 capsid peptides having AAV serotypes other than AAV1, wherein the AAV VP2 capsid peptides contain at least one amino acid substitution corresponding to at least one of the amino acid substitutions selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0318] In some embodiments, the AAV VP2 capsid polypeptide has AAV serotype 8 and comprises at least one amino acid substitution selected from the group consisting of E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:4. Specifically, the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, particularly all three of the following amino acid substitutions: D214A, K163R, and P192N.

[0319] In other embodiments, the AAV VP2 capsid polypeptide has AAV serotype 9 and comprises at least one amino acid substitution selected from the group consisting of E147S, P185G, P166R, G199R, D213A, S162R, and P191N, or any combination thereof, relative to the VP1 amino acid sequence of SEQ ID NO:5. Specifically, the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, S162R, and / or P191N, particularly all three of the following amino acid substitutions: D213A, S162R, and / or P191N.

[0320] This article also provides an AAV VP2 fusion peptide comprising one of the AAV VP2 capsid peptides listed above and a peptide ligand, wherein the peptide ligand is fused to the N-terminus of the AAV VP2 capsid peptide.

[0321] Example

[0322] 1. An adeno-associated virus (AAV) VP2 fusion polypeptide comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, for example, thereof, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the polypeptide ligand has a molecular weight up to 10 kDa.

[0323] 2. The AAV VP2 fusion polypeptide as described in Example 1, wherein the polypeptide ligand specifically binds to a cell surface molecule expressed on at least one tissue or cell type, and / or wherein, relative to an AAV VP2 capsid polypeptide that does not contain the polypeptide ligand, the AAV VP2 fusion polypeptide mediates increased transduction and / or increased tropism in at least one tissue or cell type.

[0324] 3. The AAV VP2 fusion polypeptide as described in Example 1 or 2, wherein the polypeptide ligand is selected from the group consisting of: GP2 polypeptide, Sso7d polypeptide and affinity peptide.

[0325] 4. The AAV VP2 fusion polypeptide as described in Example 3, wherein the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1 and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity therewith.

[0326] 5. The AAV VP2 fusion polypeptide as described in Example 4, wherein the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y and W; and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0327] 6. The AAV VP2 fusion polypeptide as described in any of the foregoing embodiments, the AAV VP2 fusion polypeptide further comprising a peptide linker between the polypeptide ligand and the AAV VP2 capsid polypeptide, wherein the peptide linker is selected from the group consisting of glycine-serine (GS) linkers and alanine-proline-serine (APS) linkers, more particularly wherein the GS linker has the formula [GGGGS]n, and the APS linker has the formula [APS]n, wherein n is an integer in the range of 1 to 10, particularly wherein n is 1, 2, 3, 4, 5, or 6, more particularly wherein for the GS linker, n is 1, 2, 3, or 4, and for the APS linker, n is 2, 3, 4, or 5.

[0328] 7. The AAV VP2 fusion polypeptide as described in any of the foregoing embodiments, wherein the AAV VP2 capsid polypeptide has an AAV serotype selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV or avian AAV.5, particularly selected from the group consisting of: AAV1, AAV6, AAV8 and AAV9.

[0329] 8. The AAV VP2 fusion polypeptide as described in Example 7, wherein the AAV VP2 capsid polypeptide contains at least one mutation at at least one binding site of its natural receptor, particularly wherein

[0330] a) The AAV VP2 fusion polypeptide has the AAV serotype AAV6 and contains at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:3, particularly wherein the AAV VP2 fusion polypeptide contains the following amino acid substitutions relative to SEQ ID NO:3. The VP1 amino acid sequence of NO:3 includes ai) K531E and V473D; aii) K531E, K459S, V473D and N500E; aiii) G266A and N269Q; aiv) G266A, N269Q and D590A; av) K531E, V473D, G266A and N269Q; or avi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A; among which

[0331] b) The AAV VP2 fusion polypeptide has the AAV serotype AAV8 and contains at least one amino acid substitution selected from the group consisting of: G268E, N271Q, S387A, A592Q, and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: bi) G268E and N271Q; bii) S387A; biii) G268E, N271Q, and S387A; biv) A592Q; or bv) A592D; wherein

[0332] c) The AAV VP2 fusion polypeptide has the AAV serotype AAV9 and contains at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:5, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: c1) W503A; cii) N562A and E563A; ciii) Q590A and W503A; or civ) Q590A, W503A, N562A, and E563A relative to the VP1 amino acid sequence of SEQ ID NO:5; wherein

[0333] d) The AAV VP2 fusion polypeptide has the AAV serum type AAV2 and contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO: 6 in its VP3 region; or wherein...

[0334] e) The AAV VP2 fusion polypeptide has AAV serotype AAV1 and contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: ei) V473D and N500E; eii) R514A; or eiii) V473D, N500E, and R514A relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0335] 9. The AAV VP2 fusion polypeptide as described in any of the foregoing embodiments, wherein a) the AAV VP2 fusion polypeptide has an AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, or wherein b) the AAV VP2 fusion polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the following amino acid substitutions selected from the group consisting of: relative to SEQ ID NO:7. The VP1 amino acid sequence of NO:7 comprises E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, particularly wherein bi) the AAV VP2 fusion polypeptide has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, or wherein bii) the AAV VP2 fusion polypeptide has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of: relative to SEQ ID The VP1 amino acid sequence of NO:5 consists of E147S, P185G, P166R, G199R, D213A, S162R, and P191N or any combination thereof, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D213A, S162R, and / or P191N.

[0336] 10. The AAV VP2 fusion polypeptide as described in Example 9a), wherein the AAV VP2 fusion polypeptide further comprises amino acid substitutions V473D and N500E relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0337] 11. The AAV VP2 fusion polypeptide as described in any of the foregoing embodiments, wherein the AAV VP2 capsid polypeptide lacks the first threonine residue of the corresponding wild-type AAV VP2 capsid polypeptide.

[0338] 12. The AAV VP2 fusion polypeptide as described in any of the foregoing embodiments, wherein the polypeptide ligand comprises at most 3 cysteine ​​residues, particularly at most 2 cysteine ​​residues, more particularly at most 1 cysteine ​​residue, and most particularly does not contain any cysteine ​​residues.

[0339] 13. An isolated nucleic acid encoding an AAV VP2 fusion polypeptide as described in any of the foregoing embodiments.

[0340] 14. The isolated nucleic acid as described in Example 13, wherein the isolated nucleic acid further comprises a promoter.

[0341] 15. The isolated nucleic acid as described in Example 13 or 14, the isolated nucleic acid further comprising two AAV inverted terminal repeat (ITR) sequences located upstream and downstream of the open reading frame (ORF) of the AAV VP2 fusion polypeptide, and optionally further comprising a reporter sequence, particularly wherein the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein, and more particularly wherein the reporter protein is selected from the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase.

[0342] 16. A cell comprising an AAV VP2 fusion polypeptide as described in any one of Examples 1 to 12 or a nucleic acid as described in any one of Examples 13 to 15.

[0343] 17. The cell as described in Example 16, wherein the cell is selected from the group consisting of insect cells (e.g., Sf9 cells) and HEK293 cells.

[0344] 18. The cell as described in Example 16, wherein the cell is selected from mammalian cells, including but not limited to mouse cells, non-human primate cells or human cells, selected from the group consisting of: hepatocytes, brain cells, spleen cells, kidney cells, blood cells, lung cells, muscle cells, heart cells, bone marrow cells, pluripotent progenitor cells (MPPs) (such as pluripotent hematopoietic progenitor cells) and hematopoietic stem cells (HSCs) (such as long-term hematopoietic stem cells (LT-HSCs)).

[0345] 19. A recombinant AAV (rAAV) viral particle comprising the AAV VP2 fusion polypeptide as described in any one of Examples 1 to 12.

[0346] 20. The rAAV viral particle as described in Example 19, wherein all AAV VP2 capsid polypeptides are fused to the polypeptide ligand.

[0347] 21. The rAAV viral particle as described in Example 19 or 20, the rAAV viral particle further comprising a nucleic acid sequence selected from the group consisting of: non-coding nucleic acid, protein or RNA coding sequence, expression cassette, multiple expression cassette, sequence for homologous recombination, and genomic gene targeting cassette.

[0348] 22. The rAAV viral particle as described in Example 21, wherein the expression cassette encodes the AAV VP2 fusion polypeptide as described in any one of Examples 1 to 12, particularly wherein the AAV VP2 fusion polypeptide contained in the rAAV viral particle is the same as the AAV VP2 fusion polypeptide encoded by the expression cassette.

[0349] 23. The rAAV viral particle as described in Example 21, wherein the expression cassette encodes a therapeutic nucleic acid, including but not limited to therapeutic RNA, mRNA, siRNA, miRNA, shRNA, and antisense oligonucleotides; a therapeutic protein or a therapeutic antibody or antibody fragment.

[0350] 24. The rAAV viral particle as described in any one of Examples 19 to 23, wherein the viral particle further comprises AAV VP1 and VP3 polypeptides, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the same AAV serotype selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV or avian AAV.5, particularly selected from the group consisting of: AAV1, AAV6, AAV8 and AAV9.

[0351] 25. The rAAV viral particle as described in Example 24, wherein the AAV VP1, VP2, and VP3 polypeptides contain at least one mutation at at least one binding site of the natural receptor of the AAV VP1, VP2, and VP3 capsid polypeptides, particularly wherein the AAV VP1, VP2, and VP3 polypeptides contain the same at least one mutation in the shared VP3 region of each AAV capsid polypeptide, and more particularly wherein...

[0352] a) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV6, and each contains at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:3, particularly wherein the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain the following amino acid substitutions relative to SEQ ID NO:3. The VP1 amino acid sequence of NO:3 includes ai) K531E and V473D; aii) K531E, K459S, V473D and N500E; aiii) G266A and N269Q; aiv) G266A, N269Q and D590A; av) K531E, V473D, G266A and N269Q; or avi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A; among which

[0353] b) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV8, and each contains at least one amino acid substitution selected from the group consisting of: G268E, N271Q, S387A, A592Q, and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:4: bi) G268E and N271Q; bii) S387A; biii) G268E, N271Q, and S387A; biv) A592Q; or bv) A592D; wherein

[0354] c) The AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the AAV serotype AAV9, and each contains at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:5, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:5: ci) W503A; cii) N562A and E563A; ciii) Q590A and W503A; or civ) Q590A, W503A, N562A, and E563A; wherein

[0355] d) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV2, and each contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO:6 within the shared VP3 region; or wherein...

[0356] e) The AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have AAV serotype AAV1, and each contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:7: ei) V473D and N500E; eii) R514A; or eiii) V473D, N500E, and R514A.

[0357] 26. A pharmaceutical composition comprising rAAV viral particles as described in any one of Examples 19 to 21 and 23 to 25 and a pharmaceutically acceptable excipient.

[0358] 27. The rAAV virus particles as described in any one of Examples 19 to 21 and 23 to 25, or the pharmaceutical composition as described in Example 26, are used as a medicine.

[0359] 28. A method for delivering a transgene into a cell, the method comprising contacting the cell with rAAV viral particles as described in any one of Examples 19 to 21 and 23 to 25 or a pharmaceutical composition as described in Example 26.

[0360] 29. The method as described in Example 28, wherein the cell is in a living subject, particularly a mammalian subject, and more particularly a human.

[0361] 30. A method of using rAAV virus particles as described in any one of Examples 19 to 21 and 23 to 25 or a pharmaceutical composition as described in Example 26 in a therapeutic treatment regimen, or a method of using rAAV virus particles as described in any one of Examples 19 to 21 and 23 to 25 or a pharmaceutical composition as described in Example 26 as a vaccine.

[0362] 31. A library construct comprising a nucleic acid sequence encoding an AAVVP2 fusion polypeptide comprising an AAVVP2 capsid polypeptide and a polypeptide ligand, for example, composed thereof, wherein the polypeptide ligand is fused to the N-terminus of the AAVVP2 capsid polypeptide, and wherein the polypeptide ligand has a molecular weight up to 10 kDa.

[0363] 32. The library construct as described in Example 31, wherein the polypeptide ligand contains randomized amino acids at at least 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid positions.

[0364] 33. The library construct as described in Example 31 or 32, wherein the polypeptide ligand is selected from the group consisting of: GP2 polypeptide, Sso7d polypeptide and affinity peptide.

[0365] 34. The library construct as described in Example 33, wherein the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1 and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity therewith.

[0366] 35. The library construct as described in Example 34, wherein the polypeptide ligand is selected from the group consisting of: the Sso7d polypeptide of SEQ ID NO:1, wherein amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y and W; and the Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity with it.

[0367] 36. A library comprising a plurality of library constructs as described in any one of Examples 31 to 35.

[0368] 37. The library as described in Example 36, wherein the library contains at least 10 2 10 3 10 4 10 5 10 610 7 10 8 Or 10 9 A unique library structure.

[0369] 38. The library as described in Example 36 or 37, wherein the library constructs are plasmid DNA molecules containing the nucleic acid sequence encoding the AAV VP2 fusion polypeptide operably linked to a promoter, and optionally further containing a reporter sequence, particularly wherein the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein, and more particularly wherein the reporter protein is selected from the group consisting of: EGFP, mCherry, sfCherry, sfCherry2, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase.

[0370] 39. The library as described in Example 36 or 37, wherein each library construct is present within an rAAV viral particle, wherein the rAAV viral particle contains an AAV VP2 fusion polypeptide as described in Example 4 or 5, and the AAV VP2 fusion polypeptide contained in a given rAAV viral particle is the same as the AAV VP2 fusion polypeptide encoded by the library construct present in the given rAAV viral particle.

[0371] 40. The library as described in Example 39, wherein each library construct further comprises a promoter, two AAV inverted terminal repeat (ITR) sequences located upstream of the promoter and downstream of the nucleic acid sequence encoding the AAV VP2 fusion polypeptide, and optionally a reporter sequence, particularly wherein the reporter sequence encodes a fluorescent reporter protein or a luminescent reporter protein, and more particularly wherein the reporter protein is selected from the group consisting of: EGFP, mCherry, sfCherry, mClover3, mRuby3, mApple, iRFP, tdTomato, mVenus, YFP, RFP, firefly luciferase, and nanoluciferase.

[0372] 41. The library as described in Example 39 or 40, wherein the rAAV virus particles comprise the AAV VP2 fusion polypeptide as described in Example 4 or 5, and further comprise AAV VP1 and VP3 polypeptides, particularly comprising the AAV VP2 fusion polypeptide in the rAAV virus particles and the AAV VP1 and VP3 polypeptides having the same AAV serotype selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32, 33, bovine AAV or avian AAV.5, particularly selected from the group consisting of: AAV1, AAV6, AAV8 and AAV9.

[0373] 42. The library as described in Example 41, comprising AAV VP1, VP2, and VP3 peptides in the rAAV viral particles, wherein at least one mutation is contained in at least one binding site of the natural receptor of the AAV VP1, VP2, and VP3 capsid peptides, particularly wherein the AAV VP1, VP2, and VP3 peptides contain the same at least one mutation in a shared VP3 region of each AAV capsid peptide, and more particularly wherein...

[0374] a) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV6, and each contains at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:3, particularly wherein the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain the following amino acid substitutions relative to SEQ ID NO:3. The VP1 amino acid sequence of NO:3 includes ai) K531E and V473D; aii) K531E, K459S, V473D and N500E; aiii) G266A and N269Q; aiv) G266A, N269Q and D590A; av) K531E, V473D, G266A and N269Q; or avi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A; among which

[0375] b) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV8, and each contains at least one amino acid substitution selected from the group consisting of: G268E, N271Q, S387A, A592Q, and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:4: bi) G268E and N271Q; bii) S387A; biii) G268E, N271Q, and S387A; biv) A592Q; or bv) A592D; wherein

[0376] c) The AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the AAV serotype AAV9, and each contains at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A, and E563A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:5, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:5: ci) W503A; cii) N562A and E563A; ciii) Q590A and W503A; or civ) Q590A, W503A, N562A, and E563A; wherein

[0377] d) The AAV VP2 fusion peptide and the AAV VP1 and VP3 peptides have the AAV serotype AAV2, and each contains an amino acid substitution R585A relative to the VP1 amino acid sequence of SEQ ID NO:6 within the shared VP3 region; or wherein...

[0378] e) The AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have AAV serotype AAV1, and each contains at least one amino acid substitution selected from the group consisting of: V473D, N500E, and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each contain one or more of the following amino acid substitutions relative to the VP1 amino acid sequence of SEQ ID NO:7: ei) V473D and N500E; eii) R514A; or eiii) V473D, N500E, and R514A.

[0379] 43. The library as described in Example 41, wherein a) the AAV VP2 fusion polypeptide contained in the rAAV viral particles has AAV serotype AAV1 and contains at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, or wherein b) the AAV VP2 fusion polypeptide contained in the rAAV viral particles has an AAV serotype other than AAV1 and contains at least one amino acid substitution corresponding to at least one of the following amino acid substitutions selected from the group consisting of: relative to SEQ ID NO:7. The VP1 amino acid sequence of NO:7 contains E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, particularly wherein bi) the AAVVP2 fusion polypeptide contained in the rAAV viral particle has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 fusion polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, or wherein bii) the AAV VP2 fusion polypeptide contained in the rAAV viral particle has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of: relative to SEQ ID NO:4 The VP1 amino acid sequence of IDNO:5 includes E147S, P185G, P166R, G199R, D213A, S162R, and P191N, or any combination thereof, particularly wherein the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: D213A, S162R, and / or P191N.

[0380] 44. A method for generating an AAV VP2 fusion polypeptide having at least one desired feature, the method comprising screening a library as described in any one of Examples 36 to 43 for an AAV VP2 fusion polypeptide encoded with said at least one desired feature.

[0381] 45. The method as described in Example 44, wherein the at least one desired feature is increased transduction and / or increased tropism in at least one tissue or cell type mediated by the AAV VP2 fusion polypeptide relative to an AAV VP2 capsid polypeptide that does not contain the polypeptide ligand.

[0382] 46. ​​The method as described in Example 44 or 45, the method comprising the steps of: b) contacting a library as described in any one of Examples 36 to 43 with a plurality of cells, c) isolating nucleic acid molecules from at least a portion of the cells, and d) determining at least a portion of the sequence encoding the polypeptide ligand or a fragment thereof of the at least one nucleic acid molecule isolated in step b).

[0383] 47. The method of Example 46, further comprising, prior to step a), providing a library as described in Example 39, transfecting cells with ai) a nucleic acid sequence comprising the AAV rep gene, a nucleic acid sequence encoding the AAV VP1 capsid polypeptide, a nucleic acid sequence encoding the AAV VP3 capsid polypeptide, and the library as described in Example 36, wherein each library construct further comprises two AAV inverted terminal repeat (ITR) sequences located upstream and downstream of the nucleic acid sequence encoding the AAV VP2 fusion polypeptide, and aii) incubating the cells under conditions suitable for AAV virus particle formation, optionally wherein these cells are mammalian cells, particularly HEK293 cells, or insect cells, particularly Sf9 cells.

[0384] 48. The method as described in Example 47, wherein the AAV VP1 capsid polypeptide and the AAV VP3 capsid polypeptide are encoded by the same nucleic acid sequence containing the AAV cap gene, and in particular, wherein the start codon of VP2 in the cap gene is mutated.

[0385] 49. The method as described in any one of Examples 46 to 48, wherein the plurality of cells in step b) are present in a non-human model animal.

[0386] 50. The method as described in Example 49, wherein in step c), nucleic acids from cells of a predefined tissue or cell type are isolated, particularly wherein the cells of the predefined tissue or cell type are isolated 1-21 days, 1-14 days, 7-21 days, 2-10 days, and 2-5 days after contacting the plurality of cells with the library.

[0387] 51. The method of any one of Examples 44 to 50, further comprising the step of selecting cells in which the reporter sequence is expressed.

[0388] 52. The method of any one of Examples 46 to 51, wherein step c) comprises isolating RNA from at least a portion of the cell, and step d) comprises substep di) reverse transcription of the isolated RNA, dii) PCR amplification of at least a portion of the sequence encoding the polypeptide ligand or a fragment thereof from the cDNA generated in step di), and diii) sequencing at least a portion of the polypeptide ligand sequence, particularly by next-generation sequencing.

[0389] 53. The method of any one of Examples 46 to 52, further comprising step e): determining the relative occurrence of a specific polypeptide ligand sequence in a tissue or cell type relative to the total number of polypeptide ligand sequences in said tissue or cell type.

[0390] 54. The method of any one of Examples 46 to 53, further comprising step f): generating a second library of nucleic acid sequences encoding an AAV VP2 fusion polypeptide from the nucleic acid molecules isolated in step c), and repeating steps b), c), d), and optionally a) and e) with the second library.

[0391] 55. An AAV VP2 fusion polypeptide, wherein the AAV VP2 fusion polypeptide is produced by the method described in any one of Examples 44 to 54.

[0392] 56. A method for producing AAV viral particles comprising an AAV VP2 fusion polypeptide, the method comprising transducing packaging cells with nucleic acids as described in Example 14 or 15, wherein the method causes the packaging cells to produce the AAV viral particles.

[0393] 57. A method for producing AAV viral particles comprising an AAV VP2 fusion polypeptide, the method comprising culturing cells as described in Example 16 or 17, wherein the method results in the packaging cells producing the AAV viral particles.

[0394] 58. An AAV virus particle, which is generated by the method described in Example 56 or 57.

[0395] 59. A method for preparing a pharmaceutical composition comprising AAV virus particles as described in Examples 53 or 58, the method comprising formulating the AAV virus particles with a pharmaceutically acceptable carrier.

[0396] 60. A kit comprising isolated nucleic acid as described in any one of Examples 13 to 15.

[0397] 61. An AAV VP2 fusion polypeptide comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the polypeptide ligand has a molecular weight of up to 10 kDa.

[0398] 62. An AAV VP2 fusion polypeptide comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the AAV VP2 capsid polypeptide comprises one or more mutations that eliminate or reduce binding to heparan sulfate proteoglycan (HSPG) and / or sialic acid (SIA).

[0399] 63. The AAV VP2 fusion polypeptide as described in Example 62, wherein the molecular weight of the polypeptide ligand is up to 10 kDa.

[0400] 64. An AAV VP2 fusion polypeptide comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein a) the AAV VP2 capsid polypeptide has an AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R and / or P191N, or wherein b) the AAV VP2 capsid polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the following amino acid substitutions selected from the group consisting of: relative to SEQ ID NO:7 The VP1 amino acid sequence of NO:7 comprises E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, particularly wherein bi) the AAV VP2 capsid polypeptide has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, or wherein bii) the AAV VP2 capsid polypeptide has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of: relative to SEQ ID The VP1 amino acid sequence of NO:5 consists of E147S, P185G, P166R, G199R, D213A, S162R, and P191N or any combination thereof, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D213A, S162R, and / or P191N.

[0401] 65. The AAV VP2 fusion polypeptide as described in Example 64a), wherein the AAV VP2 capsid polypeptide further comprises amino acid substitutions V473D and N500E relative to the VP1 amino acid sequence of SEQ ID NO:7.

[0402] 66. An AAV VP2 capsid polypeptide, wherein a) the AAV VP2 capsid polypeptide has an AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, particularly wherein the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R, and / or P191N, or wherein b) the AAV VP2 capsid polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the following amino acid substitutions selected from the group consisting of: relative to SEQ ID NO:7. The VP1 amino acid sequence of NO:7 comprises E147S, P185G, P166R, M211V, G199R, D213A, T162R, and P191N, particularly wherein bi) the AAV VP2 capsid polypeptide has AAV serotype 8 and contains at least one amino acid substitution selected from the group consisting of: E147S, P186G, P167R, M212V, G200R, D214A, K163R, and P192N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D214A, K163R, and / or P192N, or wherein bii) the AAV VP2 capsid polypeptide has AAV serotype 9 and contains at least one amino acid substitution selected from the group consisting of: relative to SEQ ID The VP1 amino acid sequence of NO:5 consists of E147S, P185G, P166R, G199R, D213A, S162R, and P191N or any combination thereof, particularly wherein the AAV VP2 capsid polypeptide contains one or more of the following amino acid substitutions: D213A, S162R, and / or P191N.

[0403] 67. An rAAV viral particle comprising the AAV VP2 capsid polypeptide as described in Example 66. Attached Figure Description

[0404] This patent or application document contains at least one color-drawn drawing. A published copy of this patent or application with one or more color-drawn drawings will be provided by the Patent Office upon request and payment of the necessary fees.

[0405] Figure 1 This is a schematic diagram of the AAV VP2 fusion peptide expression plasmid generated in Example 1.

[0406] Figure 2This is a schematic diagram of the cargo expression plasmid pNN001.

[0407] Figure 3 SDS-PAGE (denaturation) of the Darpin, VHH, and small protein-modified AAV8 formulation compared to CTR wtAAV8 is shown. As confirmed by MS, a small amount of VP2 wt contamination was observed in sample 4 (likely due to affinity purification overflow from AAV8 trans-VP2).

[0408] Figure 4 An AAV sandwich ELISA for EGFR and TIGIT recombinant proteins using a modified AAV8 formulation is shown.

[0409] Figure 5 The AAV8 trim level of the VP2, integrated with different brackets, is shown.

[0410] Figure 6 The in vitro infectivity of the modified AAV8 on the EGFR-overexpressing HKB11 cell line is shown. The relationship between the number of intact particles and the percentage of infected (EGFP+) cells is shown.

[0411] Figure 7 The in vitro infectivity of the anti-EGFR Sso7d-AAV8 VP2 fusion to GBM neurospheres (EGFR-enhanced clone HF-2927) was demonstrated.

[0412] Figure 8 The in vitro infectivity of the modified AAV8 on receptor-overexpressing cell lines was demonstrated.

[0413] Figure 9 The in vitro infectivity of the modified AAV6Sil2 to EGFR-overexpressing HKB11 and HKB11w.t. cell lines was demonstrated.

[0414] Figure 10 The in vitro infectivity of AAV9 modified with anti-EGFR Sso7 VP2 fusion material to GBM neurospheres was demonstrated.

[0415] Figure 11 The in vitro infectivity of the modified AAV1Sil1 to EGFR-overexpressing HKB11 and HKB11w.t. cell lines was demonstrated.

[0416] Figure 12 The amino acid frequencies at the target sites on the Lib8 Sso7d phage plasmid library are shown. The results represent MiSeq NGS results for 500–700 K filtered reads (Q>30).

[0417] Figure 13The results of the analysis of the appearance of the Lib8 Sso7d library after the third round of selection are shown.

[0418] Figure 14 The results of FACS analysis of six Sso7d constructs in EGFR-overexpressing and EGFR-knockout cells are shown.

[0419] Figure 15 This is a schematic diagram of the cargo particle SK0033.

[0420] Figure 16 The amino acid frequencies at randomized positions in the Lib8 Sso7d-AAV1Sil1 plasmid library (SK0037) are shown.

[0421] Figure 17A The results of the analysis on the occurrence of Lib8 Sso7d-VP2 AAV1Sil1 are shown.

[0422] Figure 17B The amino acid frequencies at the target sites on the Lib8 Sso7d-VP2 AAV1Sil1 plasmid library are shown.

[0423] Figure 17C The amino acid frequencies at the target sites on the Lib8 Sso7d-VP2 AAV1Sil1 AAV library are shown.

[0424] Figure 17D The deviation of the Lib8 Sso7d-VP2 AAV1Sil1 AAV library at the target location is shown.

[0425] Figure 18 The percentage of human cells in different tissues of humanized mice is shown.

[0426] Figure 19 The biodistribution of Lib8 Sso7d-VP2 AAV1Sil1 and undecorated controls in humanized mice is shown.

[0427] Figure 20 Rapid gel analysis of the RT-PCR reaction product (expected size: 403 bp) is shown.

[0428] Figure 21 The distribution of a single rcSso7d variant sequence in different organs / cells from mice injected with Lib8 Sso7d-VP2AAV1Sil1 is shown.

[0429] Figure 22 The distribution of enriched hits in different organs is shown.

[0430] Figure 23 This is a schematic representation of the barcode-coded cargo particles generated in Example 8.

[0431] Figure 24A The yield and percentage of complete particles obtained from a single barcoded Sso7d-AAV1Sil1 are shown.

[0432] Figure 24B The proportions of VP2 fusion and VP1 are shown in a single barcode-coded Sso7d-AAV1Sil1 and an undecorated control.

[0433] Figure 25 The in vitro infectivity of Sso7d-modified AAV1Sil1 to HEK293 suspension cells was demonstrated.

[0434] Figure 26 The distribution of the library in the AAV-471 formulation for mouse injection is shown.

[0435] Figure 27 The distribution of the barcoded Sso7d-VP2 AAV1Sil1 library in different organizations is shown.

[0436] Figure 28 Rapid gel analysis of RT-PCR reactants (expected size: 403 pb) is shown.

[0437] Figure 29 A rapid gel analysis of the amplicon fragment (expected size: 243 bp) used for NGS is shown.

[0438] Figure 30 The tissue distribution of the top 12 enriched spurs identified after three rounds of selection using the Lib8 Sso7d-VP2 AAV1Sil1 library in the LT-HSC population is shown.

[0439] Figure 31 This is a schematic representation of the receptor material particles generated in Example 10.

[0440] Figure 32 Rapid gel analysis of RT-PCR reactants (expected size: 608-668 bp) is shown.

[0441] Figure 33 Rapid gel analysis of amplicon PCR reactants (expected size: 484-529 bp) is shown.

[0442] Figure 34 The V-Exp library selection count distribution is shown.

[0443] Figure 35The variation analysis of V-Exp target sites after positive and negative selection is shown (data represent the percentage of wt amino acids at each given site).

[0444] Figure 36 The distribution of amino acids at the preferred VP2 positions after positive selection is shown (data represents the percentage of amino acids at the top nine preferred positions - boxed around the selected AA mutation).

[0445] Figure 37 The linker and amino acid variations at the preferred VP2 position after positive selection are shown.

[0446] Figure 38 A bar graph depicting the fold change in EC50 values ​​between EGFR-overexpressing cells and EGFP-positive cells in knockout cells is shown.

[0447] Figure 39 Bar graphs depicting the binding of AAV1 Sil1 VP2 variants with different anti-EGFR Sso7d decorations to EGFR are shown (ELISA signals with background removed at 5E+11vp).

[0448] Figure 40 The in vitro infectivity of ssAAV1Sil1 modified with anti-EGFR Sso7d to HKB11 wild-type cells was demonstrated.

[0449] Figure 41 The in vitro infectivity of ssAAVSil1 modified with anti-EGFR Sso7d to receptor-overexpressing HKB11 cells was demonstrated.

[0450] Example

[0451] Example 1: Preliminary evaluation of AAV VP2 fusion peptide decoration level in AAV8 capsid using VHH, DARPIN, and small protein scaffolds fused with the VP2 N-terminal gene.

[0452] To evaluate the feasibility of generating decorated AAVs (as described in Munch et al., Nat Commun [Nature Communications] 6, 6246 (2015)) through VP2 N-terminal gene fusion, different scaffolds were cloned into the AAV8 VP2 expression plasmid AgC1159 (VP2 DT1), which lacked a start codon encoding threonine at the N-terminus of the VP2 open reading frame. The resulting AAV VP2 fusion peptide expression plasmid (in which the AAV VP2 fusion peptide open reading frame is operatively linked to the HCMV promoter) is graphically depicted on [the image / image / etc.]. Figure 1 middle.

[0453] The scaffold was cloned into the VP2 expression plasmid:

[0454] The scaffold sequence listed in GeneArt's string DNA ordering table 1 was supplemented with 5' and 3' extensions suitable for Gibson-based cloning. In the case of VHH, the sequence was amplified by PCR using an internal expression plasmid as a template. The fragment was cloned into the HindIII-AgeI digested VP2 expression plasmid AgC1159, and correct assembly was confirmed by Sanger sequencing.

[0455] Table 1: List of scaffolds and connectors used in Example 1. A strep-TagII-GS sequence was added to the N-terminus of all constructs, and a G4S connector was added to the C-terminus.

[0456]

[0457]

[0458] *Original sequence without N-terminal or C-terminal additives (bolded)

[0459] The decorated AAV is produced as follows:

[0460] The generated VP2 fusion plasmid was combined with the rep / cap VP2 KO plasmid (containing the AAV2 rep gene and the AAV8 cap gene with a mutation in the start codon of the VP2 open reading frame (therefore encoding AAV8 VP1 and VP3, but not VP2), pHelper (encoding adenoviral proteins E2A, E4, and VA RNA), and HCMVprom-EGFP-SV40pA scAAV (pNN001; encoding eGFP and side-linked AAV2ITR under the control of the HCMV promoter) as cargo, and is schematically shown in the figure. Figure 2 (The two cells) were transfected together into suspension HEK293T / 17F cells.

[0461] In short, 100 ml (350 ml for AAV8 wt) of HEK293T / 17F suspension cells were diluted to 1.5E+06 cells / ml and transfected using PEI MAX (PEI:DNA ratio = 3:1) at a rate of 0.8 μg DNA mixture / 1E+06 cells. The plasmid mixture consisted of equimolar amounts of three or four plasmids as described in Table 2. Six days post-transfection, the samples were centrifuged at 4000 rpm for 20 min, and the supernatant was loaded at 4 ml / min onto 1 ml x 0.5 cm² x 5 cm² POROSGoPure AAVX (Thermo Fisher Scientific #A36652) mounted on an AKTA Pure instrument. The bound AAV particles were washed with 10 column volumes (CV) of wash buffer (pH 7.3) (50 mM Tris-Cl, 0.5 M NaCl, 0.01% Pluronic F-68) and eluted with 5 CV of glycine elution buffer (pH 2.7) (0.1 M glycine, 0.2 M NaCl, 0.25 M L-arginine). The elution fraction (0.25 mL) was immediately neutralized with 25 μl of 1 M Tris-Cl (pH 10). The fractions containing AAV (as assessed by UV280 signal) were combined and dialyzed using a Float-A-Lyzer dialysis unit at 100 kDa (Spectrum). TM #G235071) Dialyze overnight with PBS (pH 7.4) + 0.001% Pluronic F-68.

[0462] The concentration of intact particles (vg / ml) was assessed using qPCR. Pretreated samples were qPCR performed on a Qiagen RotorGene instrument using the KAPA probe rapid qPCR kit and the SV40pA oligonucleotide group listed in Table 3. Plasmid pNN001 was used for standard curve generation. The qPCR results are summarized in Table 4.

[0463] Table 2: List of rep / cap VP2 KO and VP2 expression plasmids used in this example, excluding pHelper and pNN001 cargoes.

[0464]

[0465]

[0466] *The VP2 KO rep2 / Cap8 plasmid (AgC1157) was generated by mutating the first threonine of VP2 to alanine (T138A).

[0467] Table 3: Oligonucleotide genome used for measuring AAV genome concentration (vg / ml) by qPCR

[0468]

[0469] Table 4: qPCR results of modified AAV8

[0470]

[0471]

[0472] The absence of VP2 (sample AAV8 VP2 KO) and the trans-presentation of VP2 (sample AAV8 trans-VP2) have only a minor effect on AAV titer. Gene fusion with the N-terminus of VP2 in various scaffolds results in a 2-7 fold reduction in AAV titer.

[0473] Evaluation of decoration level:

[0474] The presence of the VP2 fusion compound was assessed by SDS-PAGE analysis of 20 μl of affinity-purified AAV formulation under denaturing conditions. The SDS page is shown below. Figure 3 In the middle, changes in the molecular weight of VP2 were only observed in samples decorated with small proteins, while other samples (VHH and Darpin fusions) did not show detectable levels of VP2 fusions.

[0475] In addition, CE-SDS analysis (Agilent 2200 Tapestation system, P200 protein kit, denaturing conditions) was performed to semi-quantitatively evaluate the relative amounts of different VP proteins in the purified samples. Results confirmed a change in the molecular weight of VP2 in the AAV8-anti-HA small protein sample, while no detectable VP2 fusion was found in other samples. The AAV8-anti-HA small protein sample showed similar relative amounts of different VP proteins to the AAV8 wt sample. A slightly increased amount of VP2 was observed in the AAV8 trans-VP2 sample. The results are summarized in Table 5.

[0476] Table 5: Molecular weight and estimated relative amount of VP in AAV8 formulations modified with Darpin, VHH and small proteins (Tapestation)

[0477] Table 5a: Observed MW (kDa) of VP

[0478]

[0479]

[0480] Table 5b: VP Distribution (assuming a total of 60 VPs per AAV particle)

[0481] Sample ID VP3 VP2 VP1 AAV8 wt 50.6 6.1 3.3 AAV8 VP2 KO 56.8 3.2 AAV8 trans-VP2 48.3 8.6 3.1 AAV8-anti-EGFR Darpin 56.0 4.0 AAV8-Anti-MBP Darpin 55.7 4.3 AAV8-Anti-Her2 Darpin 56.6 3.4 AAV8-Anti-HA Small Protein 51.7 6.0 2.2 AAV8-Anti-TIGIT VHH 56.6 3.4 AAV8-Anti-GPR126VHH 55.4 4.6

[0482] Mass spectrometry analysis:

[0483] Due to the potential co-migration of the VHH and Darpin VP2 fusions with the VP1 band, all formulations were analyzed using LC-MS. 5 μl of untreated AAV sample was loaded onto a UPLC-I stage connected to a Synapt G2S (WATERS) quadrupole time-of-flight mass spectrometer. The sample was denatured on the column and chromatographically separated on a Waters Bioresolve RP 1x 50 mm column. The column was maintained at 80 °C with a gradient consisting of a 30% to 38% organic mobile phase over 40 min at a flow rate of 0.1 mL / min. The aqueous mobile phase consisted of 0.1% formic acid in water, and the organic phase consisted of 0.1% formic acid in acetonitrile.

[0484] The expected quality of VP1 and VP3 could be confirmed in all tested samples, and the presence of VP2 wt or VP2 fusion was confirmed only in AAV8w.t., AAV8 trans-VP2 and AAV8-anti-HA small protein samples, confirming the SDS and CE-SDS results.

[0485] AAV8 Sandwich ELISA:

[0486] To further evaluate the decoration efficiency and proper exposure of the VP2 fusion scaffold, a more sensitive sandwich ELISA assay was performed. 96-well plates were coated with 5 μg / ml of recombinant hEGFR and hTIGIT extracellular domain (ECD) proteins. After overnight incubation and blocking with 3% BSA / TBST buffer, different amounts of decorated AAV vg were added to the wells and incubated at room temperature for 2 h. After washing (3 times), the wells were incubated at room temperature (RT) with anti-AAV8 monoclonal mIgG2 (Origene AM32478SU-N) for 1 h. The wells were washed again (3 times), incubated with conjugated anti-mouse IgG-AP (Sigma-Aldrich A5153), washed again (3 times), and the signal was visualized using Attophos substrate (Roche 00000011681982001). Results are shown in... Figure 4 middle.

[0487] Compared to MS and CE-SDS, the AAV8 sandwich ELISA detected Darpin and VHH on the assembled AAV surface. It is suspected that the generated AAV contains only a small fraction of VP2 fused with either of the two scaffolds, which is detectable only by the sandwich ELISA and not by MS and CE-SDS.

[0488] Example 2: Evaluation of AAV8 decoration level using a scaffold fused with the N-terminal gene of VP2

[0489] As observed in Example 1, the AAV8-anti-HA small protein manifestation was the only decorated AAV formulation with wild-type-like VP2 decoration levels. To assess whether this phenomenon was due to the small size of the scaffold, we cloned different anti-EGFR binding domains, as listed in Table 6, into the AAV8 VP2 expression plasmid AgC1159.

[0490] Table 6: List of bracket IDs and connectors used in this example

[0491]

[0492]

[0493] *Original sequence without N-terminal or C-terminal additives (bolded)

[0494] **During the final production step, the anti-EGFR affinity (Z) EGFR -1907) Sample loss; accurate yield evaluation is not possible. Based on the peak height during affinity purification, the expected yield is similar to other purified formulations.

[0495] The decorated AAV is produced as follows:

[0496] The cloning, expression, purification, and evaluation of viral concentrations of different decorated AAV8 particle formulations were performed as described in Example 1, with the following exceptions:

[0497] • The transfection volume for each sample is 300 ml.

[0498] • Collect cells and add supernatant 4 days after transfection

[0499] • Add 0.5% Triton, 2 mM MgCl2, and 12.5 U / ml Benzonase to a bulk concentration of the harvested product; lyse at 37°C for 2 h, then add 0.5 M NaCl and centrifuge the sample at 3500 g for 30 min. Filter and clarify the lysate, then load it onto a 1 ml POROS AAVx resin.

[0500] As a control, novel formulations of AAV8-anti-EGFR Darpin and AAV8-anti-HA small protein were generated in parallel in a similar manner. Intact particle concentrations (vg / ml) were assessed using qPCR as described in Example 1. The results are summarized in Table 7c.

[0501] Evaluation of decorative level and total AAV output:

[0502] CE-SDS analysis (using an Agilent 2100 Bioanalyzer system and Protein 230 kit under denaturing conditions) was performed to evaluate the distribution of VP and total VP yield in the purified samples.

[0503] Calculation of total AAV particles / ml (vp / ml) and VP ratio

[0504] Divide the ng / μl (=μg / ml) value by the observed MW, then multiply by 1E+06 (μg to g conversion) to calculate the mole / ml value.

[0505] Multiply the mole / ml value by 6.022E+23 (Avogadro's constant) to calculate the number of molecules / ml.

[0506] • VP distribution: Calculated based on molecules / ml, assuming one AAV consists of a total of 60 VPs.

[0507] • AAV particle / ml (vp / ml): The sum of VP1+VP2+VP3 molecules / ml divided by 60

[0508] The results are summarized in Table 7 and Figure 5 middle.

[0509] Table 7: Bioanalyzer Results of Modified AAV8 Samples

[0510] Table 7a: Observed MW (kDa) of VP

[0511]

[0512]

[0513] Table 7b: VP Distribution (assuming a total of 60 VPs per AAV particle)

[0514] Sample ID VP3 VP2 VP1 Anti-EGFR Darpin(E_01) 53.1 *(1) *6.9 Anti-EGFR fibronectin (E.6.2.6) 50.6 3.5 6.0 Anti-EGFR Sso7d (E.18.4.5) 49.6 5.8 4.6 <![CDATA[Anti-EGFR Affibody (Z EGFR -1907)]]> 49.0 5.9 5.1 <![CDATA[Anti-EGFR GP2 (GaEGFR 2.2.3 )]]> 44.5 10.7 4.7 Anti-HA small protein 45.8 9.1 5.1 AAV8 wt 46.0 9.1 4.9

[0515] *For the Darpin sample, VP1 and VP2 fusions may potentially co-migrate, and an exact value cannot be assigned to the number of VP2 units. An arbitrary value of one VP2 fusion is assigned to each AAV based on a slight increase in the VP1 value.

[0516] Table 7c: Viral genome (vg) and viral particle (vp) yields / transfected cells

[0517] Sample ID vg / cells vp / cell Anti-EGFR Darpin(E_01) 2.32E+04 4.04E+04 Anti-EGFR fibronectin (E.6.2.6) 2.96E+04 1.20E+05 Anti-EGFR Sso7d (E.18.4.5) 2.29E+04 8.54E+04 <![CDATA[Anti-EGFR GP2 (GaEGFR 2.2.3 )]]> 2.77E+04 1.49E+05 Anti-HA small protein 1.34E+04 8.20E+04 AAV8 wt 3.69E+04 1.20E+05

[0518] Successful incorporation of the VP2 fusion peptide into the AAV capsid was observed, and the molecular weight of the scaffold fused with the VP2 peptide correlated with the results. Satisfactory decortication levels (>60% wt VP2 level) were achieved using scaffolds below 10 kDa. Above this threshold, a decrease in VP2 fusion incorporation was observed, particularly pronounced with an 18 kDa darpin. A slight decrease in yield (<2-fold compared to wt) was observed in all tested anti-EGFR scaffolds used in this experiment.

[0519] In vitro infectivity of modified AAV8 against EGFR-overexpressing cell lines:

[0520] To evaluate the effect of different decoration levels of the anti-EGFR-decorated AAV8 formulation, an infectivity assay was performed on HKB11 cells stably overexpressing hEGFR (HKB11_EGFR). On the day of infection, cells were resuspended in DMEM to 5E+05 cells / ml and seeded at 50 μl / well in 96-well plates (2.5E+04 cells / well). The decorated AAV8 formulation was diluted in DMEM medium and applied to the seeded cells at different concentrations based on total vp, ranging from 2E+06 to 1.56E+04 mol (final volume 100 μl). Four days after transduction, cells were isolated and FACS analysis was performed to calculate the percentage of EGFP-positive cells. Intact particle size (vg) was also calculated. Figure 6 The relationship between the number of intact particles and the percentage of infected (EGFP+) cells was depicted.

[0521] The anti-EGFR VP2 fusion peptide with high levels of decoration showed increased uptake in HKB11_EGFR cells (Sso7d > affinity > GP2). In contrast, the anti-EGFR DARPin and fibronectin scaffold fusions did not show increased infectivity compared to the undecorated AAV8 wt control, likely due to the low levels of decoration obtained with these two scaffolds.

[0522] In vitro infectivity of decorated AAV8 for glioblastoma (GBM) neurospheres:

[0523] GBM neurosphere cultures were obtained from Henri Ford Health System and were grown in suspension at 37°C and 5% CO2 in DMEM / HamF12 (Gibco #11039-021) supplemented with Gibco N2 supplement (100x; #17202-048), BSA (Sigma #A4919; final concentration 0.5 mg / ml), gentamicin (Gibco #15710-064; final concentration 0.025 mg / ml), antibiotic-antifungal agent (100x) (Ingenieur #15240-062), EGF (Peprotech #100-15; final concentration 20 ng / ml), and FGF (Peprotech #100-18B; final concentration 20 ng / ml). To validate the infectiousness results obtained in the EGFR-overexpressing HKB11 cell line, the GBM neurosphere cell line (HF-2927) with enhanced EGFR expression was infected with anti-EGFR Sso7d (E.18.4.5)-AAV8. GBM cells were seeded at approximately 40,000 cells / well in 96-well plates without destroying the neurospheres (cell number was determined by taking 200 μl of cell line and destroying the spheres to estimate cell concentration). Seeded neurospheres were infected with 1E+06 and 1E+05 moi of anti-EGFR Sso7d-decorated AAV8 and compared with undecorated AAV8 and AAV9 wt formulations containing the same EGFP cargo. EGFP signal was monitored three days post-transduction using a Zoe fluorescence imaging system (Bio-Rad). A photograph of a representative neurosphere is shown below. Figure 7 middle.

[0524] Compared with undecorated AAV8 and AAV9 formulations, AAV particles displaying the anti-EGFR Sso7d VP2 fusion peptide showed significantly increased cellular uptake in GBM neurosphere cultures of the EGFR-overexpressing cell line HF-2927.

[0525] Example 3: Evaluation of AAV8 decoration level using additional GP2 and affinity conjugates fused with the N-terminal gene of VP2.

[0526] introduction:

[0527] Additional exemplary GP2 and affinity sequences were extracted from the literature and cloned into the AAV8 VP2 expression plasmid as described in Example 1.

[0528] Table 8: List of bracket IDs and connectors used in this example

[0529]

[0530]

[0531] *Original sequence without N-terminal or C-terminal additives (bolded)

[0532] The modified AAV8 produces:

[0533] A DNA mixture containing equimolar ratios of pHelper, (DL144)CAG-EGFP-NOX single-stranded cargo, the aforementioned (AgC1157)pAAV rep2_cap8 VP2 KO, and AAV8 VP2 fusion expression plasmid was prepared and transfected into 200 ml of HEK293 suspension cells at a concentration of 2E+06 vc / ml (1.1 μg total DNA / 1E+06 cells) using FectoVIR-AAV transfection reagent (Polyplus #101000022) (DNA:FectoVIR = 1 μg: 1 μl). Following transfection, glucose was added to the transfection mixture to a final concentration of 2 g / L, and the mixture was incubated at 37°C, 110 rpm, and 6% CO2. A second transfection was performed using undecorated AAV1Sil1 combined with its corresponding barcoded cargo plasmid (A02). Three days post-transfection, 0.1 U / μl of totipotent nuclease and 20 mL of lysis buffer (500 mM HEPES, 10% Tween 20, 20 mM MgCl2) were added to the transfection mixture, and the mixture was incubated at 37 °C with stirring for 3 h. Following this incubation step, 24 mL of sucrose salt solution (5 M NaCl, 7% sucrose) was added to the lysate, and the mixture was incubated for another 20 min. The sample was centrifuged at 3500 g for 15 min, and the supernatant was filtered through a 0.22 μM filter. EDTA was added to a final concentration of 5 mM and loaded at 1 mL / min onto a pre-packed AAVX column (0.5 x 5 cm, 1 mL) (Thermo Fisher Scientific #A36652) mounted on an AKTA Pure instrument. The bound AAV particles were washed with 10 CV of wash buffer (pH 7.3) (50 mM Tris-Cl, 0.5 M NaCl, 0.01% Pluronic F-68) and eluted with 5 CV of glycine elution buffer (pH 2.7) (0.1 M glycine, 0.2 M NaCl, 0.25 M L-arginine). The elution fraction (0.25 ml) was immediately neutralized with 25 μl of 1 M Tris-Cl (pH 10). The fractions containing AAV (as assessed by UV280 signal) were combined and dialyzed using a Float-A-Lyzer dialysis unit (100 kDa, Spectrum). TM#G235071) Dialyze overnight with PBS (pH 7.4) + 0.001% Pluronic F-68, then pass it through a 0.22 μm filter unit.

[0534] Determination of titer and decoration level:

[0535] Using the SV40 pA-specific oligonucleotide group described in Table 3, the titer of the AAV vector was determined using a QX200 droplet digital PCR (ddPCR) system (Bio-Rad Laboratories). The purified formulation was pretreated as follows: 5 μl of AAV was incubated with 1 unit of DNase and 1x DNase buffer (Merck, #04716728001) in a total volume of 20 μl at 37°C for 30 min. 1 μl of 20 mg / mL proteinase K (Life Technologies, #EO0491) was added to the mixture, and the mixture was incubated at 55°C for 1 h, followed by an inactivation step at 95°C for 15 min. Different 1 / 10 serial dilutions of the treated formulation were prepared in 1x PCR Buffer II (Lifetech Corporation #N8080010), 2.5 mM MgCl2, 0.05% Pluronic F-68 (Sigma-Aldrich Corporation #K4894), and 2 ng / μl cleaved salmon sperm DNA (Ingenieur Corporation #15632011), and used as templates for PCR amplification.

[0536] Droplets were generated as follows: 5.5 μl of pretreated AAV diluent, 900 nM each of forward and reverse SV40 pA primers, 125 nM SV40 pA probe, and 11 μl of 2x ddPCR probe were mixed with ultramixing buffer (Bio-Rad Laboratories #1863024) to a final volume of 22 μl. Technical replicates were performed for each sample. 20 μl of each ddPCR assay mixture was loaded into a disposable droplet generator cartridge (Bio-Rad Laboratories). Then, 70 μL of droplet-generating probe oil (Bio-Rad Laboratories #1863005) was loaded into each of the eight wells. The cartridge was then placed inside a QX200 droplet generator (Bio-Rad Laboratories). When droplet generation was complete, a 40 μl volume was transferred to a 96-well PCR plate using a multichannel pipette.

[0537] The plate was heat-sealed with foil and placed in a C1000 Touch thermal cycler (Bio-Rad Laboratories). The thermal cycling conditions were as follows: 40 cycles of 95°C for 10 min, followed by 30 s at 95°C and 1 min at 60°C, then incubation at 98°C for 10 min, and indefinite incubation at 4°C. FAM fluorescence signals (labeled with the AAV genomic DNA sequence in each droplet) were counted using a QX200 digital droplet reader and analyzed using QuantaSoft analysis software (Bio-Rad Laboratories). To calculate the AAV titer, the droplet number was converted by multiplying by the corresponding total dilution factor and additionally by factor 2 (to account for possible re-annealing of single-stranded genomes).

[0538] CE-SDS analysis (Agilent 2100 Bioanalyzer system, Protein 230 kit, denaturing conditions) was performed to evaluate the distribution of VP and total VP yield in the purified samples.

[0539] Calculation of total AAV particles / ml (vp / ml) and VP ratio

[0540] Divide the ng / μl (=μg / ml) value by the observed MW, then multiply by 1E+06 (μg to g conversion) to calculate the mole / ml value.

[0541] Multiply the mole / ml value by 6.022E+23 (Avogadro's constant) to calculate the number of molecules / ml.

[0542] • VP distribution: Calculated based on molecules / ml, assuming one AAV consists of a total of 60 VPs.

[0543] • AAV particle / ml (vp / ml): The sum of VP1+VP2+VP3 molecules / ml divided by 60

[0544] The results of ddPCR and CE-SDS are reported in Table 9.

[0545] Table 9: QC for AAV8 formulations modified with affinity derivatives and GP2

[0546]

[0547] In vitro infectivity of modified AAV8 against receptor-overexpressing cell lines:

[0548] To evaluate the receptor specificity of the modified AAV8 formulation, infectivity assays were performed on HKB11 cells overexpressing human PDGFRb (HKB11 PDGFR+) or human HER2 (HKB11 Her2+) and NIH3T3 cells overexpressing human insulin receptor (NiH3T3 InsR+). On the day of infection, cells were resuspended in DMEM to 5E+05 cells / ml and seeded at 50 μl / well in 96-well plates (2.5E+04 cells / well). Modified AAV8 formulations and unmodified AAV8 controls, produced using the same cargo and methods in separate experiments, were diluted in DMEM medium and applied to seeded cells at different concentrations ranging from 1E+06 to 4.57E+02 moi based on viral genome concentration (final volume 100 μl). Four days after transduction, cells were isolated and FACS analysis was performed to calculate the percentage of EGFP-positive cells and the EGFP MFI. Figure 8 The relationship between the number of intact particles and the percentage of infected (EGFP+) cells, or EGFP MFI, was depicted.

[0549] Compared to the undecorated control, all tested affinity and GP2 sequences fused with AAV8 VP2 showed enhanced transduction to receptor-overexpressing cell lines.

[0550] Example 4: Evaluation of the Sso7d scaffold as a VP2 fusion on different AAV skeletons

[0551] The aim of this experiment was to evaluate the feasibility of using N-terminal VP2 fusions to graft ligand scaffolds into different AAV serotypes. In this example, a functional anti-EGFR Sso7d sequence was used as the ligand scaffold.

[0552] Sso7d-AAV6Sil2 Evaluation:

[0553] First, AAV6Sil2 was used. This backbone contains a set of mutations summarized in Table 10 to eliminate or reduce binding to heparan sulfate proteoglycan (HSPG) and sialic acid (SIA), which are the main attachment sites for AAV6. As described in Tables 10 and 11, the listed mutations were incorporated into both the rep2 / cap6 VP2 KO plasmid (T138A) and the anti-EGFR Sso7d (E.18.4.5) VP2 fusion expression plasmid (anti-EGFR Sso7d fused to the N-terminus of VP2 via G4S or (G4S)3). Cloning, expression, purification, and viral concentration evaluation of different formulations were performed as described in Example 2, with the following exceptions:

[0554] • Use CAG-EGFP-NOX single-chain cargo (DL144)

[0555] Samples were harvested 3 days after transfection.

[0556] To evaluate the functionality of the modified AAV6Sil2 formulation, infectivity assays were performed on HKB11 wild-type (wt) and HKB11_EGFR overexpressing cell lines using the same protocol described in Example 2 (1E+05 as the starting moi per vg). Results are reported in Figure 9 middle.

[0557] Table 10: Overview of the AAV6Sil2 mutant group

[0558]

[0559] Table 11: List of rep / cap VP2 KO and VP2 expression plasmids (AAV6_Sil2) used in this exam...

Claims

1. An adeno-associated virus (AAV) VP2 fusion polypeptide, comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide and is selected from the group consisting of: a GP2 polypeptide, a Sso7d polypeptide and an affinity body.

2. The AAV VP2 fusion polypeptide of claim 1, wherein the polypeptide ligand is selected from the group consisting of a Sso7d polypeptide of SEQ ID NO: 1 and a Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity thereto.

3. The AAV VP2 fusion polypeptide of claim 2, wherein the polypeptide ligand is selected from the group consisting of: a Sso7d polypeptide of SEQ ID NO: 1, wherein the amino acid residues X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 are independently selected from D, R, H, N, A, I, Y and W; and a Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity thereto.

4. The AAV VP2 fusion polypeptide of any of the preceding claims, further comprising a peptide linker between the polypeptide ligand and the AAV VP2 capsid polypeptide, in particular wherein the peptide linker is selected from the group consisting of a glycine-serine (GS) linker and an alanine-proline-serine (APS) linker, more in particular wherein the GS linker has the formula [GGGGS]n and the APS linker has the formula [APS]n, wherein n is an integer in the range of 1 to 10, in particular wherein n is 1, 2, 3, 4, 5 or 6, more in particular wherein for the GS linker, n is 1, 2, 3 or 4, and for the APS linker, n is 2, 3, 4 or 5.

5. The AAV VP2 fusion polypeptide of any of the preceding claims, wherein the AAV VP2 capsid polypeptide has an AAV serotype selected from the group consisting of: AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32.33, bovine AAV or avian AAV.5, in particular selected from the group consisting of: AAV1, AAV6, AAV8 and AAV9.

6. The AAV VP2 fusion polypeptide of claim 5, wherein the AAV VP2 capsid polypeptide comprises at least one mutation in at least one binding site of its native receptor, in particular wherein a) the AAV VP2 fusion polypeptide has the AAV serotype AAV6 and comprises in its VP3 region at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO: 3, in particular wherein the AAV VP2 fusion polypeptide comprises the following amino acid substitutions: relative to SEQ ID NO: ai) K531E and V473D of the VP1 amino acid sequence of NO:3; aii) K531E, K459S, V473D and N500E; aiii) G266A and N269Q; aiv) G266A, N269Q and D590A; av) K531E, V473D, G266A and N269Q; or avi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A; wherein b) the AAV VP2 fusion polypeptide has the AAV serotype AAV8 and comprises within its VP3 region at least one amino acid substitution selected from the group consisting of: G268E, N271Q, S387A, A592Q and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, in particular wherein the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: bi) G268E and N271Q; bii) S387A; biiii) G268E, N271Q and S387A; biv) A592Q; or bv) A592D relative to the VP1 amino acid sequence of SEQ ID NO:4; wherein c) the AAV VP2 fusion polypeptide has the AAV serotype AAV9 and comprises within its VP3 region at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A and E563A relative to the VP1 amino acid sequence of SEQ ID NO:5, or any combination thereof, in particular wherein the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: ci) W503A; cii) N562A and E563A; ciii) Q590A and W503A; or civ) Q590A, W503A, N562A and E563A relative to the VP1 amino acid sequence of SEQ ID NO:5; wherein d) the AAV VP2 fusion polypeptide has the AAV serotype AAV2 and comprises in its VP3 region an amino acid substitution of R585A relative to the VP1 amino acid sequence of SEQ ID NO: 6; or wherein e) the AAV VP2 fusion polypeptide has the AAV serotype AAV1 and comprises in its VP3 region at least one amino acid substitution selected from the group consisting of: V473D, N500E and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, in particular wherein the AAV VP2 fusion polypeptide comprises the following one or more amino acid substitutions: ei) V473D and N500E; eii) R514A; or eiii) V473D, N500E and R514A relative to the VP1 amino acid sequence of SEQ ID NO:

7.

7. The AAV VP2 fusion polypeptide of any of the preceding claims, wherein a) the AAV VP2 fusion polypeptide has an AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N relative to the VP1 amino acid sequence of SEQ ID NO:7, or any combination thereof, in particular wherein the AAV VP2 fusion polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R and / or P191N, or wherein b) the AAV VP2 fusion polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the amino acid substitutions selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N relative to the VP1 amino acid sequence of SEQ ID NO:

7.

8. The AAV VP2 fusion polypeptide of claim 7, wherein the AAV VP2 fusion polypeptide further comprises amino acid substitutions V473D and N500E relative to the VP1 amino acid sequence of SEQ ID NO:

7.

9. An isolated nucleic acid encoding the AAV VP2 fusion polypeptide of any one of the preceding claims.

10. A cell comprising the AAV VP2 fusion polypeptide of any one of claims 1 to 8 or the nucleic acid of claim 9, in particular wherein the cell is selected from the group consisting of: insect cells (e.g., Sf9 cells) and HEK293 cells.

11. A recombinant AAV (rAAV) virus particle, comprising the AAV VP2 fusion polypeptide of any one of claims 1 to 8.

12. The rAAV virus particle of claim 11, further comprising a nucleic acid sequence encoding the AAV VP2 fusion polypeptide of any one of claims 1 to 8, particularly wherein the AAV VP2 fusion polypeptide contained in the rAAV virus particle and the AAV VP2 fusion polypeptide encoded by the nucleic acid sequence are the same.

13. The rAAV virus particle of claim 11, further comprising a nucleic acid sequence encoding a therapeutic nucleic acid, a therapeutic protein, or a therapeutic antibody or antibody fragment.

14. The rAAV virion of any one of claims 11 to 13, wherein the virion further comprises AAV VP1 and VP3 polypeptides, particularly wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the same AAV serotype, the AAV serotype being selected from the group consisting of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAVrh.8, AAVrh.10, AAVrh.32.33, bovine AAV or avian AAV.5, particularly selected from the group consisting of AAV1, AAV6, AAV8 and AAV9.

15. The rAAV virion of claim 14, wherein the AAV VP1, VP2 and VP3 polypeptides comprise at least one mutation in at least one binding site of a native receptor of the AAV VP1, VP2 and VP3 capsid polypeptides, in particular wherein the AAV VP1, VP2 and VP3 polypeptides comprise the same at least one mutation in the shared VP3 region of each AAV capsid polypeptide, more in particular wherein a) the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the AAV serotype AAV6 and each comprises in the shared VP3 region at least one amino acid substitution selected from the group consisting of: K531E, V473D, K459S, N500E, G266A, N269Q and D590A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO: 3, in particular wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each comprise the following amino acid substitutions: relative to SEQ ID NO: ai) K531E and V473D of the VP1 amino acid sequence of NO:3; aii) K531E, K459S, V473D and N500E; aiii) G266A and N269Q; aiv) G266A, N269Q and D590A; av) K531E, V473D, G266A and N269Q; or avi) K531E, K459S, V473D, N500E, G266A, N269Q and D590A; wherein b) the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the AAV serotype AAV8 and each comprises at least one amino acid substitution within the shared VP3 region selected from the group consisting of: G268E, N271Q, S387A, A592Q and A592D or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:4, in particular wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each comprise one or more of the following amino acid substitutions: bi) G268E and N271Q; bii) S387A; biiii) G268E, N271Q and S387A; biv) A592Q; or bv) A592D relative to the VP1 amino acid sequence of SEQ ID NO:4; wherein c) the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides are of AAV serotype AAV9 and each comprises within the shared VP3 region at least one amino acid substitution selected from the group consisting of: Q590A, W503A, N562A and E563A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:5, in particular wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each comprise one or more of the following amino acid substitutions: ci) W503A; cii) N562A and E563A; ciii) Q590A and W503A; or civ) Q590A, W503A, N562A and E563A relative to the VP1 amino acid sequence of SEQ ID NO:5; wherein d) the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides are of AAV serotype AAV2 and each comprises an amino acid substitution R585A in the shared VP3 region relative to the VP1 amino acid sequence of SEQ ID NO: 6; or wherein e) the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides have the AAV serotype AAV1 and each comprises at least one amino acid substitution within the shared VP3 region selected from the group consisting of: V473D, N500E and R514A or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, in particular wherein the AAV VP2 fusion polypeptide and the AAV VP1 and VP3 polypeptides each comprise one or more of the following amino acid substitutions: ei) V473D and N500E; eii) R514A; or eiii) V473D, N500E and R514A relative to the VP1 amino acid sequence of SEQ ID NO:

7.

16. A pharmaceutical composition comprising the rAAV virus particle according to any one of claims 11 and 13 to 15 and a pharmaceutically acceptable excipient.

17. The rAAV virion of any one of claims 11 and 13 to 15 or the pharmaceutical composition of claim 16 for use as a medicament.

18. A library construct comprising a nucleic acid sequence encoding an AAV VP2 fusion polypeptide, wherein the AAV VP2 fusion polypeptide comprises, for example, consists of, an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the polypeptide ligand is selected from the group consisting of: a GP2 polypeptide, a Sso7d polypeptide, and an affibody.

19. The library construct of claim 18, wherein the polypeptide ligand is selected from the group consisting of: a Sso7d polypeptide of SEQ ID NO: 1 and a Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity therewith, in particular wherein the polypeptide ligand is selected from the group consisting of: a Sso7d polypeptide of SEQ ID NO: 1, wherein the amino acid residue X at positions 21, 23, 25, 28, 30, 32, 40, 42 and 44 is independently selected from D, R, H, N, A, I, Y and W; and a Sso7d polypeptide having at least 80%, 85%, 90% or 95% sequence identity therewith.

20. A library comprising a plurality of library constructs according to claim 18 or 19, in particular wherein the library comprises at least 10 2 , 10 3 , 10 4 , 10 5 , 10 6 , 10 7 , 10 8 or 10 9 A unique library construct.

21. The library of claim 20, wherein each library construct is present within a rAAV virion, in particular wherein the rAAV virion comprises the AAV VP2 fusion polypeptide as described in claim 2 or 3, and the AAV VP2 fusion polypeptide contained in a given rAAV virion and the AAV VP2 fusion polypeptide encoded by the library construct present in the given rAAV virion are identical.

22. A method of producing an AAV VP2 fusion polypeptide having at least one desired characteristic, the method comprising the steps of: b) contacting the library as claimed in claim 20 or 21 with a plurality of cells, c) isolating nucleic acid molecules from at least a portion of the cells, and d) determining at least a portion of the sequence encoding the polypeptide ligand or a fragment thereof of at least one nucleic acid molecule isolated in step b), in particular wherein the plurality of cells in step b) are present in a non-human model animal.

23. An AAV VP2 fusion polypeptide, comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the molecular weight of the polypeptide ligand is up to 10 kDa.

24. An AAV VP2 fusion polypeptide, comprising an AAV VP2 capsid polypeptide and a polypeptide ligand, wherein the polypeptide ligand is fused to the N-terminus of the AAV VP2 capsid polypeptide, and wherein the AAV VP2 capsid polypeptide comprises one or more mutations that eliminate or reduce binding to heparan sulfate proteoglycan (HSPG) and / or sialic acid (SIA).

25. An AAV VP2 capsid polypeptide, wherein a) the AAV VP2 capsid polypeptide has an AAV serotype AAV1 and comprises at least one amino acid substitution selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N or any combination thereof relative to the VP1 amino acid sequence of SEQ ID NO:7, in particular wherein the AAV VP2 capsid polypeptide comprises one or more of the following amino acid substitutions: D213A, T162R and / or P191N, or wherein b) the AAV VP2 capsid polypeptide has an AAV serotype other than AAV1 and comprises at least one amino acid substitution corresponding to at least one of the amino acid substitutions selected from the group consisting of: E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N relative to the VP1 amino acid sequence of SEQ ID NO:7 E147S, P185G, P166R, M211V, G199R, D213A, T162R and P191N of the VP1 amino acid sequence of NO:

7.

26. A rAAV virus particle, comprising the AAV VP2 capsid polypeptide of claim 25.

Citation Information

Cited By

  • Primer group and kit for detecting FLT3-ITD mutation and application of primer group and kit

    CN120119000A